Organizational Members
The GA4GH community is broad and inclusive and consists of a growing number of the world’s leading institutions in healthcare, research, patient advocacy, and information technology.
LEARN ABOUT GA4GH MEMBERSHIP
- All
- #
- A
- B
- C
- D
- E
- F
- G
- H
- I
- J
- K
- L
- M
- N
- O
- P
- Q
- R
- S
- T
- U
- V
- W
- X
- Y
- Z
With the support of the King Baudouin Foundation, Ludivine and Romain Alderweireldt-Verboogen have created Fondation 101 Génomes to help children who, like their little boy, suffer from a rare disease.
By examining a genetic database of healthy individuals who serve as controls for the research, Romain discovered that it contained many variants on the gene FBN1 considered in the scientific literature as pathogenic variants at the origin of the most severe forms of Marfan syndrome.
The discovery of apparently healthy individuals with pathogenic variants suggests that they may be genetically protected from even the most severe forms of Marfan syndrome by the action of a so-called protective (epistatic) gene that can counteract the failure of the FBN1 at the origin of the disease.
1928 Diagnostics delivers a cloud service platform for microbial analysis. We analyze resistance markers in bacteria from whole genome sequences as well as do relational analysis between samples. In just minutes hospitals get extensive information that can be used for high resolution outbreak tracing and antibiotic resistance profiling. The results are generated directly from the raw reads and requires no special skills or handling by the user.
54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market; Nearly 90% of genetic material used in pharmaceutical research is Caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.
Aalborg University Hospital, Section of Molecular Diagnostics
Aalborg, Denmark
Healthcare Research
Healthcare Care Delivery
Aalborg University Hospital North Denmark Region’s main hospital. It is also the region’s biggest workplace with approximately 6,500 employees.
Aalborg University Hospital handles highly specialized regional functions for approximately 640,000 inhabitants, including parts of Texas, region features approximately 490,000 inhabitants and basic hospital functions – apart from selected elective surgery – about 250,000 inhabitants.
AcedrA BioPharmaceuticals is a state-of-art agency located in Saudi Arabia and operating in all the region of Middle East, Turkey and Africa. AcedrA is specialized in affording and making accessible the all new in class molecules and medicines related to the gene and genomic disorders.
AcedrA BioPharmaceuticals is engaged with the Scientific community as well as the United Nations Global Compact Program to establish the necessary efforts to achieve the sustainable development goals for health through wide range of local and regional actions.
AcedrA BioPharmaceuticals is working with Public Private Partnership model of project with several governmental health institutions in Saudi Arabia like the King Fahd Medical City and the King Faisal Specialist Hospital Research Centre.
ACT Genomics is a leading precision oncology company headquartered in Taiwan with extended footprints in China, Japan, Hong Kong and Singapore. With our certified NGS platform and comprehensive genomic profiling, we help patients find the right treatments. At the same time, we collaborate with bio-pharmaceutical companies to accelerate clinical trials in drug development and CDX development. Our expertise in bioinformatics and medical interpretation enables us to deliver comprehensive and comprehensible medical reports and build cancer genomics database.
Founded in 2012, ActX helps physicians make better decisions about medical treatment, using a patient’s genetic information to guide therapy. Integrated into a physician’s normal software tools (the electronic medical record) and workflow, the ActX Service analyzes the patient’s genetic information in real time and focuses on actionable genomic alerts including drug-genome interactions and genetic risks.
Admera Health is a molecular diagnostics company focused on personalized medicine. Utilizing advanced genomic technologies and bioinformatics analysis, Admera Health delivers cost-effective clinical diagnostics spanning the continuum of care from its established, CAP-accredited laboratory.
AEGICARE TECHNOLOGY CO., LTD.
Shenzhen, China
Companies Genomic Analysis
Companies Information Technology
Aegicare is currently headquartered in Shenzhen, the Silicon Valley of China, with research centers in Silicon Valley and Pittsburgh in U.S. Our founding team members are from Peking University Dept. of Biomedical Engineering, Tsinghua University Dept. of Computer Science, Chinese Academy of Military Medical Sciences Dept. of Health Informatics, University of Illinois Dept. of Bioengineering and Carnegie Mellon University Dept. of Computer Science. Our mission is bringing clinical sequencing and artificial intelligence into mainstream medical practice to improve the quality of healthcare for billions of people.
Affymetrix is a pioneer in microarray technology and a leader in genomics analysis, and now develops and provides innovative technologies that enable multiplex and parallel analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of results into biology for a better world.
Affymetrix’ mission is to enable the translation of biological knowledge into routine practice.
AGCT GENOMICS is a leading research-based genomics company, leader in advanced medical genetics. Our company was founded with a mission: to make the latest genetic testing affordable and reachable to everyone who can benefit from it. Along with providing the latest genetic testing, we are conducting novel multidisciplinary research to advance scientific understanding of life-threatening problems. We are developing molecular medicine, building novel treatment methodologies, gene therapies to cure genetic diseases and developing technology which could help change the course of our life. Our team includes professionals in genetics, medicine, technology, and genetic counseling, and is trusted by experts to provide the most comprehensive, reliable genetic screening and support available.
Alberta Precision Laboratories (APL) is the wholly-owned subsidiary of Alberta Health Services (AHS), with the mandate to deliver high-quality, responsive diagnostic lab services to Albertans as a part of the provincial healthcare system. The Genetics and Genomics and Molecular Pathology Programs are provincial diagnostic services that include cancer genomics, cytogenomics, and genomics of hereditary disorders.
Alibaba Cloud is China’s largest cloud computing service provider which is a part of Alibaba group, our business covers companies that who need cloud computing services , including the genomics industry, Alibaba Cloud provides complete efficient and safe solutions for the management, calculation and analysis of massive genome data , and to help biotechnology companies, researchers and medical and health institutions to build a wide range of reliable, agile and intelligent basic platforms and business systems. At the same time, Alibaba Cloud enriches the gene data and tool algorithms for the genomics community with ecological partners continuously, in order to promote the development of personalized medical applications which centered on genome.
Allfocus Technologies, Inc
Parker, United States
Companies Information Technology
Healthcare technology
We are focused on Patient-Centered Care. Our goal is to help patient engagement in the collaborative medical decisions through technology.
We offer an open, integrated portfolio of healthcare information technology solutions for hospitals, physician practices, and extended care organizations.
Our Clients
•180,000 physicians
•45,000 physician Offices
•2,500 hospitals
•17,000 post-acute facilities
•100,000 electronic prescribing physicians
•40,000 in home clinicians
Our Team
•More than 6,000 team members
•20 locations (U.S., Asia, Australia, Canada, India and UK)
•Corporate Headquarters located in Chicago, IL
AllSeq has created the world’s first true Sequencing Marketplace. Our NGS marketplace helps researchers pick the best provider for their needs (based on price, technology, turnaround time, etc). AllSeq also maintains the NGS Knowledge Bank, a neutral source of information on the various sequencing technologies, platforms and applications.
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam was founded in 2002 on a bold vision to turn scientific possibility into therapeutic reality. Our progress is evident in a robust discovery platform and deep pipeline of investigational medicines, including 4 programs in late-stage clinical development.
Along Comes Hope ®
San Luis Obispo, United States
Societies and NGOs Patient Disease Advocacy
Supporting patients during their cancer journey
Our focus is helping families of children with cancer from the ages of birth – 23 years old. We provide support through financial assistance with travel for treatment, creative emotional support programs and advocacy to promote policy changes, awareness and education.
Alopax-Algo Co. Ltd. (also doing business as Biomed-Algo) is a biomedical data management and algorithm developing company in Korea. We are providing services for the researchers and clinicians in the Precision Medicine areas by providing analytical modules to manage and analyze various Omics Data. We assist researchers in (1) mining data from open-source data bases and various NGS data sets, and (2) analyzing the data to establish the researcher’s own data sets of specific fields of interest, such as diseases, cell types and biological markers. We are also developing Pathway Analysis Modules by connecting and elucidating Pathway-Gene-Disease-Drug networks to further assist pharmacologists and clinicians in their drug development, clinical decision makings and recommendation of precision therapeutics. For these activities, Alopax-Algo is equipped with knowledge and technologies in ontology/semantic web technologies, bioinformatics and molecular biology.
Amazon Web Services offers a broad set of global compute, storage, database, analytics, application, and deployment services that help organizations move faster, lower IT costs, and scale applications. These services are trusted by the largest enterprises and the hottest start-ups to power a wide variety of workloads including: web and mobile applications, data processing and warehousing, storage, archive, and many others.
Ambio Technology make genomics available to everyone, empower individuals from early childhood to 50+ with precision health solutions and allow everyone to maintain health proactively. We develop and offer personal genomic tests that cover various health issues and body conditions that people are most concerned of such as early childhood development, pregnancy health and heart, mental, blood and vision problems. We also partner with Advance Compuanalytics Inc. and Temple University School of Medicine in the United States to provide precision genomic diagnostics and personal cancer treatment solutions. The goal is to identify cancer patients who benefit from current, often cutting-edge therapies, while sparing those who do not have a particular genetic signature from the costs and side effects of certain treatments.
American Board of Genetic Counseling (ABGC)
Lenexa, United States
Societies and NGOs Professional
Certification
The American Board of Genetic Counseling (ABGC) is the credentialing organization for the genetic counseling profession in the United States and Canada. The ABGC certifies and recertifies qualified genetic counseling professionals. In this way the work of the ABGC protects the public and promotes the ongoing growth and development of the genetic counseling profession.
American College of Medical Genetics and Genomics
Bethesda, United States
Societies and NGOs Professional
Professional medical society representing medical geneticists in North America.
ASCO is a professional oncology society committed to conquering cancer through research, education, prevention and delivery of high-quality patient care.
AMES CENTRO POLIDIAGNOSTICO STRUMENTALE SRL
Napoli, Campania, Italy
Companies Genomic Analysis
Companies Life Science
Ames Specialistic Center S.r.l. is located in Casalnuovo – Naples, and has become a diagnostic center, over the years, of high specialization of national importance.
AMES was founded in 1996 as a laboratory of clinical biochemistry analysis to widen the range of services offered to occupational medicine and to environmental analyzes, but it is in the last five years that the company has consistently invested in field of medical genetics , becoming soon garrison of reference for high-tech exams, carrying out genetic, cytogenetic and molecular analysis activities of high specialization, with the aim of providing a complete service capable of satisfying the most diverse diagnostic requirements.
The AMES Center performs the pre-test, post-test clinical genetic counseling service in which individuals and families are
informed about the nature, heredity and implications of genetic diseases. The advice is also aimed at providing help to the user in order to make informed medical and personal decisions.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Analytics Engines
Belfast, United Kingdom
Companies Information Technology
Companies Genomic Analysis
Analytics Engines is a Belfast based company founded in 2008, which specializes in high performance Big Data and analytics software and services. It has a customer base across Europe and North America including Fortune 100 and NYSE/NASDAQ listed customers and has deep expertise in data integration, real-time analytics and application development for driving business outcomes in multiple sectors. The mission of Analytics Engines is to enable organizations to easily and quickly adopt big data analytics as a core part of their business and accelerate conversion of data assets into business insights.
Annai Systems, Inc.
Carlsbad, United States
Companies Information Technology
Companies Genomic Analysis
Annai Systems accelerates the discoveries driving genomic medicine by providing a “big data” platform that transports, structures, and connects genomic data otherwise stored in silos around the world.
Annoroad Gene Technology
Beijing, China
Companies Genomic Analysis
Annoroad Gene Technology is one of the top genomic analysis companies in Beijng, China
Appistry is bringing the power of genomics to next-generation medicine by making genomics data easier for researchers and clinicians to act on. Appistry CloudDx provides cost-effective access to established, laboratory developed tests so that clinically relevant genomics-based information can be usable by any physician, anywhere. Appistry also empowers researchers by providing world-class bioinformatics tools, cloud services, and software that streamline the analysis of next-generation sequencing data and provide easy scale for moving research-developed pipelines into production. In 2012, the Broad Institute selected Appistry as its authorized software commercialization partner, and in this role Appistry has provided several suites of tools that make these powerful tools for NGS analysis easier to implement and use.
Ardigen is a leading Polish company in Bioinformatics & Artificial Intelligence for Precision Medicine. Through proprietary know-how, experience and products Ardigen supports data driven Life Science & Healthcare organizations in personalizing medicine. Ardigen’s strength is in interdisciplinary team of world-class molecular biologists, bioinformaticians, statisticians, data scientists and software engineers who work closely together to unleash the potential of Artificial Intelligence applied to Life Sciences.
There are three main areas of Ardigen’s engagement: immunology, microbiome research and professional services. Genomics is always at the central point of our projects. Ardigen’s expertise spans through short and long read technologies, including but not limited to Illumina, PacBio and Oxford Nanopore Technologies.
Ardigen’s immunology solutions are aimed at providing novel and accurate companion diagnostics for immunotherapies and better understanding of the biology of interaction between cancer cells and immune system.
Ardigen’s microbiome research is focused on providing means to understand how microbiota contributes to host’s phenotype and how this knowledge can be used to support existing therapies. Developed solutions enable identification of probiotic strains, prediction of their phenotypes and growing conditions.
Ardigen also works with various biotech and pharma partners to deliver Value as a Service, focusing on our client’s business goals and providing hands-off experience with excellent communication and flexible project steering through Agile for Life Sciences.
Aridhia Informatics Limited
Edinburgh, United Kingdom
Companies Information Technology
Companies Genomic Analysis
Aridhia is a world leading health informatics company developing technology and capability that supports the management of chronic diseases, stratified medicine, and biomedical research through the use of biomedical informatics and analytics.
We offer genomics-based diagnostics tests to enable physicians to better manage their patients for better outcomes, enabling precision medicine, based on actionable molecular genetics reports.
The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to what was, at the time, the newly-emerging field of molecular diagnostics. Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP has established itself as the primary resource for expertise, education, and collaboration on what is now one of the fastest growing fields in science. AMP members influence policy and regulation on the national and international levels; ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing.
AMP’s 2,000+ members include individuals from academic and community medical centers, government, and industry; including, basic and translational scientists, pathologist and doctoral scientist laboratory directors, medical technologists, and trainees. AMP members span the globe with members in more than 45 countries and a growing number of AMP International Affiliate Organizations. The number of AMP members is growing rapidly; they are united by the goal of advancing the science and implementation of molecular pathology.
Association of Genetic Therapy
Prague, Czechia
Societies and NGOs Patient Disease Advocacy
Societies and NGOs Professional
We are voluntary organization of patients and professionals whose aim is to support the research on potential treatment of rare genetic disorders.
Linking the experts in the fields of phenogenomics, system biology, genetics, pharmacogenomics, IT and ethics to accelerate the development of new therapeutics to improve the progress in new medicines development. By this innovative approach to the basic research we create link between basic research and patients from the beginning. Instead of current approach in new drugs development which is disease-centric we advocate it to be person-centric based on holistic multi target, whole system approaches eg. by full genomic sequencing and metabolites study.
Astellas Pharma is a top 20 global pharmaceutical research company based in Tokyo. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people around the world.
AstraZeneca is one of the worlds top biopharmaceutical companies. MedImmune is the Biologics R&D arm of AstraZeneca.
“We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.”
AstridBio Technologies Kft.
Budapest, Luxembourg
Companies Information Technology
Companies Genomic Analysis
AstridBio specializes in bioinformatics focusing on research data-management, data-analysis, data storage and integration, data-mining and biostatistics. We are continuously working on ways to revolutionize the technology behind data-management and data-analysis in the world of genomics.
Ataxia Telangiectasia Children's Project
Coconut Creek, United States
Societies and NGOs Patient Disease Advocacy
The A-T Children’s Project is a nonprofit organization that raises funds to support and coordinate biomedical research projects, scientific conferences and a clinical center aimed at finding life-improving therapies and a cure for ataxia-telangiectasia (A-T). A-T is a rare, genetic disease that attacks children, causing progressive loss of muscle control, cancer, and immune system problems.
We’re building an open standard and unified platform. We want to help you operationalize biomedical data, analytics, and machine learning to deliver on the promise of precision medicine.
As a data and machine learning (ML) company, we envision the cloud technology that will transform healthcare in routine clinical genomics and artificial intelligence. We aim to provide you with the computational technologies that you need to scale data and machine learning in the labs of the future.
We empower you to build your own fully-managed precision medicine production at scale and speed with an integrated solution stack of cloud services, software technologies, and industry standards.
More specifically, we help:
Next Generation Sequencing (NGS) testing providers scale clinical diagnostics portfolio globally
Clinical researchers accelerate large-scale multi-comics data processing
Bioinformatics developers release new analysis software products at record-breaking speed
Atgenomix is a Microsoft Azure cloud partner in gold data and cloud platform competencies, a Google Health trusted partner in genomics research, and a Health Level Seven (HL7) International Gold member
Atos SE (Societas Europaea) is a leader in digital services with 2013 pro forma annual revenue of €10 billion and 86,000 employees in 66 countries. Serving a global client base, the Group provides Consulting & Systems Integration services, Managed Services & BPO, Cloud operations, Big Data & Security solutions, as well as transactional services through Worldline, the European leader in the payments and transactional services industry. With its deep technology expertise and industry knowledge, the Group works with clients across different business sectors: Defense, Financial Services, Health, Manufacturing, Media & Utilities, Public Sector, Retail, Telecommunications and Transportation.
Atos is focused on business technology that powers progress and helps organizations to create their firm of the future. The Group is the Worldwide Information Technology Partner for the Olympic & Paralympic Games and is listed on the Euronext Paris market. Atos operates under the brands Atos, Atos Consulting, Atos Worldgrid, Bull, Canopy, and Worldline. For more information, visit: atos.net
AGRF is a not-for-profit organisation enabling Australian genomics through a national network of leading edge services and expertise accessible at the local level. We assist Australia’s access to the latest genomic technologies to advance national genomics research.
The Australian Genomics Health Alliance (AGHA) brings together more than 50 partner organisations committed to integrating genomic medicine into healthcare across Australia, by building evidence on the implementation of clinical genomics into clinical practice.
AUSTRALO is a marketing company to thrive in the Lab-to-Market leap. Our mission is to funnel the transformation potential of cutting-edge Research+Innovation into its real-life application, creating, communicating, delivering, and exchanging value streams among target groups. We work with communities, thought leaders, researchers and entrepreneurs to draw leads, advocating for a trustworthy, fair and sustainable data-driven economy.
Autism Speaks
Princeton, United States
Societies and NGOs Patient Disease Advocacy
Funders and Agencies Private
Autism Speaks was founded in February 2005 and is the world’s leading autism science and advocacy organization, dedicated to funding research into the causes, prevention, treatments for autism; increasing awareness of autism spectrum disorders (ASD); and advocating for the needs of individuals with ASD and their families. Over the past 10 years, the science mission at Autism Speaks has invested over $250 million in basic and translational research aimed at turning scientific innovation into applications with real world potential to improve the quality of life and health for individuals living with ASD. Through its Autism Genetics Resource Exchange (AGRE) and MSSNG (whole genome sequencing) programs, Autism Speaks is a recognized leader in supporting genomics discovery research throughout the autism space.
AutoGenomics Inc
Vista, United States
Companies Life Science
Molecular Diagnostics kit manufacturing company
Since the Company’s inception in 1999, scientists and engineers at AutoGenomics have endeavored to create automated technologies that simplify the complex test processes inherent in genetic analysis within a format that is user friendly and increases productivity in the clinical laboratory.
Avera is an integrated health system based in Sioux Falls, SD. Avera serves South Dakota and surrounding areas of Minnesota, Iowa, Nebraska and North Dakota through six regional centers in Aberdeen, Mitchell, Pierre, Sioux Falls and Yankton, SD, and Marshall, MN. This includes a population of nearly 1 million throughout a geographical footprint of 72,000 square miles and 86 counties.
Avera Cancer Institute is made up of six regional centers and 40 outreach sites located in South Dakota and surrounding states. In addition to treating patients, Avera Cancer Institute also conducts research and participates in clinical trials.
London Diagnostics is an independent healthcare sector provider that provides a wide range of adult services to NHS (Insourced and Out Sourced), to privately insured and self-pay, patients. We have partnered with independent healthcare sector private hospitals across England. We focus on sub-specialties in Breast, MSK, Gynaecology, Physiotherapy and Health Well Being.
It is private entity which wants to work exclusively in health domain. It wants to build products and services for data analysis and managing health and biological data. It would provide solutions using open source technology ecosystem using distributed computing and in memory capabilities.
The Barcelona Supercomputing Center (BSC) was established in 2005 and serves as the Spanish national supercomputing facility. The Center hosts MareNostrum 4, one of the most powerful supercomputers in Europe and its mission is to research, develop and manage information technologies in order to facilitate scientific progress. With a total staff of more than 500 R&D experts and professionals, BSC is recognised as a first-class research center in supercomputing and in scientific fields that demand it, such as Computer Sciences, Life Sciences, Earth Sciences and Computer Applications in Science and Engineering.
The Life Sciences Department integrates the independent research of senior scientists that work on various aspects of computational biology, ranging from bioinformatics for genomics to computational biochemistry and text mining. The department participates in various large international genome networks as well as in research collaborations with major IT companies. It is involved in large projects focused on identifying personalized medicine methodologies using computational resources and on establishing both a legal framework and technical standards to share genomic data at global level. Furthermore, the department coordinates the National Spanish Bioinformatics Institute (INB) and the European Bioinformatics Infrastructure ELIXIR Spanish national node, and in the field of biomedical computational genomics the BSC has become a key reference in many large scale international projects.
BSC believes in the importance of transferring knowledge and technology developed at the center to industry worldwide, and promotes the use of HPC by local industry, as shown by licensing BSC’s know-how and founding 4 spin-offs, one of which within the Life Sciences Department.
Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC)
Houston, United States
Research Institute
The Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) was established in 1996 when the National Human Genome Research Institute (NHGRI) designated Baylor College of Medicine as one of six pilot programs for the final phases of the Human Genome Project (HGP). Then in 1999, the Center was chosen as one of three sites from the pilot program to complete the HGP.
In June 2000, scientists triumphantly announced they had deciphered the human genome, the blueprint for human life. This announcement did not mark the end of the project. In a sense, it was only the beginning.
In April 2003, the human genome project consortium announced the completion of Phase II of the HGP, which involved producing a complete, high-quality human DNA reference. Completion of this stage was a large-scale endeavor for the BCM-HGSC. The center was responsible for determining the DNA sequence of chromosomes 3, 12, and part of X. These sequences represent about 10 percent of the human genome.
BBMRI-NL is the Dutch project for biobank collaboration. BBMRI-NL was founded because co-operation between biobanks is essential in finding the answers to important research questions. BBMRI-NL is the Dutch hub within the European BBMRI project.
BC Platforms is a world leader in providing powerful genomic data management solutions to address some of the biggest healthcare challenges today by leveraging the convergence of genomics and healthcare information technologies. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. BC Platforms’ vision is to revolutionize decision making in drug development to bring clinical benefits to patients. Founded in 1997, the Company has a strong scientific heritage underpinned by 18 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors.
BD2K LINCS Data Coordination and Integration Center (DCIC)
New York, United States
Research Collaboration or Consortium
BD2K-LINCS Data Coordination and Integration Center (DCIC) is the data coordination center for the NIH Common Fund’s Library of Integrated Network-based Cellular Signatures (LINCS) program, which aims to characterize how a variety of types of cells, tissues and networks respond to disruption by drugs and other factors. The center supports data science research focusing on interpreting and integrating LINCS-generated data from different data types and databases in LINCS-funded projects. This center is co-funded by BD2K and the NIH Common Fund.
The Belgian Medical Genomics Initiative (BeMGI) network aims to play a primary role in establishing a collaborative platform devoted to medical genomics in Belgium. Its key activities include (i) boosting individual research efforts towards understanding the biology of disease by promoting collaborative exploitation of the most advanced genomic tools; (ii) developing approaches to predict clinical outcome from genomic information and fulfill a pilot role towards concerted integration of genomic information in clinical care in Belgium; and (iii) playing a catalyzing role in preparing the next generation of genomics researchers, informing medical practitioners about evolving trends in medical genomics, and conducting public outreach.
Beth Israel Deaconess Medical Center
Boston, United States
Healthcare Care Delivery
Research University
Beth Israel Deaconess Medical Center (BIDMC) is part of Beth Israel Lahey Health, a new health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.
BGI, founded in 1999 with the vision of using genomics to benefit the human race, is now the world’s largest genomics organization. In 2007, BGI’s headquarters was relocated to Shenzhen as the first citizen-managed, non-profit research institution in China.
BGI (which includes both private non-profit research institutes and sequencing application commercial units) and its affiliated offshoots, BGI Americas and BGI Europe, have established partnerships and collaborations with leading academic and government research institutions as well as global biotechnology and pharmaceutical companies, to support a variety of healthcare, agricultural, environmental and related applications.
After 15 years of development, BGI has evolved into a very broad scientific and technological organization, giving its academic and business scope global reach.
Currently, BGI comprises of 4 regions: BGI China (Mainland), BGI Asia Pacific, BGI Americas (North and South America) and BGI Europe (Europe and Africa). Relying on advanced high-throughput sequencing technology, a highly efficient data analysis capability, uniquely rich biological resources, and a multidisciplinary scientific research system, BGI can provide innovative support for global communities, novel opportunities for researchers, and a regionally tailored application services in the fields of healthcare, agriculture and the environment.
BIB Bioinformatics Barcelona Association
Barcelona, Spain
Non-profit association
Societies and NGOs Professional
Bioinformatics Barcelona Association (BIB) is a non-profit association for the provision of education and training, the promotion of advanced research, knowledge and technology transfer, the stimulation of competitiveness and innovation within the industrial sector, and the provision of greater visibility as an international node in the field of Bioinformatics.
BIB was established to meet the need for generating synergies between biology and computer science, for a stronger union between these areas, and for the development of high-quality education and training programmes in the creation of bioinformatic talent.
Constituted in 2015, BIB, currently, comprises over 40 leading institutions related to the Bioinformatic sector that develop their activities within the health, agrifood and technology sector, including Universities, Research Centres, Health Research Centres, Large Scientific Infrastructures and Companyes, among others.
The association has a critical mass of internationally recognised researchers in bioinformatics with complementary profiles, ready-and-available computational infrastructures and a strong industrial and clinical sector. Jointly, these create a highly appropriate environment to establish and pursue innovative projects among all its stakeholders for the development of new products and services, in which, by combining their efforts, organizations can go beyond their current limits.
With the cooperation of all its members, BIB, will turn Barcelona —and Catalonia at large— into the scientific cluster of reference in southern Europe, and into a strategic hub for Bioinformatics worldwide, thanks to a highly developed ecosystem and a privileged geographical location, open to the world.
The Foundation is an independent, privately-endowed charity. Through its Global Health Program it serves its mission to reduce global health inequities by accelerating the development, deployment, and sustainability of health interventions that will save lives and dramatically reduce the burden of diseases.
Bina Technologies Inc.
Redwood City, United States
Companies Genomic Analysis
Companies Information Technology
Bina Technologies builds next-generation technologies for scalable and accurate processing and management of genomic information. Bina’s Genomic Management Solution is an integrated, scalable, and comprehensive analysis platform that empowers clinical and translational researchers to gain insight from their genomic data sets. Bina’s Genomic Management Solution dramatically decreases the complexity, time, and cost of genomic analysis, accelerating the science of personalized medicine. Learn more about Bina’s product, technologies, and team at http://www.bina.com.
Center for Genetic Diagnostics and Clinical Genetics
bio.logis Genetic Information Management
Frankfurt am Main, Germany
Companies Information Technology
Development and distribution of IT-solution for professional medical and private genetic information management
BIOBANQUES Infrastructure/ Inserm US 13
Paris, France
Research Institute
Research Collaboration or Consortium
BIOBANQUES is a distributed infrastructure that builds on a landscape of 84 biobanks distributed all over France including disease-oriented studies and population-based cohorts. In addition 6 health oriented microorganism BRCs (mBRCs) are partners of the project.
It covers the whole spectrum of human diseases with more than 600 ongoing biological and clinical research programs, including 45 follow-up prospective surveys of population with 300 000 individuals included in the studies
Bioconductor is a collection of open source, open development R packages for the statistical analysis and comprehension of high-throughput genomic data. It is widely used and well-respected in the academic, government and other research communities.
BioDatomics provides genomic software and services that improve research and clinical productivity by dramatically accelerating data analysis and by making powerful analytical tools more intuitive and accessible. The Company’s BioDT™ platform is the first and currently only genomic analytics platform on the market built on and optimized for Hadoop®, a Big Data analytics engine that has proven hugely successful in other verticals.
Biogen Idec is one of the world’s leading biotechnology companies. We develop medicines that change the lives of people living with neurodegenerative diseases, hematologic conditions and autoimmune disorders.
Microbiome is the trillions of bacteria living in your gut, in your nose, on your skin and nearly everywhere else. These bugs are a life-long personal and natural protection against pathogens aggression but evidence suggests, for example, that dysregulated gut microbiomes are strongly involved in Inflammatory Bowel Diseases, Depression, Metabolic disorders and many other diseases.
BioMathematica is specialised in microbiome-related genomic data analysis and mechanistic, mathematical modeling and simulation of the microbiome to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies.
We bring our mathematical expertise and deep understanding of microbiome-related therapeutics (e.g. prebiotics, next-generation probiotics) and disease areas to your specific project. From genomic data analysis to strain optimization, metabolic modeling and personalized microbiome simulations, we want to transform microbiome-related medicine.
Biomatters was founded in 2003 with a mission to create bioinformatics solutions for the analysis, interpretation, and application of molecular sequence data.
Headquartered in New Zealand with offices in the United States, and users in more than 100 countries worldwide, our solutions enhance productivity in over 3,000 universities, research institutes and companies.
We specialize in creating powerful, integrated and visually appealing bioinformatics solutions, with a strong emphasis on ease of use and overall user experience.
Bionano Genomics, Inc. offers whole genome analysis tools to better understand the genome and its structure. Its high-throughput system Saphyr builds de novo maps of the genome by massively parallel imaging of the longest single DNA molecules in the industry. Bionano genome mapping provides comprehensive structural variation (SV) calls, identifying all types of SVs with sensitivities that far exceed those based on next-generation sequencing. When combined with orthogonal sequencing data, Bionano maps can provide the correct structure, order, and orientation to assemble reference-quality genomes.
BioReference Laboratories
Elmwood Park, United States
Healthcare Research
Companies Genomic Analysis
BioReference Laboratories is one of the largest and fastest growing full service diagnostic laboratories in the world, providing clinical testing services to physician offices, clinics, hospitals, long term care facilities and employers while also advancing drug discovery and development with disease foundations, academic and pharmaceutical partners. Our comprehensive testing capabilities and expertise spans molecular diagnostics, anatomical pathology, women’s health, oncology and rare disease genetics. BioReference, and our subsidiaries, have an international presence in more than 50 countries.
BioSymetrics brings together massive data, data mining, and real-time processing which enable data of any type, size and dimensionality to be explored and modelled with unprecedented speed and accuracy. These features lend themselves very well to challenges in the biomedical industries looking to predict outcomes and gain actionable insights in real time.
Industries and organizations in the biomedical space today realize the potential for massive data analytics and real time machine learning to improve care, enhance discoveries, gain insight into business, and enable fast data-driven decisions.
BioSymetrics has developed modular and customizable pipelines for processing raw phenotypic, imaging, drug, and genomic data sets using any combination of data types.
BIOVIA, a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Pipeline Pilot scientific data processing application provides a broad, flexible scientific foundation optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, QA/QC and manufacturing phases of product development. BIOVIA offers capabilities in scientific data management, modeling and simulation, research informatics, laboratory informatics, enterprise quality management, environmental health & safety and operations intelligence for customers in science-driven industries. Using BIOVIA technology, scientific innovators can access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and accelerating product development from research to manufacturing.
International city law firm
Birmingham Children's Hospital NHS Foundation Trust
Birmingham , United Kingdom
Healthcare Care Delivery
Healthcare Research
We are a large secondary and tertiary care children’s hospital developing 1st Rare Disease Centre in UK. We have 34 different specialties at our 350 bed hospital with over 270 000 patients seen per year. Furthermore, we see 9000 children with 500 different rare diseases per year.
Birmingham Children's Hospital NHS Foundation Trust
Birmingham , United Kingdom
Healthcare Care Delivery
Healthcare Research
We are a large secondary and tertiary care children’s hospital developing 1st Rare Disease Centre in UK. We have 34 different specialties at our 350 bed hospital with over 270 000 patients seen per year. Furthermore, we see 9000 children with 500 different rare diseases per year.
Bitcare technology inc
Plano, United States
Companies Genomic Analysis
Companies Information Technology
Personalized health and wellness company through genomics
BitGene.CN (上海曼因生物科技有限公司，Shanghai Human Gene Biotech) endeavors to provide personalized healthcare services to the mass consumers. By the interpretation of personal genetic information, we provide the customers lifestyle and nutrition advice with follow-up healthcare product/service via mobile.
BlockApps, Inc.
New York, United States
Companies Information Technology
Research Collaboration or Consortium
BlockApps is a blockchain platform provider bringing security, permission-based visibility and efficiency to enterprises of all sizes.
Bluebee offers a global bio-informatics platform to process, analyze, share and store genomics data.
With a private cloud service, Bluebee supports users in clinical diagnostics, therapeutics and research with advanced analytics for genomic data driven medicine.
Designed for cross-functional teams of clinicians and life science researchers the Bluebee platform effectively centralizes and manages genomics data processes and storage. Bluebee’s multi-layered security is designed to meet both specific organizational and regulatory data protection requirements when analyzing and storing research or clinical grade data.
Local data processing is guaranteed via “Data Residency Control” in state-of- the-art data centres. The service is available across all major European countries and US cities, as well as in Canada and Asia Pacific.
Booz Allen Hamilton
McLean, Virginia, United States
Companies Information Technology
Companies Life Science
We are a global firm of diverse, passionate, and exceptional people driven to excel, do right, and realize positive change in everything we do. We bring bold innovative thinking and a desire to be the best in our work in consulting, analytics, digital solutions, engineering, and cyber, and with industries ranging from defense to health to energy to international development. Booz Allen’s scientists, clinicians, and data analysts support the nation’s public health and medical organizations to transform research and scientific discovery through sophisticated analytics and emerging technologies.
Our hands-on Life Sciences team includes hundreds of bioinformaticians and data scientists who have experience working with and securing personal genomic and clinical data. Our work in Life Science solutions spans the research lifecycle, from visioning to complex technical implementation. We help health and life sciences organizations navigate their rapidly changing environments—from scientific program strategy, biomedical informatics, and data analysis to the translation of data into clinical decision-making. We translate client data into public health outcomes by integrating large and disparate scientific data sources, employing artificial intelligence and analytics, and applying predictive modeling.
Booz Allen is helping to refine experimental design, imbed innovative technologies to advance data collection and processing, advance precision medicine, and drive the public health mission. Visit https://www.boozallen.com/markets/health/life-science-solutions.html to learn more.
Boston Children’s Hospital is a 395-bed comprehensive center for pediatric health care. As one of the largest pediatric medical centers in the United States, Children’s offers a complete range of health care services for children from birth through 21 years of age. (Our services can begin interventions at 15 weeks gestation and in some situations we also treat adults.)
Boston Children’s Hospital is a 395-bed comprehensive center for pediatric health care. As one of the largest pediatric medical centers in the United States, Children’s offers a complete range of health care services for children from birth through 21 years of age. (Our services can begin interventions at 15 weeks gestation and in some situations we also treat adults.)
Boston Children’s Hospital is dedicated to improving and advancing the health and well-being of children around the world through its life-changing work in clinical care, biomedical research, medical education and community engagement.
Boston Children’s is ranked the number one pediatric hospital in the nation by U.S. News and World Report. It is home to the world’s largest pediatric research enterprise, and it is the leading recipient of pediatric research funding from the National Institutes of Health. It is the primary pediatric teaching hospital for Harvard Medical School. Boston Children’s treats more children with rare diseases and complex conditions than any other hospital.
Currently developing a range of nutraceuticals and immune system boosters formulated alongside traditional Australian Aboriginal plants.
The Brazilian Society of Medical Genetics (SBGM) was founded on July 15, 1986. It is a civil, scientific, non-profit organization made up mostly of physicians, but also by other professionals committed to the practice Clinical Genetics. Its mains goals are:
• To congregate specialists in the field of Clinical Genetics;
• To represent the Brazilian community of clinical geneticists at the national and international level;
• To contribute to the progress of Clinical Genetics;
• To encourage the education of new professionals in the field of Clinical Genetics;
• To organize national and international conferences and courses in the field of Clinical Genetics, in order to advance training in the field of Clinical Genetics
• To direct and supervise the activities related to professional practice in the field of Clinical Genetics in Brazil;
• To advise government agencies on the accreditation of new specialists in Clinical Genetics.
The BRCA Exchange aims to advance our understanding of the genetic basis of breast cancer, ovarian cancer and other diseases by pooling data on BRCA1/2 genetic variants and corresponding clinical data from around the world.
BRIDGenomics provides intelligence to support genomics based strategies spanning diagnostic, pharmaceutical, and life science market segments. We provide intelligence to support genomics based strategies and commercialization of services and products.
We bridge industry segments to enable optimization of your market strategy and development pipeline while addressing your needs for a robust regulatory development process.
–
BCIT is one of British Columbia’s largest post-secondary institutions with more than 48,000 students enrolled annually (16,600 full-time, 31,600 part-time). We offer practical career credentials designed for the workplace, including degrees, diplomas and certificates spanning Applied and Natural Sciences, Business and Media, Computing and Information Technology, Engineering, Health Sciences and Trades.
British Society for Genetic Medicine
London, United Kingdom
Societies and NGOs Professional
Healthcare Care Delivery
British Society for Genetic Medicine, provides a forum for professionals involved in Genetics as a clinical service and research. Its membership is in excess of 2000 and includes a wide spectrum of clinical, laboratory and research disciplines.
The Broad Institute brings together a diverse group of individuals from across its partner institutions — undergraduate and graduate students, postdoctoral fellows, professional scientists, administrative professionals, and academic faculty.
The culture and environment at the Broad is designed to encourage creativity and to engage all participants, regardless of role or seniority, in the mission of the Institute. Within this setting, researchers are empowered — both intellectually and technically — to confront even the most difficult biomedical challenges.
The Institute’s organization is unique among biomedical research institutions. It encompasses three types of organizational units: core member laboratories, programs and platforms. Scientists within these units work closely together — and with other collaborators around the world — to tackle critical problems in human biology and disease.
The California Institute of Technology (Caltech) is a world-renowned science and engineering research and education institution, where extraordinary faculty and students seek answers to complex questions, discover new knowledge, lead innovation, and transform our future.
Caltech’s 124-acre campus is located in Pasadena, California.
Cambridgene unlocks the power of multi-omics to accelerate and de-risk pharmaceutical research and development. Our advanced clinical research workflows and genetic profiling solutions accelerate the development and delivery of precision medicines.
Canada Health Infoway is an independent not-for-profit corporation created by Canada’s First Ministers in 2001, and funded by the Government of Canada. Infoway works as a strategic investor of funds provided by the Federal Government, in collaboration with the provinces and territories to transform health care through health information technology
Canadian Cancer Society
Toronto, Canada
Societies and NGOs Patient Disease Advocacy
Societies and NGOs - Research Funding
The Canadian Cancer Society is a national community-based organization dedicated to preventing cancer, saving lives and supporting people living with cancer through research funding, services and advocacy. We are Canada’s largest charity fighting all types of cancer and the leading authority on cancer statistics and information.
The Canadian Institutes of Health Research (CIHR) is the Government of Canada’s health research investment agency.
CIHR was created in 2000 under the authority of the Canadian Institutes of Health Research Act. It is an independent agency and is accountable to Parliament through the Minister of Health.
Its mission is to create new scientific knowledge and to enable its translation into improved health, more effective health services and products, and a strengthened Canadian health care system.
Composed of 13 Institutes, CIHR provides leadership and support to health researchers and trainees across Canada.
CIHR is part of the Health Portfolio which supports the Minister of Health in maintaining and improving the health of Canadians. For more information on the Health Portfolio, visit Health Canada.
Canadian Organization for Rare Disorders
Toronto, Canada
Societies and NGOs Patient Disease Advocacy
Umbrella organization for patient organizations providing services and support to rare diseases; CORD is engaged in policy, research support, organizational development and patient support
Founded in 2011, Cancer Commons is a non-profit network of cancer patients, physicians, and scientists dedicated to improving outcomes through precision oncology. Our mission is to ensure that patients are treated in accord with the latest knowledge available, and to continually update that knowledge based on each patient’s response. By tightly integrating research and care around individual patients, Cancer Commons aims both to dramatically improve individual outcomes and slash the time and cost of drug development.
Cancer Genomics Consortium
New Orleans,, United States
Research Collaboration or Consortium
Clinical Collaboration
The Cancer Genomics Consortium (CGC) is a collaboration of clinical cytogeneticists, molecular geneticists, and molecular pathologists, who are interested in applying genomic technologies to cancer diagnosis and cancer research. CGC is committed to providing high quality education and promoting best practices in clinical cancer genomics.
Since its inception, the CGC has hosted seven annual meetings bringing together the clinical genomics community to educate for best practices. This has led to numerous collaborations including the first CGC-sponsored multicenter cross-platform cytogenomic microarray study, published in Cancer Genetics in 2015. The CGC has more than 300 members from over 150 organizations in the U.S., Canada, and abroad.
Cancer Research Malaysia is a non-profit organisation funded by donations and grants to conduct research to identify better ways to prevent, detect and cure cancer for Malaysians.
Cancer Research UK is the world’s leading cancer charity dedicated to saving
lives through research. Our vision is to bring forward the day
when all cancers are cured.
CanDIG (Canadian Distributed Infrastructure for Genomics)
Toronto, Canada
Research Collaboration or Consortium
Research Institute
CanDIG connects Canada’s health research genomics data. With nodes at McGill, The Hospital for Sick Children, University Health network, and the Canada’s Michael Smith Genome Sciences Centre, CanDIG connects Canada’s largest health sequencing centres. The CanDIG platform allows queries and analyses of distributed national data sets while data remains under the control of local custodians.
CapitalBio Technology is an industry-leading life science company that develops and commercializes total health-care solutions. Our company provides a comprehensive portfolio of top-quality products to a diverse customer base ranging from biomedical researchers to healthcare professionals. Our products include an innovative and broad spectrum of microarray and microfluidic chips and related instruments, software and databases, reagents and consumables for basic and translational research, drug development, clinical diagnostics, biosafety and food safety, and molecular breeding.
In the ever-evolving and complex clinical research landscape, CDISC provides critical clarity. We develop and advance data standards of the highest quality to transform incompatible formats, inconsistent methodologies, and diverse perspectives into a powerful framework for generating clinical research data that is as accessible as it is illuminating.
CDISC convenes a global community of research experts representing a range of experiences and backgrounds. Each brings a vision, we bring the blueprint. They develop the data, we develop the platform. They provide the insights, we provide the focus. With everyone contributing their unique strengths, we’re able to harness our collective power to drive more meaningful clinical research.
CEMIC is a Leading and Referring Institution in the area of health, which, faithful to its style and its foundational objectives of excellence in teaching, research and assistance, is characterized by being a trainer of human resources and being at the service of the community and Of its members
CEMIC has as Mission Teaching and Research to Improve Medical Assistance, framed in a climate of creative work, with attitude of growth, improvement and efficiency and sustained in high ethical values.
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
Vienna, Austria
Research Institute
CeMM is an interdisciplinary research institute of the Austrian Academy of Sciences committed to advancing the understanding of human diseases through basic and biomedical research. Located in a tailor-made building in the midst of the campus of the Medical University of Vienna, Austria, CeMM is dedicated to its mission statement “from the clinic to the clinic” and fosters a highly collaborative and interactive research mindset.
CeMM currently hosts 10 principal investigators, one adjunct principal investigator and three group leaders. Focusing on medically relevant questions, CeMM researchers concentrate on human biology and diseases like cancer and inflammation/immune disorders. In support of scientific pursuits and medical needs, CeMM provides access to cutting-edge technologies and has established a strategic interest in personalized medicine.
The Center for Cancer Research & Therapeutic Development at Clark Atlanta University focuses on reducing the burden of prostate cancer disparities through research, outreach, & education.
Center for Risk Governance in the School of Public Policy and Management, Tsinghua University
Beijing, China
Research Institute
Center for Risk Governance in the School of Public Policy and Management, Tsinghua University (“Tsinghua SPPM-Center for Risk Governance”) was founded in 2013 by the School of Public Policy and Management, Tsinghua University and other institutions and scholars engaged in risk related research in China, under the support of the Ministry of Science and Technology of the People’s Republic of China. Tsinghua SPPM-Center for Risk Governance is hosted by the School of Public Policy and Management, Tsinghua University. It runs as an academic network member of International Risk Governance Council (IRGC) and works closely with both IRGC and its other network members.
The Centre for Cancer Biology carries out a world-class program of innovative research, making breakthrough discoveries in the fundamental causes of cancer, and translating these discoveries into new ways to prevent and treat this disease.
Established in partnership with SA Pathology and now embarking on a significant cooperative partnership with the University of South Australia, our laboratories carry out research in the areas of gene regulation, molecular signalling, disease-specific research, translational oncology and cancer genomics.
In addition to these laboratories, our ACRF Genomics Facility is providing access to state-of-the-art genomics research equipment, computing technology and bioinformatics expertise to the Centre for Cancer Biology and the wider research community.
Translation of new discoveries into clinical practice is strengthened by the co-localization of the laboratories within a single centre, as well as its proximity to the Royal Adelaide Hospital along with its clinical resources, the University of South Australia and the University of Adelaide, with which it shares key research facilities.
The CCB also has alliances with leading pharmaceutical companies to rapidly exploit new discoveries. The Centre aims to be a hub of internationally recognized cancer research “excellence”, achieving tangible outcomes for cancer patients.
Centre for Genetics Education NSW Health
St Leonards, Australia
Genomics Education Provider - Public Health
Research University
The Centre for Genetics Education (CGE) is the education arm of New South Wales (NSW) Clinical Genetics Services and is based at Royal North Shore Hospital in Sydney, Australia. Objectives: – Prepare health professionals with the knowledge and skills required to implement genetics and genomics effectively in their clinical practice – Contribute to relevant policy development at state and national levels and provide leadership in genetics and genomics education – Promote appropriate and equitable access to genetic services for the people we serve. CGE continues to update and build on established patient resources and programs, respond to education requests in priority areas, participate in research and work closely with key partners.
The Centre for Genomic Regulation (CRG) is an innovative centre for basic research created in December 2000 by initiative of the former Department of Universities, Research and Information Society (DURSI) of the Catalan Government. The CRG is legally constituted as a non-profit foundation and has the participation from the Catalan Government through the Economy and Knowledge Department (DECO) and the Health Department (DS), as well as from the Pompeu Fabra University (UPF), and the Spanish Ministry of Economy & Competitiveness (MINECO).
It is an international biomedical research institute of excellence whose mission is to discover and advance knowledge for the benefit of society, public health and economic prosperity.
The CRG believes that the medicine of the future depends on the groundbreaking science of today. This requires an interdisciplinary scientific team focused on understanding the complexity of life from the genome to the cell to a whole organism and its interaction with the environment, offering an integrated view of genetic diseases.
Centre for Personalised Immunology
Canberra, Australia
Research Collaboration or Consortium
Research University
The overarching goal of the Centre for Personalised Immunology (CPI) is to implement a novel human genomics pipeline from genetic discovery to clinical practice. The CPI brings together teams with track records of discovery of immunological disease in adults and children in order to consolidate our national effort to elucidate the pathophysiology of immune-mediated diseases. It will enhance capacity for the application of genomics not only to unexplained Mendelian immune disorders, but also to severe sporadic disease and more common syndromes of inflammation and autoimmunity.
The Centre of Genomics and Policy works at the crossroads of law, medicine, and public policy. Applying a multidisciplinary perspective and collaborating with national and international partners, the CGP analyzes the socio-ethical and legal norms influencing the promotion, prevention and protection of human health.
Currently, the CGP’s research covers six areas of genomics and policy: stem cell research and therapies, pediatrics, privacy, cancer, intellectual property, and biobanks (population genetics). These domains are approached using three guiding foundations: internationalization, policy development and knowledge transfer. First, CGP promotes internationalization by undertaking comparative analyses of policies and guidelines around the world. Secondly, CGP actively participates in the creation of international consortia with a view to promoting multidisciplinary policymaking. Finally, via the HumGen law and policy database, the CGP promotes knowledge transfer.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER)
Madrid, Spain
Research Collaboration or Consortium
Healthcare Research
The Centre for Biomedical Network Research on Rare Diseases (CIBERER) is the network centre devoted to rare diseases biomedical research of the CIBER Consortium depending on the Carlos III Health Institute (Ministry of the Economy and Competitiveness).
CIBERER consists of a team of over 700 professionals and integrates 62 research groups and 20 Clinical Collaborating Groups (belonging to the National Health System), being the reference centre in Spain for research into rare diseases. CIBERER’s competitive advantage stems from being the only state centre able to agglutinate the knowledge generated by diversified and network research activity, which is vital in tackling the problem of rare diseases.
CENTRO DE INVESTIGACION Y DESARROLLO EN CIENCIAS DE LA SALUD, UNIVERSIDAD AUTONOMA DE NUEVO LEON
MONTERREY, Mexico
Research University
The Centro de Investigacion y Desarrollo en Ciencias de la Salud of the Universidad Autonoma de Nuevo Leon (CIDICS) is a high-technology and high-performance facility aimed at a broader understanding of health problems and challenges constituted by independent groups working together under an inter-disciplinary problem-solving approach.
The CNAG was created on 2009 with the mission to carry out projects in DNA sequencing and analysis in collaboration with researchers from Catalonia, Spain and from the international research community.
At Cerner, we’re continuously building on our foundation of intelligent solutions for the health care industry. Our technologies connect people and systems at more than 27,000 provider facilities worldwide, and our wide range of services support the clinical, financial and operational needs of organizations of every size. Together with our clients, we are creating a future where the health care system works to improve the well-being of individuals and communities. By designing leading-edge health information technology, we offer strategies that enable organizations to know, manage and engage their populations. Our applications are developed with clinicians in mind so they can focus on people, not technology. And providers can manage their day-to-day revenue functions with our integrated clinical and financial systems. These helpful tools are designed to work for today and think for tomorrow. From the beginning, we have innovated at the intersection of health care and information technology. Our mission remains to contribute to the systemic improvement of health care delivery and the health of communities
Chelonia SA
Lugano, Switzerland
Companies Life Science
Investment & Advisory firm in Life Science industry
Chelonia SA is the Swiss investment and advisory firm focused on Life Science industry, internationally. The corporation is a 2002 spin-out of a venture partially owned by Nomura, Japanese Bank, and Mr. Silvano Coletti serial entrepreneur in Life Science and more in details genomics and drug discovery. Headquartered in Lugano, Chelonia partners mid-sized and large Pharma corporations and biotech ventures. Actually Chelonia is managing also one of the largest and global network of technology transfer offices. The portfolio of equity participations include investment in DNA testing service companies.
The Zero Childhood Cancer Personalised Medicine Program (ZCC), jointly led by Children’s Cancer Institute and Kids Cancer Centre, Sydney Children’s Hospital, is one of the most comprehensive personalised medicine programs internationally, combining molecular genomic analysis (Whole Genome Sequencing (tumour, germline DNA), whole transcriptome (RNASeq), and methylation profiling), together with in vitro drug testing of over 100 potential drugs, and drug response modelling in Patient Derived Xenograft (PDX) in vivo models, to
identify most effective personalised treatments for every Australian high-risk child cancer patient. A Multidisciplinary Tumour Board (MTB) reports evidence-based treatment recommendations to treating oncologists in a clinically actionable timeframe, providing them with the opportunity to alter the management of their patients.
We have established numerous collaborations nationally and globally, and are a partner in the NHMRC Australian Genomics Health Alliance.
You may find more information about Children’s Cancer Institute and Zero Childhood Cancer at the following URL’s:
• www.zerochildhoodcancer.org.au
• www.ccia.org.au
The Zero Childhood Cancer Personalised Medicine Program (ZCC), jointly led by Children’s Cancer Institute and Kids Cancer Centre, Sydney Children’s Hospital, is one of the most comprehensive personalised medicine programs internationally, combining molecular genomic analysis (Whole Genome Sequencing (tumour, germline DNA), whole transcriptome (RNASeq), and methylation profiling), together with in vitro drug testing of over 100 potential drugs, and drug response modelling in Patient Derived Xenograft (PDX) in vivo models, to
identify most effective personalised treatments for every Australian high-risk child cancer patient. A Multidisciplinary Tumour Board (MTB) reports evidence-based treatment recommendations to treating oncologists in a clinically actionable timeframe, providing them with the opportunity to alter the management of their patients.
We have established numerous collaborations nationally and globally, and are a partner in the NHMRC Australian Genomics Health Alliance.
You may find more information about Children’s Cancer Institute and Zero Childhood Cancer at the following URL’s:
• www.zerochildhoodcancer.org.au
• www.ccia.org.au
Peking Union Medical College Hospital (PUMCH), an institutional Faculty of Clinical Medicine affiliated to both Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS), is a renowned general hospital in China with a prestigious historical background. Designated by Ministry of Health, PUMCH is the national medical technical support center for diagnosis and treatment of severe and complicated diseases. Founded by Rockefeller Foundation in 1921, the hospital, with its gathering of notable experienced physicians, medical professionals and scientific researchers of various specialties, has maintained its leading position as one of the top-ranked hospitals in China for over 80 years. PUMCH consists of a complete spectrum of specialties with excellent, strong clinical foundations and expertise. Equipped with the most advanced medical equipments and technologies in China, the hospital, famous for its outstanding clinical professional cooperation amongst different specialties, maintains a primary role above all other hospitals in China in terms of medical treatment, scientific research and medical education.
After 85 years of development, PUMCH not only expanded in terms of experience accumulation, but also developed a completely unique medically professional culture. All medical records from history are meticulously preserved since hospital establishment, PUMCH’s library stores a prolific amount of medical records and papers in various languages, and numerous professors arc acting as national leaders in various medical specialties. PUMCH holds itself high and proud with the hospital motto, “strict assiduousness, advancement, diligence and devotion”, these exact words represents the unique PUMCH family culture generation after generation.
The PUMC Hospital consists of two campuses comprising over 170,000m2 of clinical and research working area, 1800 hospital beds, with more than 40 medical equipments and apparatus valuing over RMB 2 million as well as approximately 10 medical apparatus valued over RMB 10 million. There are 40 clinical departments and 15 adjunct departments, including 10 national key disciplines (in 12 departments) and 2 municipal key disciplines. A hospital based research center was introduced through a modern Central Lab, Clinical Trial Research Base, and the Animal Research Laboratory. Over the past decade, patient visits steadily increased, last year alone tallying up to 1,850,000 outpatient visits, 48,000 inpatient admissions and 28,000 surgical operations, with inpatient admission occupancy above 90%.
PUMCH includes 3,980 staff members, including 500 professors and associate professors and including one Chinese Academy of Sciences academician and two Chinese Academy of Engineering academicians. Fifty-seven professors serve as honorary presidents, presidents or vice-presidents in various Chinese Medical Association (CMA) specialty societies and/ or the Chinese Hospital Association (CHA), with 36 professors residing over the CMA’ s Beijing Branch. Moreover, 46 professors serve as editor-in-chief or vice editor-in-chief in over 79 state-level medical journals.
As the CAMS Institute of Clinical Medicine, the hospital has always attached great importance to scientific research. In the past 20 years, over 20 research projects received National Science and Technology Progress Awards, and 95 research projects receive ministry level or provincial awards. Within recent 5 years, the hospital conducted over 120 research projects at state level and over 130 projects at a ministry/ provincial level, including 84 projects funded by the NSCF (National Natural Science Foundation of China). Over 4000 research papers published in major Chinese or foreign medical journals within recent years.
As PUMC’s Faculty of Clinical Medicine, the hospital places great effort upon basic and continued medical education and training, emphasizing upon basic principles, methodology, training individual independence. Resident on the job training programs as well as post-graduate training programs arc amongst the most intensive and competitive nationwide. For several decades, the hospital trained numerous outstanding medical professionals, displaying an important and leading role in the development of medical sciences in China.
The hospital has 71 doctor degree mentors for 13 programs and 149 master degree mentors for 19 programs. PUMC post-doctoral training program in clinical medicine is located within PUMCH. As one of the national top-ranked clinical training centers, the hospital provides advanced training to over 600 physician fellows and 300 nursing fellows from various nationwide hospitals annually.
Within the last decade alone, PUMCH received about 20 medals or certificates from Central Government agencies and local government agencies, such as”Top Ten Hospitals in Beijing”and “Top 100 National hospitals”, bestowing great honor and pride upon the hospital for its outstanding medical service and quality patient care.
Currently, the PUMCH Healthcare Center will be established on a 75,000m2 foundation, and the construction of outpatient and surgical buildings will be built over 220,000m2. Upon completion of the two complexes, patient service, research and educational environment will greatly improve, providing an elevated plateau and quality standard for patient care, contributing to medical research and the education of medical professionals.
The Chinese Academy of Sciences is the linchpin of China’s drive to explore and harness high technology and the natural sciences for the benefit of China and the world. Comprising a comprehensive research and development network, a merit-based learned society and a system of higher education, CAS brings together scientists and engineers from China and around the world to address both theoretical and applied problems using world-class scientific and management approaches.
Children’s Hospital of Philadelphia is a leading pediatric hospital in US and the within the Genetics Department, our team is focussed on harmonizing the genomic efforts with other research collaborators or institutions.
We provide whole genome and epigenetic testing services direct-to-consumer. We do this to provide people with proactive and personalised information about how their DNA, environment and lifestyle is impacting their health and wellbeing.
CHU Sainte-Justine, the largest mother-child university hospital in Canada, is an internationally recognized leader in pediatric and maternal health research. CHU Sainte-Justine is responsible for the diagnosis and treatment of ~70% of the more serious childhood diseases in Quebec (8M people) providing access to a critical number of patients, especially for genomic studies. In 2014, CHU Sainte-Justine launched Canada’s first integrated clinical genomics centre in pediatrics through a strategic partnership with Genome Quebec.
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
Research University
Healthcare Research
Cincinnati Children’s, a nonprofit academic medical center established in 1883, is one of the oldest and most distinguished pediatric hospitals in the United States.
Clinical Services
We offer comprehensive clinical services, from treatments for rare and complex conditions to well-child care. In the 2015-16 U.S. News & World Report survey of best children’s hospitals, Cincinnati Children’s ranked No. 3 among all Honor Roll hospitals.
With more than 600 registered beds, Cincinnati Children’s had more than 1.1 million patient encounters and served patients from all 50 states and 57 countries in fiscal 2014.
Through an academic affiliation dating to 1926, Cincinnati Children’s comprises the Department of Pediatrics at the University of Cincinnati College of Medicine. We train more than 600 residents and clinical fellows a year in various pediatric specialties and offer some of the most highly ranked research-based education and training programs in the nation.
We have been an important force in pediatric research since the opening of the Cincinnati Children’ Research Foundation in 1931. Grant funding for our research has more than tripled in the last 15 years, supporting countless discoveries and the continued expansion of our areas of research.
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
Research University
Healthcare Research
Cincinnati Children’s, a nonprofit academic medical center established in 1883, is one of the oldest and most distinguished pediatric hospitals in the United States.
Clinical Services
We offer comprehensive clinical services, from treatments for rare and complex conditions to well-child care. In the 2015-16 U.S. News & World Report survey of best children’s hospitals, Cincinnati Children’s ranked No. 3 among all Honor Roll hospitals.
With more than 600 registered beds, Cincinnati Children’s had more than 1.1 million patient encounters and served patients from all 50 states and 57 countries in fiscal 2014.
Through an academic affiliation dating to 1926, Cincinnati Children’s comprises the Department of Pediatrics at the University of Cincinnati College of Medicine. We train more than 600 residents and clinical fellows a year in various pediatric specialties and offer some of the most highly ranked research-based education and training programs in the nation.
We have been an important force in pediatric research since the opening of the Cincinnati Children’ Research Foundation in 1931. Grant funding for our research has more than tripled in the last 15 years, supporting countless discoveries and the continued expansion of our areas of research.
Clarivate Analytics accelerates the pace of innovation by providing trusted insights and analytics to customers around the world, enabling them to discover, protect and commercialize new ideas, faster.
Cleveland Clinic Abu Dhabi
Abu Dhabi, United Arab Emirates
Healthcare Care Delivery
Healthcare Care Delivery
Cleveland Clinic Abu Dhabi offers genetic services through its various institutes. We are planning to start a Genomic Medicine program through our Executive Health services.
Clinical Genome Resource (ClinGen)
Washington D.C., United States
Research Collaboration or Consortium
The Clinical Genome Resource (ClinGen), launched in 2013, is an NIH-supported program to build an authoritative central resource that defines the clinical relevance of genomic variants for use in precision medicine and research.
ClinIQ Inc is a digital health company aiming to provide digital ambulatory care. We were working on an Anaesthesia product but had pivoted to provide VirusIQ screening platform – our public health screening project. We hope to create a universal risk mitigation service for early detection, prevention and containment of viral outbreaks.
Coalition of Heritable Disorders of Connective Tissue
Washington D.C., United States
Societies and NGOs Patient Disease Advocacy
In 1989 test test organizations representing constituents with various heritable connective tissue disorders joined together to form the Coalition for Heritable Disorders of Connective Tissue (CHDCT).
The goals of CHDCT are to bring about greater awareness and understanding of heritable disorders of connective tissue in medical professions and in the public at large; to encourage teaching in the schools, to train health practitioners to help identify, diagnose, and treat various heritable connective tissue disorders; and, to foster research. Members of CHDCT believe that research on one disorder can be helpful to many.
COMMUNITY AND FAMILY AID FOUNDATION
ACCRA, Ghana
Societies and NGOs Patient Disease Advocacy
Societies and NGOs Professional
Community and Family Aid Foundation is a Ghanaian registered NGO (Number 21 446/10/86) working in GHANA and the sub-region. It’s exclusively identified with promoting the empowerment of youth, women, communities, young people to manage issues concerning their development and to advocate for and work towards health, genomics and its impact on health, policies ,reforms, HRH, rights and well-being, to advocate for and on behalf of young people, in the area of , environmental health education, and other related issues that affect their total development.
“Complete Genomics is a leader in whole human genome sequencing based in Mountain View, California. Using its proprietary sequencing instruments, chemistry, and software, the company has sequenced more than 20,000 whole human genomes over the past three years. The company’s mission is to improve human health by providing researchers and clinicians with the core technology and commercial systems to understand, prevent, diagnose, and treat diseases and conditions.
Complete Genomics joined the BGI family of companies in March 2013. BGI is the world’s largest genomics services company headquartered in Shenzhen, China, providing comprehensive sequencing and bioinformatics services for commercial science, medical, agricultural, and environmental applications. BGI’s mission of supporting the development of science and technology, building strong research teams, and promoting the development of scientific partnership in the genomics field aligns with Complete Genomics’ focus.”
Complex Biological Systems Alliance
North Andover, United States
Research Collaboration or Consortium
The Complex Biological Systems Alliance (CBSA) is a global research consortium investigating fundamental questions in biology and medicine. The Alliance is a unique, independent non-profit 501(c)(3) platform for advanced scientific discourse and discovery. The CBSA hosts an international multidisciplinary team of investigators accomplished in a broad spectrum of disciplines, representing all aspects of the physical and life sciences.
The CBSA is an organizational member of the Global Alliance for Genomics and Health, an international coalition dedicated to improving human health by maximizing the potential of genomic medicine through effective and responsible data sharing. The CBSA is also a recognized Extreme Science and Engineering Discovery Environment (XSEDE) Campus. Through the XSEDE Campus Champions Program, the Alliance provides its investigators with direct access to a national consortium of supercomputing facilities supported by the National Science Foundation.
The mission of the CBSA is to further scientific understanding of biological complexity and the nature and origins of human disease. To this end, the Alliance is developing advanced data analytics software and novel experimental methods, thus placing its investigators on the cutting edge of discovery and expediting scientific publication of their research.
CBSA investigators theorize that a proposed inherent thread of molecular information is the ‘organizing principle’ in biology, linking apparently unrelated biologic phenomena across the three cellular domains of life on the planet. The CBSA is systematically studying pathologic regulation of this proposed molecular network across diverse human disorders in order to better understand human disease initiation and progression and to develop new therapeutic applications.
Comprehensive Cancer Center Network of German Cancer Aid
Heidelberg, Germany
Societies and NGOs Patient Disease Advocacy
The Comprehensive Cancer Center Tübingen (CCC-T) has made it its prime business to research this disease, to promote multi-professional co-operation, and to ensure the best possible treatment and support for cancer patients. The information on our web pages is therefore intended for patients and their relatives, as well as for physicians, nursing staff, researchers and the interested general public.
Concierge Health was developed by multiple, senior Harley Street clinicians and doctors. We provide a full range of DNA and genetic testing to assist in developing personalised treatment programmes focused on disease and cellular ageing prevention. We advocate regular genetic testing (including telomere testing) to measure the impact of our programmes at cellular level.
Congenica is a UK start-up bioinformatics company founded on pioneering research from the Wellcome Sanger Institute, NHS clinicians and genetic testing laboratories.
Our mission is to improve human health and personalised patient care by providing clinical genome analytics and clinical decision support for medical practitioners treating patients presenting with genetic disease, using our bioinformatics software, Sapientia. We aim to form strategic partnerships with leading clinical research and healthcare providers, charities and patient advocacy groups, pharmaceutical and diagnostic companies in order to develop new medical paradigms in orphan disease to transform the lives of patients.
Coral Health Research & Discovery Inc.
Vancouver, Canada
Companies Information Technology
Healthcare Delivery
Healthcare data today is siloed within organizations where they are typically stored unencrypted in central Oracle servers. Coral Health is using blockchain technology to create an accessible, secure, and scalable healthcare ecosystem that will address many of the current problems facing the industry and incrementally power the widespread adoption of personalized medicine. All data entered into the Coral Health system will be uploaded with key metadata that will allow participants – such as health authorities and genomics researchers – to perform informative research at the aggregate level, but will not reveal any identifying information on an individual basis. By facilitating access to genomic data from disparate studies, Coral Health’s network redueces the amount of redundant genome sequencing across studies. This will free up funds for new research, accelerate our understanding of the human genome, and drive further diagnostic and therapeutic discovery.
Coral Health Research & Discovery Inc.
Vancouver, Canada
Companies Information Technology
Healthcare Delivery
Healthcare data today is siloed within organizations where they are typically stored unencrypted in central Oracle servers. Coral Health is using blockchain technology to create an accessible, secure, and scalable healthcare ecosystem that will address many of the current problems facing the industry and incrementally power the widespread adoption of personalized medicine. All data entered into the Coral Health system will be uploaded with key metadata that will allow participants – such as health authorities and genomics researchers – to perform informative research at the aggregate level, but will not reveal any identifying information on an individual basis. By facilitating access to genomic data from disparate studies, Coral Health’s network redueces the amount of redundant genome sequencing across studies. This will free up funds for new research, accelerate our understanding of the human genome, and drive further diagnostic and therapeutic discovery.
Coriell Institute for Medical Research, founded in 1953 and based in Camden, New Jersey, is an independent non-profit research center dedicated to the study of the human genome. Expert staff and pioneering programs in the fields of personalized medicine, cell biology, cytogenetics, genotyping, and biobanking drive our mission.
Coriell Life Sciences
Camden, United States
Companies Genomic Analysis
Companies Information Technology
Coriell Life Sciences is expert in advising physicians on how to use genomics to understand what medications will work for their patients and which will cause harm. Through partnerships with IBM and sequencing laboratories, CLS has developed an entirely SaaS based platform for drug efficacy reporting that is inexpensive, reimbursed by MediCare and most carriers and provides immediate patient outcome benefit and financial savings.
Council For Bile Acid Deficiency Diseases
Rockville, United States
Societies and NGOs Patient Disease Advocacy
The Council for Bile Acid Deficiency Diseases is an organization that promotes a public understanding of various bile acid deficiency diseases focusing on the need for new diagnostic methods and treatments.
In particular, we strive to increase public awareness of Bile Acid Deficiency Diseases, a group of disorders that have been known to cause poor absorption of nutrients, poor growth and progressive liver failure in afflicted patients.
Counsyl
South San Francisco, United States
Companies Genomic Analysis
Companies Information Technology
Counsyl is a health technology company that offers DNA screening for men, women, and their children. Our philosophy is simple: focus on diseases where advanced knowledge makes a difference in health outcomes, whether it’s changing a behavior, pursuing preventative measures, or simply preparing for what lies ahead.
Genomics, bioinformatics and Molecular diagnostics
Established in 1998, Crown Healthcare is a well known and trusted name amongst Hospitals and Government Bodies in East Africa. With an experience of 20 years Crown Healthcare has grown to be the premier solutions provider for Medical Equipment and Supplies within the region. Crown Healthcare has the flexibility and experience to respond to healthcare needs at all levels, from the smallest local facility to projects on a national scale. With a wide range of in-house stocks at our premises, we are also able to deal with rapid reaction to emergency situations, as well as long term requirements. Whether you are looking to equip a healthcare centre or implement a national project, Crown Healthcare is able to respond with the correct quality at internationally competitive pricing. All, that is backed up by a team of professionally factory trained engineers. Know as a partner that shall deliver with value and on time.
CRS4, the Center for Advanced Studies, Research and Development in Sardinia, was founded in 1990 and is now one of the leading centres in Italy for research and development activities in information technology, bioinformatics, distributed and high-performance computing (HPC). CRS4’s research activities focus on the development of enabling technologies, physical and mathematical modelling, and computing science in high priority areas recognized as strategic at the regional, national and European levels. Current computating resources include hundred-teraflop conventional and hybrid (CPU+GPU) HPC clusters and multi-petabyte parallel and conventional storage systems. The centre is connected by a very high speed connection — multiple 10Gb lambdas — to the regional research network and to GARR, the national research network. To bridge the gap from biology to computation, the centre hosts a high-throughput genotyping and deep sequencing facility that is directly connected to its computational resources. These resources are employed on a number of fronts, ranging from the development of suites of high-throughput applications for large-scale genome-wide association studies (i.e., using MapReduce or multi-GPU multi-core systems) to the development of semantic-aware interconnections to clinical data systems based on international standards such as HL7 and openEHR.
CSIR Institute of Genomics and Integrative Biology
DELHI, India
Research Institute
Healthcare Research
CSIR-Institute of Genomics & Integrative Biology (IGIB) is a premier Institute of Council of Scientific and Industrial Research (CSIR), engaged in research of national importance in the areas of genomics, molecular medicine, bioinformatics and proteomics.
Our mission: “To translate concepts developed in basic biological research to commercially viable technologies for health care”
We’re an Australian Government corporate entity, with a Board and Chief Executive. We’re constituted by and operate under the provisions of the Science and Industry Research Act 1949 , which sets out our functions and powers, as well as those of our Minister, Board and Chief Executive. The governance, performance and accountability of our operations, including the use and management of public resources are set out in the Public Governance, Performance and Accountability Act 2013 and related rules.
The Science and Industry Research Act 1949 defines our purpose and the functions we undertake for the benefit of Australia:
To carry out scientific research for any of the following purposes:
Assisting Australian industry;
Furthering the interests of the Australian community;
Contributing to the achievement of Australian national objectives or the performance of the national and international responsibilities of the Commonwealth; and
Any other purpose determined by the Minister;
To encourage or facilitate the application or utilisation of the results of such research.
Our secondary functions include international scientific liaison, training of research workers, publication of research results, technology transfer of other research, provision of scientific services and dissemination of information about science and technology.
We operate through three lines of business:
Impact science: Nine national research business units with focus on the biggest challenges facing the nation.
National Facilities and Collections: We manage infrastructure and biological collections for the benefit of research and industry.
CSIRO Services: Commercial, customer-centric products and services for industry, government and the community.
CSIRO. We imagine. We collaborate. We innovate.
Cures Within Reach
Skokie, United States
Societies and NGOs Patient Disease Advocacy
Healthcare Research
Cures Within Reach catalyzes repurposing research to quickly and affordably improve patient lives. We connect researchers and funders, facilitate crowd sourcing and community, and identify alternative financing models and incentives. Repurposing tests existing drugs and devices to create treatments for unsolved diseases.
Curoverse, Inc.
Boston, United States
Companies Information Technology
Curoverse provides an open source platform for conducting clinical research and delivering health care with genomic and other forms of biomedical data. Based on the Arvados project, the platform gives organizations powerful capabilities for managing data, running reproducible pipelines, doing real-time genomic analysis, and distributing analyses across datasets stored at multiple institutions. The system is designed to support the emerging API standards for the Global Alliance, and it runs both on premise and on public clouds.
Cypher Genomics
San Diego, United States
Companies Genomic Analysis
Companies Information Technology
Cypher Genomics is a leading genome informatics company offering a highly accurate, rapid and robust interpretation software solution for users of human genome sequencing. The proprietary, automated genomic interpretation platform allows clinical laboratories to tune Cypher Genomics’ market leading sensitivity and specificity profiles to develop molecular tests for diagnostic and prognostic use and pharmaceutical companies to discover biomarkers from genome sequence data in sample sizes typical of early stage drug development studies. Through Mantis™, the genome interpretation software as a service offering, and Coral™, a biomarker discovery service, Cypher Genomics can improve health care and reduce costs by facilitating improved diagnostic accuracy and earlier interventions, optimizing therapeutic approaches and reducing adverse drug reactions. Cypher Genomics is located in San Diego, California.
Cancer research and clinical care institution; a primary teaching affiliate of Harvard Medical School
Danish National Genome Center
København (Copenhagen), Denmark
Research Institute
Healthcare Research
Danish National Genome Center is a new government agency and an authority within the Danish Healthcare system. Danish National Genome Center’s primary task is to lay the foundation for the development of better diagnostics and more targeted treatments for patients using whole-genome sequencing (WGS).
Dante Labs mission is to make advanced genomic testing accessible to everyone. We offer direct-to-consumer genetic tests at affordable prices.
Data Fellas is a data first company.
We develop solutions for data analysis at small or large scale.
Data Fellas focuses its activities at adding value to existing data using cutting edge machine learning models, scalable technologies and advanced analytics methods like probabilistic programming.
Our preferred domain of activity is health, beginning with genomics. We developed the only scalable interoperable solution to share genomics data, the Med@Scalle project (https://github.com/med-at-scale/).
Med@Scale implements the GA4GH specifications and uses ADAM to scale at any dimensions.
At Data4Cure we believe in changing the way we acquire, process and apply biomedical knowledge. With the Biomedical Intelligence(TM) platform we provide a data-driven system equipped with a map of human biology that is inferred and continuously updated from large multidimensional omics data. Our platform helps research and clinical organizations establish a perpetual cycle of data accumulation, knowledge discovery and application to ultimately improve patient care.
Database Center for Life Science, Research Organization of Information and Systems
Kashiwa, Japan
Research Institute
DBCLS/ROIS has been promoting research and development to realize the integration of life science databases since 2006 and is currently trying to adopt RDF technology for database integration. We are a collaborative member of the “Life Science Database Integration Project” conducted by the National Bioscience Database Center/Japan Science and Technology Agency.
Databiology
San Francisco, United States
Companies Information Technology
Companies Information Technology
Databiology is a software company delivering biomedical information management and orchestration for the life sciences and healthcare sectors. Databiology’s platform functions as a central data and analysis management hub for conducting end-to-end biomedical research, sitting at the intersection between an organization’s data, analytics applications and technology infrastructure.
DataDirect Networks (DDN) is the world leader in massively scalable storage. Our data storage and processing solutions and professional services enable content-rich and high growth IT environments to achieve the highest levels of systems scalability, efficiency and simplicity. DDN enables enterprises to extract value and deliver business results from their information. Our customers include the world’s leading online content and social networking providers, high performance cloud and grid computing, life sciences, media production, and security and intelligence organizations. Deployed in thousands of mission critical environments worldwide, DDN’s solutions have been designed, engineered and proven in the world’s most scalable data centers to ensure competitive business advantage for today’s information powered enterprise.
Datar Genetics is a leading provider of clinical genetics and genomics services in India and pioneering precision medicine across several therapeutic areas such as oncology, cardiology, neuro-psychiatry and neonatal screening.
DeepMed I/O is a newly founded personalised medicine company based in the UK. Our mission is to use AI to deliver personalized care solutions for patients, thus prolonging their survival and improving their quality of life. Our exceptional team of experienced bioinformaticians and machine learning experts utilize state of the art tools such as Association Rule Mining and Deep Learning to deliver predictive models with practical use in the clinic.
Department of Biosciences, Mohammad Ali Jinnah University
Karachi, Pakistan
Research University
Research University
Department of Biosciences, Mohammad Ali Jinnah University, Karachi, Pakistan is involved in genomic medicine research and teaching.
Department of Medical Genetics, Oslo University Hospital
Oslo, Norway
Healthcare Care Delivery
Healthcare Research
Department of Medical Genetics, Oslo University Hospital, is Norway’s largest medical genetics department, providing genetic services to approx 60% of Norway’s population (3 million people). The department covers all aspect of medical genetics services from laboratory diagnostics to clinical genetics and genetic counselling. The department has extensive research activities and is together with University of Oslo, running The Norwegian Sequencing Centre (www.sequencing.uio.no), the national research infrastructure for next generation sequencing.
Dhitiomics Technologies provides molecular diagnostic services, leveraging some of the most experienced researchers and experts in the field of genomics, healthcare and technology.
The team at Dhitiomics Technologies aims to provide deeper insight into diagnosis for rare and difficult diseases through clinical genomics, collaborating with subject matter experts, and provide personalized research to help patients and clinicians predict, prevent and pre-empt diseases better, to help make an informed choice for patients. Dhitiomics Technologies is currently supported by Genomics Labs @ Genotypic Technology, Bengaluru
An Israeli innovative startup developing the Genetic Ecosystem Platform for digital genetics enabling anonymous genetics based on Distributed Ledger Technology.
DNAtix’s leadership team consists of experts in the fields of Genetics, Blockchain, Cyber Security,
encryption and Data Storage with the vision of reshaping Genetics and Medicine. The company’s advisory
board includes leading figures in Medicine, Law and Business Strategy. DNAtix is developing the leading
infrastructure and marketplace for the Genetic world based on advanced Blockchain technologies.
Digitalica Health is a technology based company that provides services and products for the biomedical informatics field as well as for personalised surgery processes. This company provides a set of tools focused on clinical trial management, research hipothesis generation and clinical decision support. We offer services to deploy them within your institution according to health informatics standards and applying best practice in clinical information modelling.
Our mission is to provide the knowledge to researchers and clinicians to understand the secrets of diseases from the analysis and use of biomedical “Big Data”. We provide solutions using deep learning to enable healthcare providers to improve clinical outcomes, clinical researchers to understand the information from Next Generation Sequencing (NGS) data and academics to gain insights into the biological data.
Launched in 1992, Discovery Health is South Africa’s largest healthcare administrator which also provides managed care services to over 2.9 million lives across 16 medical schemes. This includes the Discovery Health Medical Scheme, South Africa’s largest open medical scheme, covering more than 2.6 million lives.
The DLR Projektträger (DLR-PT) is a project management organization in the German Aerospace Centre (Deutsches Zentrum für Luft- und Raumfahrt e. V.). DLR-PT is a non-governmental, non-profit organization for the promotion of the sciences. It is mandated by the German Federal Ministry of Education and Research (BMBF) and other Federal Ministries for the implementation of programme-related research project funding. In this regard, PT-DLR is responsible for the administration of a funding budget of approximately more than 1 billion € per year and involved in a variety of research fields – amongst others: information technology, education research, and life sciences. Within life sciences, the health research department of DLR-PT promotes biomedical and clinical research, administrating an annual budget of about 200 million € on behalf of the BMBF.
DNA ID is a company designed for patients, to take back control of their health data. We have a core mission of helping medical research accelerate treatments by creating an open access data platform that puts control back in the patients hands. By operating as a marketplace, we are on the patients side, and helping patients have a voice in research is our main priority. Through patient-reported outcomes, passive data collection, patient registries, genomic and digital health data, we can put together a more complete picture of real world evidence.
DNAdigest
Great Shelford, United Kingdom
Societies and NGOs Professional
Research Collaboration or Consortium
The objectives of DNAdigest are to educate, facilitate, and engage on issues regarding access to genomic data for research. We are a non-profit organisation founded in Cambridge, UK. We are a community of individuals from diverse backgrounds who all want to see data used to its full potential for the benefit of patients.
DNAnexus provides a global network for sharing and management of genomic data and tools to accelerate genomic medicine. The DNAnexus cloud-based platform is optimized to address the challenges of security, scalability, and collaboration, for organizations that are pursuing genomic-based approaches to health, in the clinic and in the research lab. The DNAnexus team is made up of experts in computational biology and cloud computing who work with organizations to tackle some of the most exciting opportunities in human health, making it easier—and in many cases feasible—to work with genomic data. With DNAnexus, organizations can stay a step ahead in leveraging genomics to achieve their goals. The future of human health is in genomics. DNAnexus brings it all together.
DNArails focuses on big data analytics in genomics, assisting the interpretation of genetic variations, and providing the new insights into disease by machine learning. The mission of DNArails is to enhance the efficiency of biomedical research and clinical diagnosis.
DNArails Genomics Analysis Platform is a cloud-based genomics computing tool, designed to solve the above mentioned problems. DNArails Genomics Analysis Platform provides simplified data management and analytical sequencing data to gain meaningful insights in biomedicine through visualization and user-friendly interface
DNAstack develops a high performance, scalable solution for genomic data management, analysis, and visualization.
DNV GL
Oslo, Norway
DNV GL is a third party company offering accreditation and certification services across industries including healthcare.
DNV GL is a world-leading certification and risk management company, driven by the purpose of safeguarding life, property and the environment. They help businesses assure the performance of their organisations, products, people, facilities, and supply chains through certification, verification, assessment and training services. Operating in more than 100 countries, 15,000 professionals are dedicated to helping customers make the world safer, smarter and greener. DNV GL Business Assurance is currently certifying and accrediting 2400 healthcare providers worldwide, and is involved in testing and certification of the quality and safety of medical devices. DNV GL continuously invests in research and collaborative innovation to provide customers and society with operational and technological foresight.
NACG is an independent association open for organizational and individual members that brings together leading stakeholders in clinical genomics across the Nordics.
Mission: NACG partners work together and learn from each other to lift performance standards. We aim at responsible sharing of trustworthy data for improved diagnosis and treatment, and as a resource for research.
Focus is on practical collaboration through cross-disciplinary workshops and projects, and all outcomes are documented and made available to the public through the NACG website.
Dragon Master Foundation
Wichita, United States
Research Collaboration or Consortium
Funders and Agencies Private
Dragon Master Foundation strives to speed up biomedical discovery by facilitating basic research through big data sharing.
Our aim at DREAMgenics is to improve people’s life quality and health by focusing on:
– Making all genomic knowledge applicable to health issues available to doctors in such an easy and intuitive way that doctors can take advantage of the most recent advances in research issues thus enabling the development of Personalized Medicine.
– Helping scientists and pre-clinical researchers perform new breakthroughs to be used by doctors and specialists for a continuous health care improvement.
For all this, DREAMgenics develops clinic and research-oriented services and products under the common principle: a useful and clear genome interpretation directed to professionals.
We work with biopharmaceutical and other life science companies with services and solutions that improve your probability of success, connecting insights with superior delivery for better outcomes. Quintiles’ success begins and ends with your success. We share your goals and collaborate with you, bringing an industry recognized depth of expertise and breadth of perspective to shape better ideas. Our award-winning people, processes and technology drive predictable and efficient delivery around the globe. With more than 32,000 employees working in about 100 countries, we have helped develop or commercialize all of the top-100, best-selling drugs on the market in 2013. And it’s all done with an unwavering dedication to ethics and high quality, in the pursuit of success in human measures. – See more at: http://www.quintiles.com/about-us/our-focus#sthash.B4u62Rr4.dpuf
Eagle is a bioinformatics software and services company dedicated to accelerating the opportunities offered by genomics and new data generation technologies to address some of the world’s key challenges in healthcare, food and environment.
Eagle Nebula
Princeton, New Jersey, United States
Companies Genomic Analysis
Companies Genomic Analysis
In our team, leading bioinformatics scientists work closely with experienced software engineers and IT professionals. Our software engineering team gained their strong experience by working with the world’s major genome sequencing companies and precision medicine companies. Our team is passionate in working together in building the Eagle Nebula platform to support the future of genomics research
EdgeLeap is a data science company, offering innovative data solutions to life sciences industry. EdgeLeap provides expertise and technology for integration and mining of diverse large-scale biological data and current knowledge. We optimize our client’s data analytics processes by identifying opportunities to turn their data into actionable knowledge, hence enabling better informed decision making.
Edico Genome, developer of the world’s first next-generation sequencing Bio-IT processor, DRAGEN™, is helping usher in the new era of precision medicine by enabling customized treatments and data-driven insights tailored to the individual. At the heart of personalized medicine is next-generation sequencing (NGS), which is growing at an unprecedented pace. By increasing the speed and accuracy of NGS data analysis, such as whole genome sequencing, Edico Genome’s computing platform makes it easier to discover links between DNA sequence variations and human disease, allowing clinicians and researchers to reveal answers more quickly.
Around the world there are still many diseases for which no effective treatments exist and many patients who do not have adequate access to the medicines they need. As a global pharmaceutical company addressing these unmet medical needs, Eisai is committed to making contributions to better healthcare for patients and their families around the world through its business activities.
Lilly unites caring with discovery to make life better for people around the world. We make medicines that help people live longer, healthier, more active lives.
Elimu Informatics
Richmond, United States
Companies Information Technology
Companies Genomic Analysis
Our focus in on clinical decision support. We have developed a PGx CDS service, and we’re now working on a reanalysis service. We organized and taught “Introduction to Human Genomics for Clinical Informaticists” (https://vimeo.com/channels/elimufall2017genomics)
The mission of ELIXIR is to build a sustainable European infrastructure for biological information supporting life science research; arranged as a Hub at the European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI) in Hinxton, UK and Nodes distributed throughout Europe providing data resources; bio-computing capacity; infrastructure for data integration; and services for the research community, including training and standards development.
The European Bioinformatics Institute is part of EMBL, Europe’s flagship laboratory for the life sciences. EMBL-EBI provides freely available data from life science experiments covering the full spectrum of molecular biology. While we are best known for our provision of bioinformatics services, about 20% of our institute is devoted to basic research. Our extensive training programme helps researchers in academia and industry to make the most of the incredible amount of data being produced every day in life science experiments.
We are a non-profit, intergovernmental organisation funded by EMBL member states. Our 500 staff represent 43 nationalities, and we welcome a regular stream of visiting scientists throughout the year. We are located on the Wellcome Genome Campus in Hinxton, Cambridge in the United Kingdom.
EMC Corporation operates as the leading provider of information storage systems, software, networks, and services.
ENA/EVA/EGA
Wellcome Genome Campus, United Kingdom
Research Collaboration or Consortium
Public Funders
The core mission of the European Genome-phenome Archive (EGA), European Variation Archive (EVA), and European Nucleotide Archive (ENA) is to provide the basic infrastructure to enable global public sharing of genetic data. The EGA is a service and database for permanent archiving and sharing of genetic and phenotypic human data resulting from biomedical research projects. It provides the necessary security required to control access in accordance with participant consent, providing access only to authorised researchers and clinicians. The ENA captures and presents information relating to experimental workflows that are based around nucleotide sequencing. The ENA is a partner in the International Nucleotide Sequence Database Collaboration (INSDC) to provide worldwide exchange and replication of all public nucleotide sequences. The EVA is an open-access database of all types of genetic variation data from all species.
Encrypgen, LLC
Coconut Creek, United States
Companies Information Technology
Companies Genomic Analysis
We are developing a secure and open database for storing and sharing genomic data and empowering donors though value sensitive design.
The European Organisation for Research and Treatment of Cancer (EORTC) is a pioneer in promoting multi-disciplinary cancer clinical research and pan-European collaboration and links a network of more than 2,500 clinicians and scientists in more than 300 hospitals in over 30 countries. It encompasses all aspects of cancer research, from translational research and new drug development to large phase III clinical trials and meta-analyses.
EORTC Headquarters in Brussels handles some 30 protocols that are permanently open to patient entry, over 50,000 patients who are in follow-up, and a database of more than 180,000 patients. Full clinical, scientific, operational, quality assurance, and regulatory support for clinical and translational research projects is provided by the EORTC Headquarters staff who augment this support with strong expertise in biostatistics, clinical study design and methodology, endpoint definition and analysis, and new initiatives in imaging and long term survivorship.
EORTC studies have contributed to success stories in drugs development including the registration of several drugs by the United States Food and Drug Administration and the European Medicines Agency. The EORTC has a proven track record in establishing new standards, e.g. RECIST, QoL, etc., and in changing clinical practice.
Through its scientific strategy, the EORTC aims to define the future of cancer therapy. It recognizes that the role of pragmatic data and related methodology need to be developed within multi-stakeholder platforms, and with this goal in mind, the EORTC participates in projects such as those put forth by the Innovative Medicines Initiative. Such activities make the EORTC one of Europe’s leading players in transforming experimental discoveries into new treatments with a significant clinical impact for the benefit of patients.
EPFL offers complete study courses in Engineering, Life Sciences, Basic Sciences, Environmental Sciences, Architecture and Management. Research conducted at EPFL covers science subjects and themes in the fields of technology, health, environment, construction, energy and mobility. With its state-of-the-art technology platforms and flagship projects such as coordinating the European consortium for the Human Brain Project or its International Wyss Center for Bio- and Neuro- Engineering, EPFL has rapidly become one of the most renowned science institutions in Europe.
Epigenetiks Genetik Biyoinformatik Yazilim A.S.
Istanbul, Turkey
Companies Life Science
Companies Genomic Analysis
Epigenetiks offers consultancy services in experiment design and application to shed light on life and health sciences questions, data analysis services to analyse and store experiment results on a secure platform, bioinformatics services, and personalised medicine applications to end-users.
Epilepsy Society
Chalfont St Peter, United Kingdom
Healthcare Research
Societies and NGOs Patient Disease Advocacy
Epilepsy Society is the largest medical charity in the field in the UK. Its headquarters are in Chalfont St Peter, Buckinghamshire and it works in close partnership with the National Hospital for Neurology and Neurosurgery in London.
The Society’s globally unique NHS epilepsy assessment facility, the Sir William Gowers Centre, provides individual assessment, rehabilitation training and ground-breaking research opportunities and sees approximately 3,000 people whose epilepsy is difficult to manage each year. The unit’s success-rate is high, with many patients seeing a considerable improvement in the control of their seizures. Around 20 per cent of those admitted are found to have been wrongly diagnosed and do not have epilepsy.
The Society has long supported genetic and genomic research in the epilepsies, helping with the inclusion of people with epilepsy in genetic research, providing the necessary infrastructure and resources, and has a record of publications in the area. The Society has also sought input from people with epilepsy on research, and raised awareness about the value and outcome of genomics research in the epilepsy community.
#EQUINIX gives intelligent colocation to house mission critical IT engines in our international business exchanges (IBX). Think interconnection platforms #datacentre #datacenter #colo #carrier neutral.
For #IoT think #IOA as we are at the intersection of Cloud & as a Service (aaS) providers, network service providers and Health IT customers enabling the digital economy.
We are seeing Pharma, LifeScience and Healthcare increasingly need to run their businesses in close proximity to their service providers. The #EQUINIX Cloud Exchange (ECX) AKA Health Information Exchange, is just one example of this activity within 150+ International Business Exchanges (IBX) around the world.
e.g. #neuroscience “cells that fire together, wire together”. “The stronger interconnection, the faster the message can travel down the pathway.”
Era7 is a research intensive SME dedicated to NGS. We have special interest in Bacterial Genomics nd Metagenomics and in Cancer Genomics. We do an intensive use of AWS (Cloud Computing). We release all the software we develop under an Open Source license (AGPLv3). An example of our software research projects is Bio4j. Bio4j is a bioinformatics platform that integrates Uniprot, Gene Ontology, Refseq, NCBI taxonomy and EnzymeDB in a graph database. This project has been selected by Google for its program Google Summer of Code
Largest Academic Hospital of the Netherlands
ESAC, Inc. provides research data management, bioinformatics, and healthcare information technology solutions for government, commercial and academic clients. Headquartered in Rockville, MD, our mission is to play a vital role in helping clinicians, scientists and researchers across the globe improve all aspects of human health.
Estonian Biobank is the population-based biobank (51,515 gene donors) of the Estonian Genome Center at the University of Tartu (EGCUT). There are a team of 51 people working at the research unit and the biobank. The research unit is divided into three workgroups: biostatistics, bioinformatics and functional genomics. The support structure consists of an IT unit and administrative staff.
Euformatics is a Finnish SME, expert in genome interpretation and quality systems.
We provide transparent, easy-to-use and flexible tools based on peer-reviewed open source software. Our award-winning software omnomicsNGS supports interpretation of the genetic basis of human diseases and drug response. We help medical doctors and molecular genetics laboratories in providing better precision medicine.
The European Molecular Biology Laboratory is an intergovernmental organisation specialising in basic research in the life sciences with 21 member states, three prospect and two associate member states.
The European Society of Human Genetics (ESHG) is a non-profit organization. Its aims are to promote research in basic and applied human and medical genetics, to ensure high standards in clinical practice and to facilitate contacts between all persons who share these aims, particularly those working in Europe. The Society will encourage and seek to integrate research and its translation into clinical benefits and professional and public education in all areas of human genetics.
Ewha Institute For Biomedical Law & Ethics
Seoul , South Korea
Research University
Research University
Responding to the urgent need to tackle today’s pressing legal, institutional, and ethical issues in biomedical science, the Ewha Institute for Biomedical Law and Ethics was founded in 2005 at Ewha Law School. Designated as a bioethics and policy center by the Korea Ministry of Health and Welfare in 2006, the institute has focused on studying law and legislature in bioethics and promoting legal scholarship in this field. The center changed its name to the Ewha Institute for Biomedical Law and Ethics (EIBLE) in 2007, with the purpose of expanding the area of studies into health law and health policy, as well as playing a crucial role in the field by encouraging practical, substantial research. So far, the institute has dedicated itself not only to establishing related laws and policies and demonstrating leadership in academia, but also invigorating social discussions among academics, practitioners, and policymakers in health law, health policy, food and drug regulation, science and technology policy, and bioethics.
Fabric Genomics is a computational genomics company offering end-to-end genomic data analysis and reporting solutions to clinical labs, country sequencing programs and life science companies. Fabric’s software platform enables the accurate, rapid analysis of genetic variants to identify disease-causing genes and clinically-actionable genomic signatures from gene panels, exomes, and whole genomes. By accelerating the access to insights related to the cause of genetic diseases, Fabric Genomics is leading the way in precision healthcare.
Farsight Genome Systems provides clinical laboratories with a cloud-based solution for sequencing-based patient testing.
The FinnGen research project is based on a public-private partnership that involves nine Finnish biobanks, all Finnish University Hospitals and their respective Universities, the Finnish Institute of Health and Welfare (THL), the Finnish Red Cross Blood Service and several international pharmaceutical companies. FinnGen will construct a unique resource of 500 000 Finns that enables ambitious study designs to improve our understanding of the genetic background of diseases. The project aims to improve human health through genetic research by combining genome information with digital health care data, and ultimately identify new therapeutic targets and diagnostics for treating numerous diseases.
Fitgenes is an international provider of genetics-based personalised, preventative healthcare and wellness services. Fitgenes has developed Pracware™, a highly-scalable proprietary cloud-based platform, to allow its services to be delivered to patients directly through Fitgenes owned clinics and also indirectly through a network of distributors and Certified Practitioners covering Australia, New Zealand, Singapore, Malaysia, Hong Kong and the USA.
Foundation Medicine is leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease.
The FRANCE GENOMIQUE infrastructure brings together the capacities and expertise of the main French genomic and bioinformatics platforms.
Created through grant support from the French government initiative, “Investments for the Future” (« Investissements d’Avenir »), the prime objective of France Génomique is to reinforce and maintain French research in Production Genomics and Data Analysis at the highest level of international competitiveness and performance through state-of-the-art technology.
France Génomique provides researchers from both academia and industry with access to the most advanced technology platforms in France, together with advice and support for their projects, expertise of the highest level and a multidisciplinary network of skills, as well as the opportunity to participate in ambitious projects at national and international level.
Frontier Science is a not-for-profit corporation that has gained an international reputation as a highly capable data management and statistical organization, collaborating with research networks, pharmaceutical companies and others in the design, conduct and execution of clinical trials and long-term observation studies. Our mission at Frontier Science is to collaborate with investigators and sponsors to conduct scientifically meaningful high-quality clinical trials, while advancing the application of statistical science and practice and data management techniques in science, health care and education.
Fulcrum Genomics
Somerville, United States
Companies Genomic Analysis
Companies Information Technology
Fulcrum Genomics is a consulting partnership structured as an LLC that provides consulting services to life science companies and academic institutions in the areas of bioinformatics and genomics.
FullDNA has identified the need for creating a tool for healthcare professionals to access useful valuable genetic data from the big data pool of 21 million publications and growing daily roughly 2.5 million new publications every year
The Functional Genomics Data Society (FGED) works with other organizations to develop standards for biological research data quality, annotation and exchange. We facilitate the creation and use of software tools that build on these standards and allow researchers to annotate and share their data easily. We promote scientific discovery that is driven by genome wide and other biological research data integration and meta-analysis.
At Fundació Sant Joan de Déu-Institut de Recerca Sant Joan de Déu one of our main aims is to provide and improve high quality healthcare to our patients. To do so we advocate for FAIR data and we are eagerly looking forward to enabling genomic data sharing through Global Alliance for Genomics and Health (GA4GH) standardization. Research groups within FSJD –IRSJD have a huge experience in genomic and clinical data management focused on rare diseases. These groups are composed by multidisciplinary teams which address clinical, diagnostic and treatment aspects of our patients. We have actively collaborated in data driven networks as Transbionet (Translational Bioinformatics Network, coordinated by Spain’s Elixir node https://inb-elixir.es/transbionet) and Genomic-based Personalized Medicine in non-Diagnosed Neurological Rare Diseases (URDCAT, Generalitat de Catalunya https://www.urdcat.cat/home), we are also active members of fourteen European Reference Networks, four Spanish rare disease network areas (CIBERER) and we also belong to biobank and innovation national platforms (ITEMAS). By participating in the GA4GH initiative we think that we could contribute with meaningful insights to advance in a better quality of life for people that live with a rare disease.
The Garvan Institute of Medical Research is one of Australia’s leading biomedical research institutes, pioneering study into the most widespread diseases affecting our community today, including cancer, neurodegenerative and mental diseases, disorders of the immune system, diabetes and obesity, osteoporosis and other skeletal disorders
Founded in 1990, GATC Biotech has analyzed millions of samples and has an international reputation as expert for RNA- and DNA-sequencing projects of all sizes. From single samples up to large scale projects, from Sanger to next and third generation sequencing GATC Biotech offers a solution for every customer request. Furthermore, we trust in strong partnerships ensuring doctors to diagnose diseases more precisely and to guide them quickly to treatment decisions and make personalized medicine real.
GB HealthWatch is a nutritional genomics company. We study gene-diet-disease interactions. Our mission is to help prevent common chronic diseases through targeted, gene-based nutritional and dietary intervention. We aim to inform people about the scientific basis of chronic diseases, support them with nutrition management products and services and empower them to take control and live better lives.
Geisinger Health System is an integrated health services organization widely recognized for its innovative use of the electronic health record, and the development of innovative care models such as ProvenHealth Navigator® and ProvenCare®. As one of the nation’s largest rural health services organizations, Geisinger serves more than 3 million residents throughout 48 counties in central, south-central and northeast Pennsylvania. The physician-led system is comprised of approximately 23,500 employees,including a 1,200-member multi-specialty group practice, nine hospital campuses, two research centers and a 467,000-member health plan, all of which leverage an estimated $7.7 billion positive impact on the Pennsylvania economy. The health system and the health plan have repeatedly garnered national accolades for integration, quality and service. In addition to fulfilling its patient care mission, Geisinger has a long-standing commitment to medical education, research and community service.
GENALICE is a highly innovative biomedical big data company, with headquarters in the Netherlands. GENALICE designs and builds groundbreaking software solutions for ultra-fast, highly accurate and cost-effective DNA data processing and analysis on general-purpose hardware. With GENALICE MAP, the company has produced the first Next-Generation Sequencing (NGS) data processing pipeline with true population power. By partnering with world-renowned research institutes and healthcare companies, GENALICE is committed to unlocking the potential of whole genome, exome and transcriptome shotgun sequencing for biomarker discovery and clinical application.
GenCipher provides genetic counseling and genomic health consultations for individuals and physicians.
Founded in 2000, Gene By Gene, Ltd. (http://www.genebygene.com) is a CAP-accredited and CLIA-registered genetic testing company that serves consumers, researchers, and physicians. Gene by Gene offers a wide range of regulated clinical diagnostic tests, as well as research use only (RUO) tests. The Family Tree DNA division (http://www.familytreeDNA.com) of Gene by Gene is a pioneer and leader in DNA testing for genealogy and ancestry. The company operates the largest genetic genealogy database in the world and has provided more than 5 million discrete genetic tests. Gene by Gene is privately held and headquartered in Houston, Texas.
Gene42 builds patient-focused software for genomic medicine. Our product, PhenoTips, helps clinicians and researchers collect better phenotype data and arrive at a diagnosis.
GeneAdviser is an online marketplace for genetic testing, making it easy for doctors to search for and order tests from accredited labs.
Combining easy online searching and ordering functions with quality metrics, GeneAdviser enables more doctors around the world to use genetic testing in their practice.
Genetic testing shows huge potential in cancer treatment, neurology, pharmacogenomics and preventative medicine, but our team was inspired specifically by the unmet need for testing for rare diseases. Although our website will list tests for a range of purposes, our social mission is to make tests for rare diseases more accessible.
GeneDock is a Chinese startup company providing web-based genomics data analysis cloud service. Our customers include academic institutions, genome sequencing centers and clinical institutions.
Geneformics is an Information Technology company that develops and sells software products and services that help genomics practitioners streamline the management of next-generation sequencing data. By employing compression and other advanced technologies, Geneformics’ products improve the efficiency of data storage – on-premises and in the cloud – and accelerate file sharing over the network.
Geneis is a high-tech enterprise which engaged in scientific research, product development and clinical services of biomedicine. The seasoned core members of Geneis master mature clinical urgent technology, part of which will be transformed and benefit patients. Over the past 10 years, the Geneis, with deep accumulation and abundant experiences in human genome, cancer genome, molecular pathology, reproductive medicine and other fields, is in the forefront of technology R&D and clinical practice. In particular, the Geneis provide precison medicine solution and full management program of health for users, covering molecular pathological diagnosis of tumors, preimplantation genetic screening, non-invasive prenatal genetic diagnosis, intestinal microbial detection, single cell sequencing and other areas.
Founded in 2012, we are a London based start-up committed to personalising medicine.
To achieve this, we’ve built a strong team with extensive expertise in pharmacogenetics, pharmacology, big data analytics, business strategy, the NHS and creative design.
A year after forming we were fortunate to win the IC tomorrow Digital Health Contest with our first product, an iPad based e-prescribing tool. More recently we won a place on the prestigious Wayra Acceleration Program.
Genekang focus on Human whole genome and exome data analysis, using cloud computing technology, and hope to incorporate clinical data, health data and provide solutions for health.
Cracking the ‘One Size Fits All’ theory of medical science while inculcating the philosophy of “You are unique, and so should your medical treatment be”, K & H was founded in 2019. Dr. Kalyan Uppaluri and Dr. Hima Challa along with their impeccable team of experts with world knowledge in technology as well as molecular biology have pioneered and established the concept of genomic sciences and personalised medicine in order to improvise the medical treatment processes in India.
The thought first originated when Dr. Kalyan was working on genomics at Stanford University during his early research of Post-graduation. It took about 4 years of detailed analysis for the entire team of Scientists, Doctors, and the technology experts to bring in the whole new idea into its functional shape.
Generation Scotland is a resource of high
quality, ethically consented samples and data
for genetic and health related research.
The Scottish Family Health Study has 24,000 participants from 7,000 families.
GENESNLIFE HEALTHCARE PVT LTD (GNL) as a Leading Molecular Genetics Diagnostics And Research Company, established by a group of Human Genetics Scientists and Clinicians in the year 2011. GNL is a fast growing company with its array of genetic testing services in elucidating the Genetic basis of diseases, Personalized Medicine, Genetic Counseling and Biomedical Research.
Genestack Limited
Cambridge, United Kingdom
Companies Information Technology
Companies Genomic Analysis
Genestack is a startup based in Cambridge, UK, in the fast moving domain of genomics. We are building a novel platform for computational biology research, aimed at biologists, bioinformaticians and developers.
Genestack’s Genomics Operating System is a next generation cloud OS, providing a unified ecosystem, free of dependencies on file formats, locations, tool versions and other routine stuff. Scientists can just concentrate on doing bioinformatics, getting from data to results quickly.
We are unique in putting absolute data reproducibility at the core of our architecture. We also provide the ability for third-party developers to build genomics apps for our platform. Our users are in pharma, biotechs, academia and healthcare.
“We are developing a platform where users can share their DNA, that can be later used by medical research companies. We will provide our users with many reports compiled with information extracted from their DNA, including ancestry and health reports.
This platform is going to be based on many interconnected services, including blockchain, big data and cloud computing.
“
Genetic Alliance is one of the world’s leading nonprofit health advocacy organizations. Its network includes more than 1,200 disease-specific advocacy organizations, as well as thousands of universities, private companies, government agencies, and public policy organizations. The network is a dynamic and growing open space for shared resources, creative tools, and innovative programs.
Since 1986, Genetic Alliance has defined the intersection of health and genetics. Originally founded as an alliance for support groups, our work has evolved along with the growing health advocacy movement and the rapid advancement of genetic technology. While our roots are in genetics, we recognize that meaningful solutions that improve health must be multidisciplinary. To that end, we apply solutions in health and disease, practice and prevention, and on the local and global level. Through our broad and diverse partnerships, we have created a dynamic network that serves as an open space for sharing valuable resources, creative tools, and innovative programs.
Genetic Alliance UK
London, United Kingdom
Societies and NGOs Patient Disease Advocacy
Research University
Genetic Alliance UK is the national charity working to improve the lives of patients and families affected by all types of genetic conditions. We are an alliance of over 180 patient organisations.
Our aim is to ensure that high quality services, information and support are provided to all. We actively support research and innovation across the field of genetic medicine.
Genetic Counselling Asia (GCA) provides private genetic counselling, conducts training and consultation. GCA was set up to bridge the gap of existing services, increase access to patients (clients) and to expand genetic counselling practice in Asia.
As a global leader in R&D genomics services, GENEWIZ leads the way in providing superior data quality with unparalleled technical support to enable researchers around the world to advance their scientific discoveries faster than ever before.
Our customers at top-tier pharmaceutical, biotechnology, and academic institutions, as well as cutting-edge start-ups, rely on GENEWIZ’s proprietary technologies for consistent, reliable, high-quality data, even on the most difficult projects. A full-service provider, GENEWIZ provides Sanger DNA sequencing, gene synthesis, molecular biology, high throughput/next generation sequencing, bioinformatics, and GLP regulatory services.
GeneXplore Diagnostics and Research Centre
Ahmedabad, India
Healthcare Care Delivery
Research Institute
We work in genetic diagnosis focusing on IVF, Oncology and Neurology. Our samples flowin from across India channeled through clinicians. We undertake karyotype, microarray, NGS, Sanger sequencing approach to detect mutation and report to clinician.
GENEXYX is a team of bioinformaticians, experts in data security, software engineers and IT entrepreneurs with the average of 18 years of hands-on experience in Europe and the United States who decided to join forces to build a technological solution to help the bioinformatics sector meet the rapidly growing demand for genomic services by providing an integrated scalable environment for storage, analysis and sharing of large data sets produced by the Next-Generation Sequencing.
GeneYouIn (GYI) is a Canadian personalized medicine company with a suite of products that help healthcare practitioners make better-informed treatment decisions based on an individual’s genetic make-up.
The GeneYouIn vision promotes an optimal balance of clinical utility, patient empowerment, and cost-efficient, targeted genome analysis.
We believe the immediate future will see genetic insights become standard inputs for the optimizing of patients’ health and wellness. We develop applications addressing the needs of both healthcare consumers and front-line care providers. Historically, access to genetic knowledge has been limited, not so much by sequencing costs as by the cost of analysis, interpretation and custom reporting. As a significant step towards automating genome annotation and reporting, we have developed Pillcheck™.
Geneyx is a private company, based in Tel Aviv, Israel. Founded in July 2018. We are 5 founders and 7 full-time employees. Geneyx has developed a cloud-based solution for GDPR/HIPAA compliant management of integrated genetic and medical data. We have solved the tough problem of DNA storage. the problem was that DNA inherently exposes its owner identity – even when being stripped of name and ID numbers. Geneyx provides the testing labs and the hospitals with a comprehensive secondary and tertiary analysis pipeline, free storage and sharing abilities of genetic data – without compromising privacy at any stage in the process. Geneyx offers the scientific community safe access to a reliable and diverse source of quality genetic data: The data that was generated for clinical and diagnostics purposes in many testing labs around the world and was aggregated by Geneyx.
Genialis is a bioinformatics company from Slovenia, a spin-off form the Bioinformatics laboratory at the University of Ljubljana. We provide data management, processing and interactive real-time analysis solution for NGS and other biomedical data. Genialis Platform is unique for its modular nature, the visualization rich approach and the agility to adapt it to further needs. By integrating in-house and public databases at all omics levels, we facilitate mining novel insights in research and production processes. Application build on our platform also supports the data dissemination of research data, which is easily accessible to explore by other researches and the whole community, interested in the data. Our system has been licensed by Garvan Institute and Baylor College of Medicine with the latter acknowledging impact on new discoveries. Benefits include reduction of repetitive tasks, reproducibility and traceability of data analysis, all empowering biologists and clinicians to perform data analysis autonomously.
GenoBank.io is the first anonymous DNA Test kit with blockchain
Our Patent Pending DNA Saliva Kit, will allow our users to participate and take advantage of the Genomic Revolution maximizing privacy by using Blockchain Networks to keep track of all the data sets and Genomic Reports (insights) without exposing their personal data!
A spin-off of the University of Ghent (Belgium), Genohm was originally established in Ghent as a 2 person bioinformatics shop in 2002. Building upon extensive bioinformatics consulting expertise within the life sciences, biotechnology and university hospital research markets, in 2010 Genohm put together SLims, a unique LIMS or Laboratory Information Management System.
SLims provides laboratories with one integrated LIMS + Electronic Lab Notebook + order management environment that tracks data and samples from the original sample shipment down to the result from lab machines and in-silico analysis pipelines. The platform provides an environment to support the increasing complexity of handling, sharing, analyzing and understanding data generated by any laboratory active in research, next-generation sequencing, diagnostics or biobanking.
In May 2011 Genohm opened its new Headquarters at the EPFL Innovation Park in Lausanne, Switzerland and in 2016 a US branch in Durham, NC, while keeping its European branch offices in Ghent. Today Genohm serves customers in Europe and the US.
GenoLogics Life Sciences Software Inc.
Victoria, Canada
Companies Life Science
Companies Information Technology
Our Vision: “We catalyze life sciences research with a collaborative data management software platform, advancing early detection, prevention, and treatment of disease.”
Advances in genomics, proteomics, and related sciences introduce a whole array of new diagnostics and companion therapeutics to traditional health care methods, which will have a monumental impact on society in the coming years. As researchers, clinicians, and genetics experts begin to incorporate desktop sequencing technology into their labs and clinics, the goal of improving human health through personalized medicine will start to become a reality for the general population. With its lab information management software (LIMS) products, GenoLogics is uniquely positioned to enable this leading-edge research and diagnostic work.
GENOMAP BIOINFORMATICS
Buenos Aires, Argentina
Companies Genomic Analysis
Companies Information Technology
Genomap Bioinformatics is a company providing services on analysis and interpretation of NGS genomic data.
Genome British Columbia is a non-profit research organization that invests in and manages large-scale genomics and proteomics research projects and enabling technologies focused on areas of strategic importance such as human health, forestry, fisheries and aquaculture, energy and mining and agri-food.
Genome Canada is a not-for-profit organization that acts as a catalyst for developing and applying genomics and genomic-based technologies to create economic and social benefits for Canadians. Genome Canada connects ideas and people across public and private sectors to find new uses for genomics, invests in large-scale science and technology to fuel innovation,and translates discoveries into applications, new technologies, societal impacts and solutions across key sectors of national importance, including health, agriculture, forestry, fisheries & aquaculture, energy, mining, and the environment.
Genome Center for Alzheimer's Disease
Philadelphia, United States
Research University
Research University
The Genome Center for Alzheimer’s Disease (GCAD) is an NIA funded project to identify genetic variants that cause, influence risk, or protect against this disorder, and to identify the underlying genes affected by these variants. GCAD harmonizes all AD-relevant genetic data and phenotype data to be compatible for use in subsequent analysis. All GCAD results and derivative data are distributed to Alzheimer’s Disease Sequencing Project and other AD investigators.
Genome Center for Alzheimer's Disease
Philadelphia, United States
Research University
Research University
The Genome Center for Alzheimer’s Disease (GCAD) is an NIA funded project to identify genetic variants that cause, influence risk, or protect against this disorder, and to identify the underlying genes affected by these variants. GCAD harmonizes all AD-relevant genetic data and phenotype data to be compatible for use in subsequent analysis. All GCAD results and derivative data are distributed to Alzheimer’s Disease Sequencing Project and other AD investigators.
The Genome Institute of Singapore (GIS) is a national initiative with a global vision that seeks to use genomic sciences to achieve extraordinary improvements in human health and public prosperity. As a centre for genomic discovery, the GIS will pursue the integration of technology, genetics and biology towards academic, economic and societal impact.
Génome Québec is an economic development organization that contributes to strengthening the competitiveness of the genomics innovation system in order to maximize its socioeconomic impact in Québec. It does so by funding major genomic research initiatives and putting in place the tools necessary for scientific and strategic development in the field.
Génome Québec is helping to accelerate the discovery of new applications for genomics in strategic areas such as health, forestry, the environment and agrifood.
Gene and wisdom constitute us , we use these to make a gift to the world.
Our mission is to provide genomic and other OMICs based machine intelligent solutions for better diagnostics and therapeutics.
We are a non-profit consortium collaborating to sequence 100,000 Asian individuals genomes to help accelerate population specific medical advances and precision medicine.
GenomeDenmark
København (Copenhagen), Denmark
Research Collaboration or Consortium
Healthcare Research
GenomeDenmark is a national platform for sequencing and bioinformatics, which includes universities, hospitals and private firms. The key vision of GenomeDenmark is to create a reference genome and facilitate genomics research at the highest international level and increased national coordination as well as synergy in the field of genomics through broad cooperation across research fields and sectors.
Genomedia® Inc. works on efficient and labor-saving Genome data processing by providing one-stop solution from sample preparation to data analysis/visualization, using Next Generation sequencer.
Genomeplus is a provider of genetic information, understanding and education. We are providing information and education to patients and carers
and health professionals working in pharmaceutical, biotechnology and medical device industries.
Genomes.io is a DNA and health data bank. We aim to securely sequence and store 1 billion genomes in our DNA data bank and become the world’s largest, most secure and trusted genomic and health data marketplace to power the personalised medicine revolution.
Using homomorphic encryption and the Ethereum blockchain, we can provide our users with control over their genome sequence. This allows users to control access to segments of their genome in a repeat consent model to trusted professionals in a private and anonymous manner in exchange for money.
Our platform acts as a genomic data aggregator that provides research organisations with a more efficient data acquisition model in which they do not have to take liability for security or ownership of the data. By doing so, Genomes.io operates a more equitable model in which individuals own, control and get paid for the data they wish to share.
The Genomic Medicine Alliance aims to create collaboration ties between academics, researchers, regulators, and the general public interested in all aspects of genomics and personalized medicine. The Alliance provides the means to establish networks and to encourage collaborative work towards advancing the Genomic Medicine discipline, focusing in particular on translating results from academic research into clinical practice.
In particular, the Genomic Medicine Alliance aims to: (a) Encourage and catalyze multidisciplinary collaborative research between partner institutions and scientists, particularly from emerging countries, (b) Liaise among research organizations, clinical entities and regulatory agencies in areas related to genomic medicine, (c) Facilitate the introduction of pharmacogenomics and advanced omics technologies into the mainstream clinical practice, (d) Produce and propose guidelines and recommendations in all areas pertaining to genomic medicine, always in close collaboration with other scientific academic entities, agencies and regulatory bodies, (e) Develop, independently or in close collaboration with partner institutions, and coordinate educational activities in the area of genomic medicine.
Genomic Medicine Sweden
Solna, Sweden
Research Collaboration or Consortium
Research Collaboration or Consortium
The Genomic Medicine Sweden (GMS) initiative aims to strengthen precision medicine across the country. This will be accomplished through the implementation of large-scale sequencing techniques in Swedish healthcare, resulting in improved healthcare, strengthened Swedish research in the area, and provides a foundation for innovation and collaboration with industry. With a patient-centered view, initial efforts will focus on rare diseases, cancer, pharmacogenomics, infectious diseases, and subsequently be extended to the complex diseases (e.g. noncommunicable diseases). GMS will be implemented as a broad collaborative project between different societal stakeholders including healthcare providers, universities with medical faculty, Science for Life Laboratory (SciLifeLab), industry and patient organizations. In order to deliver top tier diagnostics and research, thus enabling individually adapted therapies and follow-up strategies, regional genomic medicine centers (GMC) are currently under development together with a national informatics infrastructure. GMS will also offer a unique research resource for Sweden to identifying disease-causing events that could pave the way for new drug development, and enhance collaboration with industry. In summary, GMS provides Sweden with an opportunity to take an international forefront position in the field of precision medicine.
Genomics Education Programme
Birmingham , United Kingdom
Education in Genomics in Healthcare
Healthcare Research
The Genomics Education Programme (GEP) is the England’s NHS’s method of ensuring its staff have the knowledge, skills and experience to ensure that the health service remains a world leader in genomic and precision medicine – particularly for NHS England Genomic Medicine Centres (GMCs) and the contribution to the 100,000 Genomes Project.
The GEP is achieving this through a three-fold approach:
Directly supporting those professionals involved in the 100,000 Genomes Project and Microbial Genomes work.
Supporting the wider transformation of services to integrate genomic technologies into healthcare.
Upskilling existing staff so they can make the most of genomic technologies in their work.
Genomics England is a company owned by the UK Department of Health set up to deliver the 100,000 Genomes Project. This flagship project will sequence 100,000 whole genomes from NHS patients by 2017. Genomics England has four main aims: to bring benefit to patients; to create an ethical and transparent programme based on consent; to enable new scientific discovery and medical insights; to kickstart the development of a UK genomics industry
Genomics Facility, Icahn School of Medicine at Mt Sinai
New York, United States
Healthcare Research
Healthcare Care Delivery
–
Genomics plc seeks to use the totality of human genetic variation to understand human biology. We work with pharma companies to help them use genomics to ‘de-risk’ their drug development process.
Genomix4Life S.r.l. is a high tech start-up, spin-off of the University of Salerno, engaged in research and development in genomics and bioinformatics applied to human health, that provides also a wide range of structural and functional genomics, bioinformatics analyses and data storage services to research and industry worldwide.
The Company staff comprises highly qualified professionals with long-standing expertise in molecular biology, genomics and bioinformatics, focused on the applications of the latest technologies for nucleic acid analysis by next-generation sequencing and microarrays.
GenomOncology LLC
Cleveland, United States
Companies Genomic Analysis
Companies Information Technology
GenomOncology has developed a proprietary technology platform to streamline the use of next generation sequencing data (NGS) in medicine and research.
Genomsys is a startup company working on solutions for genomics data storage, transport and manipulation
Genonymous Sciences provides personalised medicine solutions to patients, physicians and diagnostic laboratories.
Genoox is a big data platform for analyzing and managing genetic data in the cloud. Genoox helps medical experts provide personalized treatments to their patients based on genetic and clinical data rapidly and accurately. At the same time, Genoox enables clinical disease researchers finding genetic patterns and similarity in mutations easily and intuitively. Our platform use unique deep learning methods and dedicated compression algorithms for solving the storage and analysis challenges exist today in the clinical genomics space.
At Genospace, we are Digital Architects of Genomic Medicine™. Genospace has built a comprehensive platform for advancing research, pathology and clinical care to enable interpretation, analysis, reporting and collaboration of complex genomic and other biomedical data. We support research, pathology and clinical care. Learn how leaders in precision medicine are powered by Genospace at www.genospace.com.
Genotypic is now India’s Genomics Technology Hub and our vision is to make it the world’s Genomics Technology Hub. Genotypic is SAP enabled and ISO 9001:2008 Accredited Company. AGILENT Certified Genomics Service Provider with specilization in targeted resequencing, arrays designs and large genomics projects.
Genotypic’s Genomics Lab includes – Ion PGM, Ion Proton, SOLiD5500xl, Nextseq500 and MiSeq; Agilent microarray platform, qPCR machines, Sanger, Molecular Biology lab and Genome informatics Unit.
Genomics, NGS, Microarray, Agilent, SureSelect – Targeted resequencing, array design, Next Generation sequencing, solexa, solid, 454, helicos, Pacbio, sequence annotation, analysis, ion torrent, miseq, Nextseq500 (world’s first NCBI SRA data from Nextseq500 is from Genotypic).
Genowise corporation is a genetic testing company located in Suzhou, China. Genowise offers (1) genetic testing services and (2) turn-key solutions for genetic testing to any institutions that want to jump-start genetic testing services.
GENyO. Centre for Genomics and Oncological Research: Pfizer-Universidad de Granada-Junta de Andalucia
Granada, Spain
Research Institute
Research Collaboration or Consortium
GENYO is a mixed centre with stakes held by the Regional Ministry of Economy, Innovation, Science and Employment, the Regional Ministry of Equality, Health and Social Policies, the University of Granada and the pharmaceutical company Pfizer. This centre has been devised as a space for excellence research in genomic medicine, focussing on the comprehensive study and understanding of the genetic basis of human diseases in general, placing special emphasis on cancer and its genetic disorders related to inheritance.
GENYO was created as a multidisciplinary research space, where different professionals from the healthcare, university and business areas interact, making it possible to generate new systems to diagnose, prevent and treat diseases based on the joint and coordinated application of first-rate knowledge in the different areas of genetics.
Georgetown University Innovation Center for Biomedical Informatics
District of Columbia, United States
Research University
Higher education and academic organization; Center for innovation in Biomedical Informatics
Georgetown University, O’Neill Institute for National and Global Health Law
Washington D.C., United States
Research University
The O’Neill Institute for National and Global Health Law at Georgetown University was established in 2007 through the generous philanthropy of Linda and Timothy O’Neill to respond to the need for innovative solutions to the most pressing national and international health concerns. Housed at Georgetown University Law Center in Washington D.C., the O’Neill Institute reflects the importance of public and private law in health policy analysis. The O’Neill Institute draws upon the University’s considerable intellectual resources, including the School of Nursing & Health Studies, School of Medicine, the Public Policy Institute, and the Kennedy Institute of Ethics.
Georgian Foundation for Genetic and Rare Diseases (GeRaD)
Tbilisi, Georgia
Societies and NGOs Professional
Societies and NGOs Patient Disease Advocacy
Georgian Foundation for Genetic and Rare Diseases (GeRaD), was formed in 2009. GeRaD represents a group of people personally affected by the problem of rare diseases in Georgia (patients and parents, medical professionals, researchers etc). Today GeRaD unites several groups of patients with rare diseases. At the same time Foundation collaborates with most of the medical professionals and researchers working in the field of rare diseases in Georgia; most of them are members of the GeRaD Medical Advisory Board. Along with the membership in other large European organizations working in the field of RD, GeRaD is a member of EURORDIS. Our organization is participating in a number of projects financed within the EU Program of Community Action in the field of Public Health and some international research programs. Executive Director of the organization, Dr. Oleg Kvlividze is the country representative in CNA/EURORDIS, member of the IRDiRC Executive Committee and ORPHANET-Georgia information Scientist.
German Cancer Research Center (DKFZ) / National Center for Tumor Diseases (NCT)
Heidelberg, Germany
Research Institute
Healthcare Research
–
Genomics, Bioinformatics, Geromics, and Rejuvenomics company.
GigaScience is a collaboration between BGI and BioMed Central, presenting an online open-access open-data journal and integrated repository. We publish ‘big-data’ studies from the entire spectrum of life and biomedical sciences. To achieve our goals, the journal has a novel publication format: one that links standard manuscript publication with an extensive database (GigaDB) that hosts all associated data and provides data analysis tools and computing resources.
We are a science-led global healthcare company with a mission: we want to help people to do more, feel better, live longer.
The vaccines, medicines and consumer healthcare products that we research and develop can improve people’s health and well-being, ultimately helping them to live life to its fullest and contribute to the prosperity of their communities.
Global Gene Corp is an innovative, data-driven genomics data and application company with expertise in data acquisition and subsequent application
A global rare disease advocacy organization working to eliminate the challenges of rare disease. Helping equip advocates through educational tools and resources to become successful activists for their disease. Working with over 800 rare disease organizations and helping build new successful efforts for additional rare diseases that have no coordinated efforts.
A global rare disease advocacy organization working to eliminate the challenges of rare disease. Helping equip advocates through educational tools and resources to become successful activists for their disease. Working with over 800 rare disease organizations and helping build new successful efforts for additional rare diseases that have no coordinated efforts.
Global Genomic Medicine Collaborative (G2MC)
Durham, United States
Societies and NGOs Professional
Research Collaboration or Consortium
The Global Genomic Medicine Collaborative (G2MC) was established as a not-for-profit organization based in the United States in 2016 with the goal of enabling the implementation of genomic medicine worldwide in order to improve individual and population health. Starting from a gathering of 90 leaders in genomic medicine from the US and 25 other countries in 2014, G2MC is now an organization of over 200 members involved in G2MC working groups (Education, Evidence, Policy, and Advocacy) and actively participating in the development of flagship projects that provide opportunities for strategic partnerships and demonstration pilot projects in several countries simultaneously. The G2MC builds upon the work of global organizations such as the Global Alliance for Genomics and Health (GA4GH) to promote and facilitate the coordination and development of the genomic agenda across the globe, as well as to offer guidance and resources to nations and organizations in need. As such, the G2MC strategically coordinates global genomic medicine by (1) offering an authoritative portal that governments and other organizations can use to find the expertise needed to implement genomic medicine; (2) providing a platform by which participants can share experience to contribute to the success of new programs around the world; and (3) providing an opportunity to assist less resources nations in filling gaps in how genomic medicine is implemented. Specific to this last aim, in addition to developing the Cape Town Declaration, the proceedings from the 2018 International Conference in Cape Town, South Africa yielded a strong desire from the G2MC membership to develop and drive programs in less resourced regions of the globe to better understand their implementation challenges and to develop evidence that will drive further development. As such, the G2MC and its international partners are at the beginning of an era of data sharing, policy development, standardization, and education about the use of genome-based technology to maintain health and treat disease. Membership within the G2MC comes from across the continents, with representation from many countries: Australia, Belgium, Brazil, Canada, Chile, Colombia, England, Estonia, France, Germany, Greece, India, Indonesia, Israel, Italy, Japan, Jordan, Korea, Kuwait, Netherlands, New Zealand, Qatar, Singapore, Sri Lanka, Sweden, Thailand, the UK, and the USA. Most relevant to this initiative, G2MC members also includes representation from the African continent, including Egypt, Ghana, Mali, Nigeria, Rwanda, Tunisia, Zimbabwe, and of course South Africa
Global Variome Ltd is an international non-governmental organisation that is working to ensure that all information on genetic variation and its effect on human health can be collected, curated, interpreted and shared freely and openly.
The Human Variome Project provides a central coordinating function for national and international efforts to integrate the collection, curation, interpretation and sharing of information on variation in the human genome into routine clinical practice and research. We are an active and growing Consortium of over 1,100 individual researchers, healthcare professionals and policy makers and organisations from 81 countries that collaborate to develop and maintain the necessary standards, systems and infrastructure to support global-scale genomic knowledge sharing. The Project itself is not directly involved in the development and operation of physical data storage and sharing infrastructure; that is the responsibility of international disease groups, national consortiums/health systems and individual members. Rather, the Project exists to assist these groups by:
Collaboratively developing technical standards and harmonised, common approaches so that data from different sources can be easily shared in an interoperable manner that is sensitive to the ethical, legal and social requirements of both the data sources and consumers;
Coordinating an international platform to facilitate discussion of Genomics in global health with the aim to foster necessary professional interaction and debate in the area of genomics, global health, and service delivery and safety;
Linking world leading professionals and institutions with genomics professionals, researchers and academics in all parts of the world, facilitating knowledge exchange and interactive debate;
Establishing a global evidence base for knowledge sharing in medical genetics and genomics and bringing relevant issues to the attention of Ministries of Health, Science and Technology and Education.
The Globus Genomics solution addresses the challenges that researchers face when dealing with NGS analysis on a large scale. It combines state-of-the-art algorithms with sophisticated data management tools, a powerful graphical workflow environment, and a cloud-based elastic computational infrastructure. Globus Genomics is software-as-a-service, delivered as a monthly subscription with the appropriate level of resources to meet your specific needs.
Gnosis Data Analysis (Gnosis DA) is located in Heraklion, Crete, Greece. Our mission is to empower companies and research institutions with powerful data analysis solutions and services. We have long experience in advanced statistics and machine learning, particularly in Predictive Analytics, which identifies trends hidden in the data, and Causal Analysis, which enables targeted interventions.
GNS Healthcare is a big data analytics company that empowers payers, providers and pharmaceutical companies to make intelligent data-driven decisions. We unlock knowledge within complex data, enabling personalized, actionable predictions and precision targeting.
For 15 years, GNS has been committed to developing and deploying the most sophisticated mathematical and computational platforms to help our partners improve health and reduce costs.
Google Inc.
Mountain View, United States
Companies Information Technology
Companies Genomic Analysis
Google’s mission is to organize the world’s information and make it universally accessible and useful.
Government of India, Ministry of Science & Technology, Department of Biotechnology
New Delhi, India
Funders and Agencies Public
–
Government of Western Australia, Department of Health, Public Health and Clinical Services Division
Perth, Australia
Funders and Agencies Public
The Public Health and Clinical Services Division’s goal is to protect the health of the Western Australian community by promoting health, preventing disease and managing risks.
The Public Health and Clinical Services Division is responsible for development, coordination and delivery of a wide range of statewide public health policy and programs.
Grandomics Biosciences Co., Ltd is an innovative company that specializes in translating the advanced technologies of bioinformatics, genomics and internet into the clinical application for healthcare. The company has a professional team which expertise in the cutting-edge biological information technology and genomics. Here the internet technology is combined with genomics creatively by our experts, making it a brand new business model in the field of healthcare and internet.
GSG (Genomics Science Group)
Edinburgh, United Kingdom
Companies Genomic Analysis
Companies Information Technology
Genomics Science Group specializes in managing projects in the field of bioinformatics and computational genomics. The aim of Company is to provide technological capabilities for storing, processing and analyzing DNA for scientific and commercial research purposes.GSG strategy envisages participation in research of human genome projects, that employs GSG Computing Storage for DNA digital samples.GSG is an international group of organisation that brings together life science resources. These resources include databases, software tools, training materials, cloud storage and supercomputers. Develop ways that sensitive data from biomedical research can be discovered and accessed by scientists.
H3ABioNet is a Pan African Bioinformatics network established to support H3Africa researchers and their projects while developing Bioinformatics capacity within Africa for genomics research. The network includes 34 Bioinformatics research groups distributed amongst 15 African countries and 2 partner Institutions based in the USA.
Hammerspace
San Mateo, United States
Companies Information Technology
Companies Information Technology
Hammerspace delivers a global data environment which spans across data centers, AWS, Azure, and Google cloud infrastructure. With origins in Linux, NFS, open standards, flash and deep file system and data management technology leadership, Hammerspace delivers the world’s first and only solution to connect global users with their data and applications, on any existing data center infrastructure or AWS, Azure and Google services.
Hasso Plattner Institute is a university excellence center for IT Systems Engineering in Potsdam, Germany. It offers an outstanding education in the field of software systems engineering – from bachelor to PhD.
Since establishment, Health and Global Policy Institute has been working to help citizens shape health policies by generating policy options, and to bring stakeholders together as a non-partisan think-tank, as is stipulated in the mission statement. One of the Institute’s guiding principles is independence, not to be restricted by interests of any organization or political party.The Institute will continue to maintain political neutrality and independence from any organization in conducting its activities.
Health Data Research UK is leading the delivery of the Digital Innovation Hub Programme – a UK-wide initiative to enable the safe and responsible use of health-related data at scale for research and innovation.
Proposed in the Industrial Strategy: Life Sciences Sector Deal in December 2017, between 3-5 Digital Innovation Hubs will be created in regions across the UK to connect health-related data for research and innovation, within a single interoperable, trusted and secure governance framework. This will enable accredited researchers, scientists and innovators to work together and safely and securely use data to harness scientific knowledge and emerging technologies, across populations of between 3-5 million people.
The long-term ambition is to build towards full UK population coverage (65M people), to rapidly enable researchers and innovators to engage with a meaningful dataset.
This four-year programme (September 2018 to July 2022) is funded by the UK Research and Innovation’s Industrial Strategy Challenge Fund, receiving £37.5M, and is part of the Data to Early Diagnosis and Precision Medicine Challenge.
Healthcursor Consulting assists clients in understanding the issues and implications, and their optimal options, regarding digital healthcare. We work with Pharma, Biotech and Lifesciences companies to create use cases on digital technologies adoption and implementation. Healthcursor is recognised as Global Digital Health 100 by Journal of mHealth.
Hijiyin is a personal genomics and health management company, offering direct-to-consumer personal genome test and interpretation. Hijiyin is dedicated to provide accurate predictions of health risks, with subsequent personalized healthcare by deciphering both genomic data and acquired disposition.
As global leaders in data management and cloud infrastructures, combined with decades of industry leading experience in managing the toughest and most demanding health data environments, Hitachi Data Systems offers the highest availability and performance with unparalleled scalability and simplified management. More importantly we work with our customers to accelerate genomics research activities and create added value from this unique data resource.
Hong Kong Hereditary Breast Cancer Family Registry
Hong Hong , Hong Kong SAR China
Societies and NGOs Professional
The Registry was set up to
1) Fund raise for genetic testing in Hong Kong
2) Provied awareness of Hereditary Breast and Ovarian Cancer Syndrome
3) Provide courses for teaching of the Syndrome in Hong Kong and planning for other parts of Asia
4) Research in Hereditary Breast and Ovarian Cancer Syndrome
Hong Kong University of Science and Technology
Clear Water Bay, Hong Kong SAR China
Research University
Research University
Established in 1991, The Hong Kong University of Science and Technology (HKUST) is an international research university dedicated to top-notch education and research. Founded on its mission to advance learning and knowledge through teaching and research particularly in science, technology, engineering, management and business studies complemented by humanities and social sciences, as well as assisting in Hong Kong’s socioeconomic development, this young and ambitious University has gone beyond the wildest dreams of many, climbing high in international esteem and reaping numerous honors and accolades.
The Human Genetics Society of Australasia is a vibrant professional society of 1000 members that promotes the practice of diagnostic and clinical genetics in Australia and New Zealand. Formed in 1976 and formally incorporated in 1977, the Society holds an Annual Scientific Meeting each year with visiting international and national speakers.
The Human Genetics Unit is the only comprehensive genetics and genomics center in Sri Lanka. It is engaged in providing clinical services, research and education.
Human Genome Organisation (HUGO) is the international organisation of scientists involved in human genetics. HUGO was conceived in 1988, at the first meeting on genome mapping and sequencing at Cold Spring Harbor. From an initial group of 42 scientists from 17 countries, HUGO has increased its membership to almost 2,000 members, from over 92 countries in a period of only two decades. Over the years, HUGO has played an essential role behind the scenes for the human genome project. With its mission to promote international collaborative efforts to study the human genome and the myriad issues raised by our increasing knowledge of the genome, HUGO has had noteworthy successes in some of the less glamorous, but nonetheless vital, aspects of the human genome project.
As a truly international organisation, HUGO has refocused its efforts towards the medical implications of genomic knowledge. Looking forward, HUGO is working to enhance the genomic capabilities of the emerging and developing countries of the world. The excitement and interest in genomic sciences in Asia, the Middle East, South America and Africa are palpable and our hope is that these technologies will help to aid national development and worldwide health.
Human Pangenome Reference Consortium
Santa Cruz and St. Louis, United States
Research Collaboration or Consortium
Healthcare Research
A comprehensive collection of diverse and highly accurate human reference genomes is critical to complete our understanding of genetic variation and disease and realize the promise of genomic medicine. The Human Pangenome Reference Consortium (HPRC) was established in 2019 in an effort to address this important problem, and aims to modernization of the human reference to include a collection of diverse and highly accurate, haplotype-phased genome assemblies. In meeting this goal, the HPRC initiative will generate new technical standards in genome sequencing, assembly methods, and pangenomic tool development to ensure comprehensive variant discovery. Critical to this work is the commitment to open data sharing, and the use of scalable and reproducible cloud-based workflows for reference production, quality assessment, and error-correction. Central to our work is the establishment of an Ethics and Policy framework that enshrines concepts of transparency, engagement, and cultural awareness. In this initiative, the HPRC aims to to foster interactions in the area of genomics and ethical oversight, develop of strategies to cross-evaluate and measure gaps in genomic diversity, and support educational programs to ensure consistency in training and equitable access to the pangenome reference data.
The Huntington Society of Canada (HSC) is a national network of volunteer Chapters and Area Representatives, governed by a volunteer Board of Directors, and supported by full-time and part-time staff at the Society’s office. The network includes professional Family Service (FS) staff at Huntington Disease Resource Centres across the country, and part-time FS workers who are available on an on-call basis to provide support to HD families in areas of the country not served by a Resource Centre. – See more at: http://www.huntingtonsociety.ca/about/organizational-structure/#sthash.QCFg33uR.dpuf
World’s first Science-backed digital preventive health doctor. iamYiam® is an award winning preventive personalised digital health “doctor” that combines big health data, genetics and academic research with the help of 4 proprietary Artificial Intelligence/Machine Learning-based algorithms to deliver a personalised activity & nutritional plan that is to be executed though the platform of vetted therapists and curated supplements. iamYiam Limited and the iamYiam Foundation (non-profit charitable entity) are all about science backed preventive health and customised care that fast tracks the progress on one’s health across one’s life journey – from childhood to retirement.
iamYiam’s approach of combining contemporary scientific research with traditional health practices has already been recognised in its field and awarded the Seal of Excellence for Research and Innovation from the European Commission in Aug 2016, named the leading trend by FORBES Mag in Jan 2017 and in the top 10 of UK Health Tech to watch in 2017. iamYiam has also been featured in most high profile publications such as Financial Times, Marie Claire, The Times, Grazia, Times Magazine, British Airways Business Life etc…
The core of the algorithms is to quantify/rate and standardize published research papers in the preventive health space in order to then interpret the data and make it accessible and digestible to the public. These algorithms gave birth to a product which starts from smart preventive diagnosis (via dynamic health & lifestyle questionnaires), takes into account individuals’ genetic makeup (via a genetic test across health 40 parameters) and health goals in order to recommend an ever evolving and learning ultra-personalised activities and nutritional plan. Individuals can then take action on the platform.
“IDI EIKON is nowadays providing ICT tools to health actors that demand data evidencing, documenting and justifying the use of certain treatments in daily clinical practice, as well as the ideal moment to use certain medications or doses (“”Treat to Target””) following the common standard of clinical pathways agreed by experts in each pathology.
These tools allow:
• The rapid entry of data by multi-disciplinary teams and even the patient himself (Patient-reported Health Outcomes)
• Tools to help in the decision making in daily clinical practice, and not a posteriori
• Organization of care processes to homogenize and standardize patient monitoring and monitoring processes
• Access to important volumes of Real World Data (RWD) to understand and analyze the impact of care plans and treatments in the health system as a whole, facilitating the future development of predictive models.
However, these tools, in the next future, must reach the new realm of “”Personalized Medicine”” where Genomics is a key cornerstone.
Making compatible “”common standard clinical pathways”” with “”Personalized Medicine”” is the main challenge of IDI EIKON in the next years.
IDI EIKON aims to approach Genomic tests outcomes in a M2M “”interoperable way”” in order to increase the critical mass needed for improving the decision making in daily clinical practice.
“
At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.
IMGT®, the international ImMunoGeneTics information system®
Montpellier, France
Research University
Research Institute
IMGT®, the international ImMunoGeneTics information system® http://www.imgt.org, is the global reference in immunogenetics and immunoinformatics, created in 1989 by Marie-Paule Lefranc (Université de Montpellier and CNRS). IMGT® is a high-quality integrated knowledge resource specialized in the immunoglobulins (IG) or antibodies, T cell receptors (TR), major histocompatibility (MH) of human and other vertebrate species, and in the immunoglobulin superfamily (IgSF), MH superfamily (MhSF) and related proteins of the immune system (RPI) of vertebrates and invertebrates. IMGT® provides a common access to sequence, genome and structure Immunogenetics data, based on the concepts of IMGT-ONTOLOGY and on the IMGT Scientific chart rules. IMGT® works in close collaboration with EBI (Europe), DDBJ (Japan) and NCBI (USA). IMGT® consists of sequence databases, genome database, structure database, and monoclonal antibodies database, Web resources and interactive tools.
The Indian Society of Human Genetics (ISHG) is devoted to the growth and dissemination of knowledge of human genetics and its related fields in India. The Society conducts annual meetings, symposia and workshops to promote awareness of the current developments in the field.
Apart from the Indian Journal of Human Genetics, it also publishes monographs and books. The membership of ISHG is open to all those who are engaged in the study and research in human genetics and its related areas.
The Indiana University School of Medicine, including Regenstrief Institute and the Indiana Clinical and Translational Sciences Institute, provide medical education, research, clinical care, medical informatics, and translational programs for the State of Indiana. The IU School of Medicine educates the largest student body in the U.S. on 9 campuses across the state. It has over 2,000 full time faculty and approximately 825,000 square feet of dedicated research space, including the only NCI-designated cancer center in Indiana. It has research affiliations with IU Health, Eskenazi Health, and the Roudebush VA Hospital.
Indoc is a not-for-profit company that helps medical research teams manage, share and analyze their complex data, including genomic, imaging and clinical research data. We employ rigorous standardization processes that govern how information is recorded and exchanged in order to define and format the vast array of diverse data, and to optimize federation by ensuring that data in one system is understood by another. Many of the studies we support collect various types of molecular and ‘omics data to identify potential biomarkers for diagnosis and prognosis of disease. Centralized management of genomics data introduces a unique set of challenges including a very diverse set of data modalities, large and ever-growing datasets and files, and harmonization with existing ‘omics databases and standards and workflows, including GA4GH. By taking advantage of existing standards and workflows we ensure a thorough capture of all data and associated metadata, while harmonizing with other ‘omics databases. As Indoc also supports open sharing of data, we have developed policies and guidelines on data privacy and governance, outlining how data are collected, stored, and accessed.
INESC-ID is a leading research institution in Portugal with strong international ties among the genomic research community across Europe and the Americas. Over the years, INESC-ID has conducted multiple research initiatives in bioinformatics and computational biology.
Innova Sierra Pty Ltd (NextOmics)
Melbourne, Australia
Companies Genomic Analysis
Companies Information Technology
Innova Sierra is a Research Service Provider (RSP) with a division, NextOmics, focused on NGS Life sciences Big data analysis, based out of Melbourne, Australia
Innovative Medicines Initiative
Brussels, Belgium
Funders and Agencies Public
Funders and Agencies Private
The Innovative Medicines Initiative is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research.
Inscripta is building the world’s first benchtop genomic engineering platform. This platform will enable research labs to routinely perform high scale genome engineering experiments with the push of a button.
Insight Centre for Data Analytics, National University of Ireland, Galway
Dublin, Ireland
Research Institute
The Insight Centre for Data Analytics was created to realise this vision. Insight is a joint initiative between University College Dublin, the National University of Ireland at Galway, University College Cork, and Dublin City University. Insight was established in 2013 by Science Foundation Ireland with funding of €75m.
At Insight we combine the skills of leading researchers with cutting-edge technologies from diverse research areas. We work closely with industry partners to develop next-generation data acquisition and analytics solutions for important and diverse application areas.
InSilico DB is a powerful combination of user-friendly interface, one of the largest public collections of gene expression data available, and seamless connections to major analysis tools.
Inspire2Live is a patient advocacy organisation whose aim is to get cancer under control by 2021. We are firmly convinced that this is achievable provided cancer sufferers, doctors and researchers worldwide all work together to share knowledge, data and inspiration. Unfortunately, faculties, research groups and universities are currently engaged in very unhealthy competition. Inspire2Live brings these various players together with groups of highly informed patients. All these stakeholders are then encouraged to work on optimising the processes involved so that new ideas, therapies and treatments are made available much faster to patients, not just in the Netherlands but all over the world.
The Institut National du Cancer (National Cancer Institute) is the pre-eminent health and science agency dedicated to cancer control in France. INCa has been created under the Public Health Act of 9 August 2004 and is empowered with a national coordination mandate of the Cancer Control activities. It is attached to both the Ministries of Health and of Research. INCa supports the full spectrum of activities that have value in a comprehensive cancer control strategy and ensures the timely implementation of the national cancer control plans. As per its mandate, Inca’s missions encompass public health, research, care & patient’s life, and information to people & professionals. INCa conducts studies and survey, provides recommendations and guidelines, implements coordinated programs and supports activities following open & competitive calls for project proposals, and independent evaluation and selection.
The Institute for Systems Biology is a nonprofit biomedical research organization based in Seattle, Washington. It was founded in 2000 by systems biologist Leroy Hood, immunologist Alan Aderem, and protein chemist Ruedi Aebersold. ISB was established on the belief that the conventional models for exploring and funding breakthrough science have not caught up with the real potential of what is possible today. ISB serves as the ultimate environment where scientific collaboration stretches across disciplines, where our researchers have the intellectual freedom to challenge the status quo, and where grand visions for breakthroughs in human health inspire a collective drive to achieve the seemingly impossible. Our core values ensure that we always keep our focus on the big ideas that eventually will have the biggest impact on human health. – See more at: http://www.systemsbiology.org/about-isb#sthash.QWpGbQGl.dpuf
Institute of Biosciences and Medical Technology–BioMediTech
Tampere, Finland
Research Institute
Research University
BioMediTech is a joint institute of Tampere University of Technology and University of Tampere, Finland. BioMediTech performs multidisciplinary research and education, from genetics to engineering. Its mission is to make pioneering discoveries and innovations in life sciences.
Institute of Cancer Research, Oslo University Hospital
Oslo, Norway
Healthcare Research
Healthcare Care Delivery
The Institute of Cancer Research has a central role within the field of cancer research in Norway. It has an emphasis on translational science based on in-house research, and the Institute is a key partner in the Oslo University Hospital Comprehensive Cancer Center. The Oslo University Hospital is the largest hospital structure in Norway.
We take care of patients and their families with genetic disorders, especially with developmental delay. We have considerable knowledge in the field of Syndrome diagnostics and we are part of the german syndicate for hereditary breast and ovarian cancer as well as for hereditary nonpolyposis colorectal cancer.
The focus of our research lays on the study of causes for developmental delay and brain malformation. Furthermore we characterize brain tumors genetically and functional for targeted therapy. In cooperation we analyze genetic variations in tumors, cell lines and animal models.
The Institute of Clinical Molecular Biology (IKMB) drives research aimed at creating a systemic understanding of complex human diseases as well as the phenotype of healthy ageing by using genomic technologies. This includes validating the resulting models at the molecular level (in vitro/in vivo) and their translation into the human diagnostic or therapeutic experiment. With its dedicated sequencing infrastructure – including three Illumina HiSeq2000 and 3 HiSeq 2500 machines – the institute supports not only its own diverse research curriculum, but also collaborates with a wide network of clinicians and researchers, both within Germany and world-wide. The Kiel sequencing center is among the largest within Europe and the largest academic facility in Germany. Starting in 2015, we will take a leading role in the German VarWatch initiative, a newly established, national collaboration and infrastructure to catalogue and classify rare genetic variants according to their clinical significance.
Institute of Environmental Science and Research
Porirua, New Zealand
Research Institute
Research Collaboration or Consortium
The Institute of Environmental Science and Research (Māori: Te Whare Manaaki Tangata, Taiao hoki) is a New Zealand Crown Research Institute (CRI). Its purpose is to deliver scientific and research services to the public health, food safety, security and justice systems, and the environmental sector to improve the safety of, and contribute to the economic, environmental and social well-being of people and communities in New Zealand.
Institute of Human Genetics - Hannover Medical School
Hannover, Germany
Research University
Healthcare Research
The main focus of research at the Institute of Human Genetics at Hannover Medical School (Hannover, Germany) lies within the investigation of a large variety of genetically caused diseases. A major goal is the exploration of the influence of genetically altered genes and chromosomes on the development of hereditary cancer in different entities. This includes the identification of predisposing mutations in families with previously unknown genetic causes. Our medical staff is highly involved in diagnosing and attending to an ever increasing number of families with suspected genetically caused (cancer) diseases that seek our advice. With respect to our work within the field of hereditary breast and ovarian cancer as well as hereditary bowel cancer we serve as a cytogenetic reference laboratory for international multi-center treatment studies for ALL, AML, CML and MDS in both, adults and children.
The National Institute of Genomic Medicine (INMEGEN) is the eleventh National Institute of Health, founded in 2004, as a result of work done since 2001 by the Promoter Institute of Genomic Medicine Consortium, formed by the National Autonomous University of Mexico, the National Council of Science and Technology of the Ministry of Health, and the Mexican Health Foundation.
The INMEGEN is a national and international leader in genomic research and its main objective is to contribute to the health care of Mexicans through the development of scientific research projects with leading technology, human resources training excellence and generation of genomic applications innovative practices to improve health care, while complying with universal ethical principles and respect for human rights.
Instituto Nacional de Saúde Doutor Ricardo Jorge
Lisboa, Portugal
Research Institute
Healthcare Research
The Instituto nacional de Saúde Doutor Ricardo Jorge (INSA) is a public organization of the Portuguese Ministry of Health, endowed with scientific, technical, administrative, financial and property of its own.
Founded in 1899 by Ricardo Jorge (Porto, 1858 – Lisbon, 1939), as the laboratory arm of the Portuguese Health System, INSA develops a triple role as State Laboratory in the Health Sector, National Reference Laboratory and National Health Observatory.
INSA has operating units at its headquarters in Lisbon, one center in Porto (Centre for Public Health Dr. Gonçalves Ferreira ) and Águas de Moura, Palmela (Centre for Vectors and Infectious Diseases Dr. Francisco Cambournac).
INSA is organized in technical and scientific terms, in six major departments:
Food and Nutrition Department
Infectious Diseases Department
Epidemiology Department
Human Genetics Departament
Health Promotion and non Communicable Disease Prevention
Environmental Health Department
All operative units composing the departments develop multidisciplinary programmes in problem-areas of Public Health, namely performing R&D, health monitoring, training, laboratory external quality assessment and laboratory services.
The Intel Health & Life Sciences Group (HLS) is responsible for leading a cross-company strategy to grow the company’s value, footprint, and revenue in the healthcare and life science sector. Our technologies power many of the next-generation platforms — EHR infrastructure, coordinated care, telehealth, remote diagnostics, mobile health, genomics, and personalized medicine, that are required to deliver sustainable, affordable, high-quality healthcare to billions of people worldwide. Follow us at @IntelHealth
Interactive Biosoftware is a software company focusing on practical software applications for health care and life sciences, particularly in the field of human genetics and genomics. It is the creator of the Alamut software suite used by hundreds of diagnostics and research genetics laboratories worldwide.
Intermountain Healthcare is an internationally recognized, nonprofit system of 22 hospitals, a Medical Group with more than 185 physician clinics, and an affiliated health insurance company, SelectHealth. Our 33,000 employees serve patients and plan members in Utah and southeastern Idaho. Whether you need a flu vaccination or the latest in cancer treatment, we offer a full range of services, from urgent care to home care to the region’s most advanced trauma centers. Providing excellent care of the highest quality at an affordable cost is at the heart of our mission.
The International Agency for Research on Cancer (IARC) is the specialized cancer agency of the World Health Organization. The objective of IARC is to promote international collaboration in cancer research. The Agency is inter-disciplinary, bringing together skills in epidemiology, laboratory sciences and biostatistics to identify the causes of cancer so that preventive measures may be adopted and the burden of disease and associated suffering reduced. A significant feature of IARC is its expertise in coordinating research across countries and organizations; its independent role as an international organization facilitates this activity. The Agency has a particular interest in conducting research in low- and middle-income countries through partnerships and collaborations with researchers in these regions.
International Cancer Genome Consortium
Toronto, Canada
Funders and Agencies Public
Research Collaboration or Consortium
The International Cancer Genome Consortium is a voluntary scientific organization that provides a forum for collaboration among the world’s leading cancer and genomic researchers to obtain a comprehensive description of genomic, transcriptomic and epigenomic changes in 50 different tumor types and/or subtypes which are of clinical and societal importance across the globe.
International Human Epigenome Consortium
Montreal, Canada
Research Collaboration or Consortium
Funders and Agencies Public
The International Human Epigenome Consortium (IHEC) is a global consortium with the primary goal of providing free access to high-resolution reference human epigenome maps for normal and disease cell types to the research community. The epigenome reference maps will be of great utility in basic and applied research. They are likely to have an immediate impact on the understanding of many diseases, and will hopefully lead to the discovery of new means to treat or manage them.
International HundredK+ cohorts Consortium
Durham, United States
Societies and NGOs Patient Disease Advocacy
Research Collaboration or Consortium
The International HundredK+ Cohorts Consortium (IHCC) aims to create a global platform for translational research – cohort to bedside and cohort to bench – informing the biological and genetic basis for disease and improving clinical care and population health.
We are bringing large cohorts together to encourage data sharing, improve efficiencies and maximize benefits in addressing scientific questions none could answer alone. We have formed three teams focused around data standards and interoperability, scientific strategy and cohort enhancements, and policy and bio-data sharing to address the value and challenges of combining large cohort data across borders.
Our member cohorts aim to recruit 100k participants or more, are disease-agnostic, have available biospecimens, and have longitudinal follow-up activities. We recognize, however, that cohorts from under-represented populations and low and middle-income countries (LMICs) may not fit some of these criteria, so exceptions are made to be inclusive as possible.
We are also continuously looking for novel cross-cohort scientific programs from our members. To gather ideas, we periodically open Requests for Ideas (RFIs). Many of the ideas from RFIs include rare conditions, exposures and genotypes as well as consanguinity, founder populations studies and other unique training opportunities that may potentially be addressed by bringing several large cohorts together.If your cohort is interested in joining IHCC, contact us for more information.
The International Rare Diseases Research Consortium (IRDiRC) teams up researchers and organizations investing in rare diseases research in order to achieve two main objectives by the year 2020, namely to deliver 200 new therapies for rare diseases and means to diagnose most rare diseases.
International Society for Biological and Environmental Repositories
Vancouver, Canada
Societies and NGOs Professional
ISBER is the largest international forum that addresses the technical, legal, ethical, and managerial issues relevant to repositories of biological and environmental specimens. ISBER is a professional society of individuals and organizations who share an interest in promoting consistent, high quality standards, ethical principles and innovation in biospecimen banking by uniting the global biobanking community. ISBER invites all sub-components of government, academia, the private sector, and manufacturers to become active participants of the society.
We develop advanced data management, connectivity, and analytics technologies that help our clients make breakthroughs in healthcare, financial services, government, utilities, and other industries that demand the highest software performance and reliability.
Leading organizations around the world such as Kaiser Permanente, NHS Scotland, TD Ameritrade, Petrobras, and many more rely on our products to power their core enterprise systems.
Intertrust Technologies Corporation is an international holding company for its many innovative technologies, a strategic investor in several startup companies, and a proud thought leader in technological innovation. Intertrust has developed several brands in the realm of digital trust, data privacy, internet security, and content protection.
Invitae is a genetic information company whose mission is to bring genetic information into mainstream medical practice to improve the quality of healthcare for billions of people.
Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. IQVIA is the largest Healthcare Data Science Company and leader in Human Data Science Technology.
Iwate Tohoku Medical Megabank Organization was founded at Iwate Medical University to restore medical services in the areas stricken by the Great East Japan Earthquake and Tsunami on March 2011 and to establish a next-generation medical care system. The organization is conducting a large-scale genomic cohort study primarily in the disaster-stricken areas in cooperation with Tohoku University Tohoku Medical Megabank Organization.
Ixlayer is a precision health testing platform that enables health systems and Pop-Gen organizations with the following:
Roll out their projects 7-12 months faster to their patients/population compared to developing the cloud and CRM tools by themselves.
Roll out patients/population health engagement projects by running surveys using sms, email, and web portal
Model each user, the cohort they belong to and deliver personalized results based on different attributes or their meta data. ixLayer platform was designed based on a Health-data-graph structure that depicts relations of each user’s genotype, phenotype and health data using tagging system.
Engage physicians to access data with specific action tailored for health providers.
Enable electronic consent and data de-identification for research studies.
The Japan Agency for Medical Research and Development (AMED) engages in research and development in the field of medicine, establishing and maintaining an environment for this R&D, and providing funding, in order to promote integrated medical R&D from basic research to practical applications, to smoothly achieve application of outcomes, and to achieve comprehensive and effective establishment /
maintenance of an environment for medical R&D.
Japan Science and Technology Agency-National Bioscience Database Center
Tokyo, Japan
Funders and Agencies Public
Funding Agency having functions of research management and developmentin Science and Technology.
The Japan Society of Human Genetics (JSHG) was established in 1956. The mission of JSHG is to promote researches in human genetics and clinical practice of medical genetics. To accomplish this mission, JSHG publishes its official journals, Journal of Human Genetics and Human Genome Variation, and organizes Annual Meeting of JSHG every year.
Solomonbrothers Medical Technology focuses on Precision Medicine. We have a professional independent medical laboratory in China, whose area is about 1600 square meters. Based on the standard of tumor molecular detection, the clinical diagnosis and scientific research platform has been set up and provided a total solution with medical qualification for cancer researchers, clinical oncologists, biological pharmaceutical companies, patients and their families. Up to now, we have developed four class product line including cancer prevention, diagnosis, treatment and care. There are totally 17 series, such as SMT Core, SMT One, SMT ctDNA and SMT CTC. Many top three hospitals collaborate with us in clinical diagnosis and scientific research. Our effort has won us praise from clinical experts and patients.
Jisc
Bristol , United Kingdom
Companies Information Technology
National Research & Education Network
Jisc offers digital services and solutions for UK education and research. The charity does this to achieve its vision for the UK to be the most digitally advanced education and research nation in the world.
Working together across the higher education, further education and skills sectors, Jisc provides trusted advice and support, reduces sector costs across shared network, digital content, IT services and procurement negotiations, ensuring the sector stays ahead of the game with research and development for the future.
Johns Hopkins University School of Medicine
Maryland, United States
Research University
Research University
At John Hopkins University of Medicine, we educate medical students, graduate students and postdoctoral fellows to practice patient-centered medicine, to study the prevention and treatment of disease, and to excel in health care delivery and in the basic sciences.
Joint Research Centre
Geel, Belgium
Research Institute
Government Institution (Directorate General of the European Commission)
The Joint Research Centre (JRC) is the European Commission’s science and knowledge service which employs scientists to carry out research in order to provide independent scientific advice and support to European Union (EU) policy.
KP’s Precision Medicine/ Genomics (PM/G) program focuses on utilizing genomics to provide more effective, accessible, personalized care by integrating evidence-based genomics into well-designed patient-centered care pathways.
KP has CLIA/CAP certified genetic testing capabilities.
KP’s Interregional Genetic Workgroup identifies best practices for utilizing genetic information to advance care delivery. It also maintains an interregional genetic testing resource (IGTR) which provides accessible clinical and laboratory decision support for evidence-based genetic test selection at the most affordable price.
The KP Research Bank (KPRB) is building a collection of biospecimen, EHR, and survey data from 500,000 members in all regions to advance medical knowledge.
Kanteron Systems is a privately held Healthcare IT – Biomedical Informatics company founded in 2005 with an award-winning solution that takes existing hospital enterprise systems to a whole new level by integrating genomics, pharmacogenomics, digital pathology, radiology, biosensors, and analytics into a single unified workflow. Furthermore, with our “SPLIT” software we finally enable the use of any cloud for healthcare images and data in a completely secure way that is transparent for the user. With offices in New York (USA), Lima (Peru), and Valencia (Spain), Kanteron Systems’
King's College London
London, United Kingdom
Healthcare Research
Healthcare Care Delivery
King’s Health Partners (KHP) is one of six Academic Health Science Centres (AHSCs) in England designated by the Department of Health. It brings together a world-leading research led university (King’s College London) and three successful NHS Foundation Trusts (Guy’s and St Thomas’, King’s College Hospital and South London and Maudsley). KHP is a founding member of the South London NHS Genomics Medicine Centre which is part of the 100,000 Genomes Project.
King's College London
London, United Kingdom
Healthcare Research
Healthcare Care Delivery
King’s Health Partners (KHP) is one of six Academic Health Science Centres (AHSCs) in England designated by the Department of Health. It brings together a world-leading research led university (King’s College London) and three successful NHS Foundation Trusts (Guy’s and St Thomas’, King’s College Hospital and South London and Maudsley). KHP is a founding member of the South London NHS Genomics Medicine Centre which is part of the 100,000 Genomes Project.
Knome, Inc. is a leading provider of human genome interpretation systems and services. We have helped clients in two dozen countries identify the genetic basis of disease, tumor growth, and drug response. Designed to accelerate and industrialize the process of interpreting whole genomes, exomes, and gene panels, Knome’s big data technologies are helping to smooth the healthcare industry’s transition to molecular-based, precision medicine.
KPMG LLP
London, United Kingdom
IT Consulting - Life Sciences
One of the largest global professional services company and one of the Big Four auditors.
L3 Bioinformatics Limited
Hong Kong, Hong Kong SAR China
Companies Information Technology
Companies Genomic Analysis
L3 is a young and energetic company where IT talents, renowned professors and top-notch industrial partners like BGI work together to invent and develop the future computing technologies for bioinformatics.
It’s never easy to develop state-of-the-art technology which advances genomics analysis. We need biologists who understand the bleeding edge problems in genomics analysis. We need experts who knows how to design advanced algorithms to cope with the problems. We need seasoned IT engineers who know how to put together the right computing architecture for the designed solutions. And perhaps the hardest of all, we need a team of all above-mentioned, who can work together.
Lab7 Systems’ vision is to reduce the level of hands-on data management by bioinformaticians, scientists, and IT teams who are struggling with the massive amounts of data that are being generated by modern analytical technologies, such as next-generation sequencing, mass spectrometry, cellular imaging, fMRI, and others. We understand that there is a critical need to develop a tool that will integrate the disparate and often disjointed scientific software toolkit that is being used, and thereby free up the valuable human resources who are currently tasked with doing this. We are all scientists from each of our core constituencies who have at one time or another faced the same issues, so we bring this intimate knowledge to our development process.
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories.
Labsquare
Brest, France
Research Collaboration or Consortium
opensource community for genomics software
Labsquare is a community of developers for building opensource genomics software. We are making native and simple GUI using Qt technology.
Leucine Rich Bio Pvt Ltd
Bangalore, India
Companies Genomic Analysis
Companies Information Technology
Leucine Rich Bio is a Bioinformatics company based in Bangalore, specializing in Next Generation Sequencing (NGS) Data Analysis & Interpretation. Our area of focus is in Human Genome Interpretation, especially for clinical use. We use advances in the area of Computer Science, Information Science, Data Management, Statistics and Systems Biology to solve complex problems in Genomics.
Lexent Bio is building liquid biopsy technology will help oncologists and their patients understand if they are responding to treatment, sooner and more accurately than currently possible.
As the UK’s designated institute for chemical and bio-measurement and home of the Government Chemist, we deliver world-leading measurement science to solve complex global challenges, ensuring trust and confidence in the thousands of measurements performed routinely within the UK to improve quality of life.
Our world-leading research covers the areas of diagnostics, advanced therapeutics, safety and security. It underpins some of the biggest challenges of our time, including neurodegenerative diseases, cancer and antimicrobial resistance.
Our core research involves performing high accuracy measurements with known uncertainties.
We play a leading role in standardisation of measurements across the world so that, for example, a medical test result obtained in London can be compared directly with test results from hospitals in Sydney, Seattle or Shanghai.
We provide traceability for routine chemical and bio-measurements within the UK in order to support comparison of measurement results between laboratories, support product development and help support current regulation.
Lifebit Biotech Limited
London, United Kingdom
Companies Information Technology
Companies Genomic Analysis
Lifebit is democratising muti-omics, biomedicine & big data analysis with its AI-powered cloud-based system. This enables developers & researchers, no matter their computational & analysis training level, & their organisations, to instantly run & scale such analysis in a cost-speed-efficient and reproducible way that automates analysis processes, learns from the data & provides actionable insights.
LifeMap Sciences, Inc.
Marshfield, United States
Companies Genomic Analysis
Companies Information Technology
The company’s primary product offering, the GeneCards Suite, is comprised of an integrated biomedical knowledgebase and premium tools that enable researchers to effectively navigate the universe of human genes, proteins, cells, biological pathways, diseases, and the relationships between them. The knowledgebase includes three key databases that integrate information from over 100 sources: GeneCards®, the leading human gene database, MalaCards, the human disease database, and LifeMap Discovery®, the cells and tissues database. The GeneCards Suite premium tools are a set of biomedical data analysis applications that leverage the GeneCards Suite knowledgebase for gene variant prioritization and RNAseq and microarray gene set analysis to deliver enhanced results, including from the unprecedented quantities of data derived from next generation sequencing (“NGS”). The premium tools include VarElect, the NGS phenotyper, GeneAnalytics™, a novel gene set analysis tool, and GeneALaCart, the GeneCards batch querying application.
LifeNome Inc. is a revolutionary personalized wellness genomics company combining advanced computational genomics algorithms with artificial intelligence to transition from association-based interpretations of genomics data towards clusters of data.
The LifeOmic Precision Medicine Platform (PMP) is a revolutionary cloud-based healthcare solution engineered to store and manage everything from whole genome sequences to large-scale data sets for proteomics, metabolomics, transcriptomics, and others that haven’t been invented yet. LifeOmic PMP serves as an aggregation point that can unlock the tremendous value tucked away in myriad existing systems – or largely discarded by current workflows that only store textual reports.
Limbus Medical Technologies GmbH
Rostock, Germany
Companies Information Technology
Companies Genomic Analysis
Limbus Medical Technologies GmbH is a medical device manufacturer. We offer high-performance and scalable cloud solutions for clinical diagnostics.
Linkage Biosciences
South San Francisco, United States
Companies Life Science
Companies Genomic Analysis
Linkage Biosciences is a molecular diagnostics company developing and marketing products that dramatically improve and expedite complex genetic testing. The company is focused on histocompatibility and immunogenetics as it relates to solid organ and stem cell transplantation.
LShift Ltd.
LONDON, United Kingdom
Companies Information Technology
Research Collaboration or Consortium
LShift is an independent software development company with offices in London and Berlin. It was founded in 2000 in Shoreditch, London, by developers and designed to provide the ideal conditions in which the best levels of technical services can be offered to clients. Our model has proven successful again and again in the many long-standing relationships we have developed with our clients in the academic, public and private sectors.
Lund University is a comprehensive university with a strong research profile (Member of LERU). 35000+ students and 4000 PhD students. Turnover 840 MEURO (2/3 research)and ranking around position 100
Luxembourg Centre for Systems Biomedicine (LCSB)
Belvaux, Luxembourg
Research University
Research Institute
The LCSB’s research aims to understand the determinants of health and disease. The research programme focuses on the determinants and biological mechanisms of diseases using a systems approach by investigating all influences from genes to environment and computationally model these with mathematical approaches.
Maastricht UMC+ is a collaboration between the University Hospital Maastricht
(azM) and the Faculty of Health, Medicine and Life Sciences at the University of
Maastricht. Maastricht UMC+ has three mutually reinforcing core tasks:
+ Patient care: We provide diagnostics and treatment, from basic care to top clinical
and top referral care to the most complex patients;
+ Research: We do scientific research, from fundamental to applied, that complements
and contributes to the specializations within patient health care;
+ Education and Training: We train new generations of doctors and researchers.
In addition to these three core tasks, we realize that creating value from knowledge
is becoming increasingly important.
Macrogen was established on June 5, 1997, based in the Genomic Medicine Institute of the Seoul National University College of Medicine. In February 2000. It is the first Korean bio venture to be listed on the KOSDAQ.
Since then, Macrogen has continued to be actively engaged in R&D fields for genetic and genomic analyses. In addition to providing services to clients around the world, Macrogen contributes to the advancement of bioindustries through a wide range of CSR activities.
Macrogen is committed to leading innovation in precision medicine in the 21st century by providing personalized genomic information. It is also realizing achievements in the global genome analysis market in various sectors, thanks to its superior technological expertise.
We have tools and we have several tools in development focused on researchers and their scientific work. At this time we can create customized tools for any need in the Healthcare Environment, starting from a web environment with cloud computing to immediate management in android. In our slide Multicellular Vision around the Patient we reflect our mission and vision. https://magmarketintelligence.com/index.php/en/associations-of-sick/
Manchester Academic Health Science Centre (MAHSC)
Manchester, United Kingdom
Healthcare Research
Healthcare Care Delivery
Manchester Academic Health Science Centre (MAHSC) is a partnership between The University of Manchester and six National Health Service (NHS) organisations, uniting leading healthcare providers with world-class academics and researchers.
The MAHSC partners care for a regional population of three million, with some of the greatest health needs in the UK. We also make a contribution globally through research, education, healthcare and knowledge transfer. The exceptional level of integration across our partnership drives outstanding performance: 30% of commercial trials in England now take place in our Network, and we train 70% of the country’s healthcare scientists.
The discoveries and knowledge we generate are underpinned by excellent laboratories and patient care facilities throughout the city region, including integrated platforms in genetics, metabolomics and proteomics, and advanced imaging. In the last few years our work has led to the discovery of new treatments for rare diseases, transformations in breast cancer care, and improvements in detecting problems associated with diabetes that can prevent sight loss.
Our clinical informatics infrastructure provides safe and secure access to more than half a million patient records across primary and secondary care, and has opened up a new global market in large scale and real world study designs led from Manchester, including the largest commercial trial in the UK.
Mapmygenome is a leading Indian molecular diagnostics company that leverages state-of-the-art DNA sequencing and SNP Genotyping technologies coupled with latest research to screen for genetic predisposition and diagnose complex genetic disorders. The company is founded and funded by some of the most successful serial entrepreneurs and investors with a vision to improve 100 million lives by 2020. Mapmygenome has carved out a niche for itself. Mapmygenome is backed by 17+ years of experience in genomics, and stemmed from Ocimum Biosolutions. We offer personalized health solutions based on genetic tests that help people know more about themselves.
MapR delivers on the promise of Hadoop with a proven, enterprise-grade platform that supports a broad set of mission-critical and real-time production uses. MapR brings unprecedented dependability, ease-of-use and world-record speed to Hadoop, NoSQL, database and streaming applications in one unified distribution for Hadoop. MapR is used by more than 700 customers across ad media, consumer products, financial services, government, healthcare, manufacturing, market research, networking and computers, retail/online and telecommunications as well as by leading Global 2000 and Web 2.0 companies. Amazon, Cisco, Google, Teradata and HP are part of the broad MapR partner ecosystem. Investors include Google Capital, Lightspeed Venture Partners, Mayfield Fund, NEA, Qualcomm Ventures and Redpoint Ventures. MapR is based in San Jose, CA.
Massachusetts Eye and Ear Infirmary
Boston, United States
Healthcare Research
Healthcare Care Delivery
Massachusetts Eye and Ear Infirmary is a specialty hospital providing patient care for disorders of the eye, ear, nose, throat, head and neck. Founded in 1824, MEEI is an international leader in Ophthalmology and Otolaryngology research and a teaching partner of Harvard Medical School.
Massachusetts General Hospital works to provide care in all corners of the world – locally, nationally and globally – by partnering with underserved communities to build, improve and sustain health care delivery and healthier communities.
Matchmaker Exchange project was launched in October 2013 to find genetic causes for patients with rare disease. This involves a growing federated platform (Exchange) to facilitating the matching of cases with similar phenotypic and genotypic profiles (matchmaking) through standardized application programming.
Maverix Biomics, Inc.
San Mateo, United States
Companies Genomic Analysis
Companies Information Technology
Maverix Biomics, Inc. provides researchers with a cloud-based platform to manage, analyze, and visualize genomic data, build Communities of Discovery, and place their data in context with the latest public data from the full spectrum of life, including human, plant, animal, or microbial organisms.
Mayo Clinic’s mission is to inspire hope and contribute to health and well-being by providing the best care to every patient through integrated clinical practice, education and research. Our primary value is “The needs of the patient come first.”
MB Omica is newly established Medical technologies company developed by medical, molecular genetic and bioinformatic specialists. Company is developing innovative and alternative methods for analyzing the human genome data. The main activities of the company are the analysis of human genome data, research of integration of genetic data into clinical practice, simplification of routine genetic analysis and the automation of its processes. The company’s activities are based on the latest research findings and the application of advanced genetic technologies to the development of medical innovations in order to individualize and improve treatment.
McGill University is one of Canada’s best-known institutions of higher learning and one of the leading universities in the world. With students coming to McGill from some 150 countries, our student body is the most internationally diverse of any research-intensive university in the country. McGill was founded in 1821 thanks to a generous bequest by James McGill, and since then, we’ve grown from a small college to a bustling university with two campuses, 11 faculties, some 300 programs of study, and 39,500 students. The University also partners with four affiliated teaching hospitals to graduate over 1,000 health care professionals each year.
MDS Technologies Ltd
Chippenham, United Kingdom
Companies Information Technology
Companies Genomic Analysis
MDS is partnering with Genomics England Ltd and the 100k Genomes Project to deliver and manage the secure IT platforms, tools, datacenter and assurance that enable researchers, the NHS and other genomics leaders to deliver truly personalised medicine.
MedGenome Inc. is a genomics-based diagnostics and research company delivering the best of health care by decoding genetic information contained in an individual’s genome. It is a founding member of GenomeAsia 100K initiative to sequence 100,000 genomes in South, North and East Asia.
MedGenome has a CLIA / CAP certified NGS lab in Foster City, CA and offer NGS Informatics services along with sequencing services. Its unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized health care. MedGenome is also a market leader for genomic diagnostics in South Asia and a leading provider of genomics research services globally.
The heart of MRC’s mission is to improve human health through world-class medical research. To achieve this, we support research across the biomedical spectrum, from fundamental lab-based science to clinical trials, and in all major disease areas. We work closely with the NHS and the UK Health Departments to deliver our mission, and give a high priority to research that is likely to make a real difference to clinical practice and the health of the population.
The MRC’s mission, as set out in our Royal Charter, is to
– Encourage and support research to improve human health.
– Produce skilled researchers.
– Advance and disseminate knowledge and technology to improve the quality of life and economic competitiveness of the UK.
– Promote dialogue with the public about medical research.
MediSapiens is a bioinformatics and software development company with a strong background in pharmacogenomics and translational research. We excel at creating flexible and efficient solutions designed to provide scientists with a way to quickly analyze and visualize vast amounts of data an turn it into knowledge that fuels innovation and drives medicine forward.
We have created powerful and intuitive software platforms to manage, integrate and analyze complex multi-dimensional datasets, such as genomic sequencing and other biomedical data. Our mission is to help pharmaceutical industry and clinical organizations to design more effective personalized drugs against life-threatening diseases.
We are dedicated to promoting human health by deciphering genomic data and monitering the expo-some (meaning all exposures from the environment) information. A professional team is making use of the state-of-the-art genome technology. High throughput genetic data will be generated which we are willing to make good share and applications.
The current mode of genetic testing for medical treatment purposes restricts its use to individuals with overt disease or a known family predisposition. An extension to healthy individuals is presently not desirable as this would consume scarce healthcare resources at a low benefit-to-cost ratio and potentially take a large psychological toll as most individuals carry one or more predispositions. Megeno is developing novel processes and service products that are geared towards using personal genetic information in healthy individuals as an element (among others) to prevent diseases well before the appearance of clinical symptoms. The company’s “Personalised Health Surveillance” concept is a subscription service, based on genomic data as well as additional phenotypic information supplied by the individual, thereby offering individuals and eventually health care systems a cost effective approach to reduce future disease burden.
Melbourne Genomics Health Alliance
Melbourne, Australia
Research Collaboration or Consortium
Research Institute
The Melbourne Genomics Health Alliance links the clinical, research and teaching strengths of its seven founding members to integrate genomic medicine into everyday healthcare for the betterment of patients.
Melbourne Health is one of Australia’s leading public healthcare providers. Our mission is simple – to provide world-class healthcare for our community by embracing discovery and learning, building collaborative relationships, and engaging patients in their care.
We are redefining the concept of patient engagement and modernize cancer care.
Mendelics is the leading genomic-based clinical diagnostics laboratory in Brazil. The company focuses in exome and genome sequencing applied to rare genetic diseases and cancer.
Merck & Co., Inc. (“Merck” or the “Company”) is a global health care company that delivers innovative
health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care
products, which it markets directly and through its joint ventures.
Metis Genetics combines technology and innovation to increase the accessibility of high-quality, affordable genetic counseling to support the implementation of genomic medicine.
We work in partnership with large-scale genetic testing laboratories (academic and commercial), healthcare systems, insurance payers and government entities by providing a scalable genetic counseling solution that increases the availability of genetic counseling to all patients.
The experienced professionals at Metis Genetics are dedicated to improving access to genetic counseling services in a way that is clinically- appropriate for patients, supports the local genetic counseling community and is cost-effective for our partners.
Contact us at support@metisgenetics.com to learn more.
MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time, panoramic, and full-life-cycle equipment and systems for precision medicine, precision agriculture, precision healthcare and other relevant industries. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.
Microsoft
Los Angeles, United States
Companies Information Technology
Companies Genomic Analysis
–
Ministry of Science, Technology and Productive Innovation
Buenos AIres, Argentina
Funders and Agencies Public
Funders and Agencies Public
MINCYT’s mission is to finance research, provide infrastructure, promote the harmonious link between the academic and productive systems and disseminate the knowledge produced by scientific-technological work and its applications in society.
We finance genomics research projects and precision medicine and provide support in ethics and regulations in Genomics.
We are Canada’s only nonprofit organization solely focused on mitochondrial disease, dysfunction and health (MDDH.) Our mission is to improve the treatment, quality of life, and long-term outlook for all individuals affected by MDDH via research, advocacy, education, and support.
MolecularMatch is a digital health company whose mission is to simplify the delivery of personalized medicine. Our company was founded on the principle that both physicians and patients should be able to quickly and easily get access to real time actionable molecular information in order to enhance clinical decision making. We have created an extensive database with oncology tailored analytics that allows users to quickly find real-time information about targeted drugs and clinical trials.
The Monarch Initiative provides tools that use semantics and statistical models to support navigating through multi-scale spatial and temporal phenotypes across in vivo and in vitro model systems in the context of genetic and genomic data. These tools will provide basic and clinical science researchers, informaticists, and medical professionals with an integrated interface and set of discovery platforms to reveal the genetic basis of disease, facilitate hypothesis generation, and identify novel candidate drug targets.
Monash University Faculty of Medicine, Nursing and Health Sciences
Monash, Australia
Research University
The Faculty of Medicine, Nursing and Health Sciences is the University’s largest research faculty. World-class researchers work across disciplines including laboratory-based medical science, applied clinical research, and social and public health research.
The faculty is also home to a number of leading medical and biomedical research institutes and groups, and has contributed to advances in many crucial areas: in vitro fertilisation, obesity research, drug design, cardiovascular physiology, functional genomics, infectious diseases, inflammation, psychology, neurosciences and mental health.
Mount Sinai Hospital is an internationally recognized acute care academic health sciences centre affiliated with the University of Toronto that is dedicated to delivering the best medicine and best patient experience. It is focused on excellence in patient and family-centred care, innovative education and leading-edge research.
Murdoch Childrens Research Institute is the preeminent child health research institute in Australia, and is recognised globally for its child health discoveries.
Researchers at the Institute work side-by-side with doctors and nurses from our Melbourne Children’s campus partners, The Royal Children’s Hospital and the University of Melbourne’s Department of Paediatrics. This provides our researchers with much greater interaction with patients for research and gives us the ability to more quickly translate research discoveries into practical treatments for children.
Our team of 1500 researchers is focused on combating emerging conditions affecting child health like allergy, diabetes and obesity, as well as finding answers to unsolved problems like cancer and genetic conditions.
We bring together large multi-disciplinary teams to work on problems together. Our research priorities include:
Adolescents
Allergies & autoimmune conditions
Cancer
Brain & mind development
Genomics & personalised medicine
Healthcare innovation
Murrieta Genomics
Murrieta, United States
Research Collaboration or Consortium
Companies Genomic Analysis
We are a genomic sequencing incubator looking to assist the next wave of genomic-related entrepreneurs and scientists realize their vision through access to technology and mentorship.
MAKING HEALTHCARE MORE PERSONALISED
myDNA was founded on the belief that healthcare can be improved and by providing personalised health and wellbeing advice you can transform lives for the better.
Our genomic analyses reports are developed by a team of specialists with expertise in clinical and molecular genetics, molecular biology, pharmacy, genetic counselling, sports dietetics and general practice and make available to health care professionals and subsequently consumers evidence based actionable advice to better understand and improve health and wellbeing.
Mydnabox is a personal genomics and health management company. We help people access, understand and benefit from the human genome.
MyGene2 is a free, public, searchable site developed by families with rare conditions, clinicians, and researchers to openly share health and genetic information with one another by creating “family profiles.” This makes discovering the genetic basis of rare conditions and their diagnosis easier.
The National Cancer Centre Singapore (NCCS) has through the years evolved to become one of the leading regional centres for the research and treatment of cancer. Undoubtedly, it is home to the largest number of researchers, surgeons and oncologists attending to the growing number of cancer patients. Since it became a national cancer centre in 1999, it has pioneered the one-stop multi-disciplinary approach, where today the doctors also sub-specialise to have an edge in developing a deeper understanding of the various cancer types. With the NCCS attracting the best talents in the research and medical community, it has been able to provide the best in cancer care and is a leader in clinical cancer trials as well as clinical cancer genetics services. We have a full fledged clinical cancer genetics service providing genetic testing to patients.
The National Cancer Center Research Institute (NCCRI) was established in 1962 as a department of the National Cancer Center (NCC), and has been the nation’s leading cancer research institute for nearly 50 years. It is now internationally recognized for major contributions to various aspects of cancer research worldwide. The mission of the NCCRI is to advance our knowledge of cancer prevention, diagnosis and therapy, toward the ultimate goal of cancer control.
–
National Center for High-performance Computing, National Applied Research Laboratories
Hsinchu, Taiwan
Research Institute
Research Institute
National Center for High-performance Computing (NCHC), founded in 1991, is Taiwan’s only national-level supercomputing center. The NCHC possesses a large computing and networking platform facilities for use by domestic academia and the general public. The NCHC plays a leading role in Taiwan’s cloud technology services by integrating high performance computing (HPC), storage, and networking to provide cloud services in storage, big data analysis, and scientific and engineering simulation.
The goal of the NCHC is to become an internationally renowned HPC center that promotes scientific discovery and technological innovation. Since its inception, the NCHC has been dedicated to strengthening Taiwan’s HPC and networking infrastructure. The NCHC has planned and implemented pilot research programs in HPC, cloud computing, as well as big data processing methods and applications. The NCHC provides professional technologies and platform services to academia, government, and industry, and helps to cultivate domestic talent in HPC-related fields.
In order to effectively support Taiwan’s technology research, the NCHC constructed technology R&D platforms to support domestic and foreign R&D teams in developing HPC and big data applications, which cover engineering and science, environmental and disaster prevention, biomedicine, and digital cultural content creation. The NCHC hopes to achieve the goal of becoming an HPC center of international caliber and a base for HPC applications and R&D collaborations within the Pacific Rim region.
The National Health and Medical Research Council (NHMRC) is Australia’s peak body for supporting health and medical research; for developing health advice for the Australian community, health professionals and governments; and for providing advice on ethical behaviour in health care and in the conduct of health and medical research.
The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.
The NHLBI stimulates basic discoveries about the causes of disease, enables the translation of basic discoveries into clinical practice, fosters training and mentoring of emerging scientists and physicians, and communicates research advances to the public. It creates and supports a robust, collaborative research infrastructure in partnership with private and public organizations, including academic institutions, industry, and other government agencies. The Institute collaborates with patients, families, health care professionals, scientists, professional societies, patient advocacy groups, community organizations, and the media to promote the application of research results and leverage resources to address public health needs. The NHLBI also collaborates with international organizations to help reduce the burden of heart, lung, and blood diseases worldwide.
National Human Genome Research Institute
Bethesda, United States
Funders and Agencies Public
Research Institute
The National Human Genome Research Institute began as the National Center for Human Genome Research (NCHGR), which was established in 1989 to carry out the role of the National Institutes of Health (NIH) in the International Human Genome Project (HGP). The HGP was developed in collaboration with the United States Department of Energy and begun in 1990 to map the human genome. In 1993, NCHGR expanded its role on the NIH campus by establishing the Division of Intramural Research to apply genome technologies to the study of specific diseases. In 1997 the United States Department of Health and Human Services renamed NCHGR the National Human Genome Research Institute (NHGRI), officially elevating it to the status of research institute – one of 27 institutes and centers that make up the NIH. With the human genome sequence complete since April 2003, scientists around the world have access to a database that greatly facilitates and accelerates the pace of biomedical research. The history of the HGP, the history of genomics, and the history of NHGRI, are inextricably intertwined.
National Institute for Health and Welfare (THL)
Helsinki, Finland
Research Institute
Research Institute
THL owns THL Biobank which has a remarkable collection of genomic data that can be used for research and linked with health data and samples. We have thus a history of sharing genomic data globally. In addition, Finnish Genome Institute will be established in THL in 2019. The tasks of the institute is to promote use of genomic information in health care and research; increase genomic understanding; build a national reference and variant data base; give guidance to the stakeholders.
The National Institute for Health Research (NIHR) is based in England, and is funded through the UK Department of Health to improve health and wealth of the nation through research. It is a large, multi-faceted and nationally distributed organisation. Together, NIHR people, facilities and systems represent the most integrated clinical research system in the world, driving research from bench to bedside for the benefit of patients and the economy.
National Institute of Environmental Health Sciences
Durham, United States
Public Funders
Research Institute
NIEHS conducts and supports a breadth of genomics research, some highlights below. In addition to the numerous grant support for genomics/epigenomics studies, NIEHS has several intramural research labs focusing on the intersection of environment and genetics. * Genome Integrity and Structural Biology lab investigates fundamental mechanisms of genetic stability and instability; e.g., DNA damage/repair, DNA and chromosome replication, genome mutation, among others. * The Mammalian Genome group focuses efforts on understanding the role of epigenomic transcriptional regulation, particularly repetitive elements, on an organism’s response to environmental exposures. * Environmental Epigenomics and Disease lab characterizes underlying factors that contribute to variability in human toxicological response. * The Environmental Genetics group seeks to understand role of genetic background as a susceptibility factor in pulmonary effects of environmental stimuli. More specifically, the group utilizes a variety of genetic and omics approaches to identify and validate susceptibility genes in mouse models with goal to translate to identifying individuals with disease susceptibility. * The Genetic Susceptibility and the Environment group takes a life-course approach to studying environmental exposures from prenatal period onwards and interactions with genetic and epigenetic factors in the etiology of respiratory and allergic disease. The research heavily relies on GWAS approaches. In addition, NIEHS has sponsored development of the NIEHS Environmental Genome Project as well as the Environmental Polymorphism Registry (EPR). The Environmental Genome Project examines the relationship between environmental exposures, inter-individual sequence variation in human genes, and disease risk in U.S. populations. Similarly, the EPR acts as a DNA registry to assist researchers interested in genetic polymorphisms in “environmentally sensitive genes.†Furthermore, our Office of Data Science is currently developing a ‘catalog’ to facilitate discovery of intramural epigenomic datasets.
DDBJ Center collects nucleotide sequence data as a member of INSDC (International Nucleotide Sequence Database Collaboration) and provides freely available nucleotide sequence data and supercomputer system, to support research activities in life science.
National Institutes of Health
Bethesda, United States
Research Institute
–
National Marrow Donor Program
Minneapolis, United States
Societies and NGOs Patient Disease Advocacy
Healthcare Research
For the thousands of people diagnosed every year with life-threatening blood cancers like leukemia and lymphoma, a cure exists. Over the past 25 years Be The Match®, operated by the National Marrow Donor Program® (NMDP), has managed the largest and most diverse marrow registry in the world. We work every day to save lives through transplant.
Netherlands Center for Personalized Cancer Treatment
Utrecht, Netherlands
Research Collaboration or Consortium
–
NeuroGen is a pioneer biotech company within Bangladesh that provides genetic test for a wide spectrum of diseases. We conduct regular sequencing and microarray analysis within our laboratory and conduct analysis with NeroGen proprietary genomic analysis softwares. Our primary disease focus is cancer, neurodevelopmental disorders, cardiovascular diseases and rare disorders. The future plan includes the development of machine learning to efficiently conduct genetic diagnostics for whole genome sequencing.
We are a specialist consulting group working with health systems around the world. Our mission is to enable people to live healthily for longer by accelerating the development and application of precision medicine technologies.
New York Genome Center
New York, United States
Research Collaboration or Consortium
Research Institute
The New York Genome Center (NYGC) is at the forefront of transforming biomedical research and clinical care with the mission of saving lives.
As a consortium of renowned academic, medical and industry leaders across the globe, NYGC focuses on translating genomic research into clinical solutions for serious disease.
Our member organizations are united in this unprecedented collaboration of technology, science, and medicine.
Newtopia is a personalized health company leveraging genetic testing and the latest engagement science to inspire individuals to make the right lifestyle choices to live healthier lives.
NEXUS is a newly-established ETH Technology Platform dedicated to enable discovery and translational research for better understanding of human disease and accelerating clinical investigations for personalized health. The pillars of NEXUS are two closely integrated units – Clinical Bioinformatics (CB) and Theragnostics Discovery (TD) – that develop and offer technologies for the analysis of multidimensional genomic data and their integration with medical information and provide robotic systems, genome-scale gene manipulation tools, chemical compound collections and advanced cell systems to discover and interfere with disease-causing cell circuits.
National Digital and Data services for the NHS
NIAGADS is the National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site. NIAGADS is a national genetics repository created by NIA to facilitate access by qualified investigators to genotypic data for the study of genetics of late-onset Alzheimer’s disease. It is the coordinating center for the Alzheimer’s Disease Sequencing Project, which is working to identify new genomic variants contributing to both increased risk of and protection against developing Late-Onset Alzheimer’s Disease
Novogene is a company with expertise in genome assembly, bioinformatics and next-generation DNA sequencing. We aim to provide advanced genomic solutions worldwide, and make contribution to life science and human health by bioinformatics.Novogene provides services for customers from domestic and foreign universities, research institutes, hospitals, and pharmaceutical enterprises. Within the past four years, Novogene has completed numerous major projects, with findings acknowledged and published by top-ranked journals such as Science and Nature series. Through working in partnership with everyone from research institutes to health care hospitals, Novogene hopes to cooperate with you to develop the unlimited potential of ever changing world of genomics.
NRGene is a leader in complex genome de-novo assembly and Big-Data analytics of next generation sequencing data. NRGene’s technology enables accurate and cost effective reconstruction of individual genomes, by applying a varying-coverage sequencing approach and proprietary haplotyping algorithms. NRGene’s roots are in the Ag-Bio domain where it has established strategic collaborations with some of the largest multinational agricultural entities. In 2016, NRGene entered the space of clinical genomics and began offering a comprehensive suite of Big-Data analytics solutions to enable efficient and high-throughput discovery of biomarkers associated with clinical features and drug response.
nSight Labs is a boutique bioinformatics and biomedical informatics systems integrator which delivers innovative and transformative solutions to reduce the amount of time it takes to arrive at insights guiding key clinical decisions. Located in North Carolina Research Triangle Park, we are founded by industry experts with backgrounds from a range of leading healthcare and life sciences organizations and top technology companies.
nSight Labs is currently engaged in the following activities:
– Vaccines discovery for the world’s top 2 BioPharma’s R&D
– Genomics consent services development for a foreign ministry’s national-citizens genomics research initiative
– Addressing disparities in care, with AI-accelerated cancer genetic risk assessments to increase access to screenings to at-risk populations
– Driving value-based medicine by ensuring correct Rx and doses through PharmX innovation and AI-recommender systems for script formularies and Rx routing
– NLP of clinical notes, clinical trials data / biometrics data, and research literatures (pathogenicity) for integration into tertiary pipelines
– Preparation of genomic data commons utilizing Gen3, AnVIL Gen3 and Terra
– GA4GH & BioSphere alignment in terms of standards and toolsets
– Supporting clinicogenomics, conducting GWAS for T2D, CAD, SARS-CoV-2 for CDO, and 1000s of CDOs at national-level
– Supporting SARS-CoV-2 viral genomics, proteomics, and clinicogenomics / immunology and epidemiology
– Support Genomics Big Data and R&D Data Lakes for 500K patients GWAS with UK Biobank genotypic assay data
NSilico is the provider of easy-to-use data management and analytics software for the life sciences and healthcare industries. The company’s offerings are based upon a unique and unrivalled blend of biological, computing, software-development and clinical experience and expertise which enables us to provide our customers with solutions which significantly increase the efficiency and accuracy of their work. Our offerings are based on the following core principles:
Simplicity. We focus on making our software platforms as easy to use as possible. Our core bioinformatics product is called Simplicity™ for this very reason.
Speed. We focus on making on making the processing and interrogation of “-omic” data as quick as possible. To do this we have developed proprietary algorithms to enable massively parallel processing on our platforms.
Scalability. We focus on making on making our platforms as scalable as possible. Because our platforms are Cloud-based, our solutions can be implemented across the full range of organization sizes and data requirements.
Security. We focus on making on making our platforms as secure as possible. Our platforms are secure to FDA 21 CFR Part 11, HIPPA and ISO/IEC 27001:2005 standards
The Nuclear Receptor Signaling Atlas seeks to improve the discoverability, accessibility and citability of ‘omics-scale datasets in the field of nuclear receptor signaling.
Nuclear receptors (NRs) comprise a large superfamily of conserved ligand-regulated transcription factors that, along with their coregulators, govern tissue-specific expression of target genes in myriad developmental and physiological processes, including immunity, reproduction, and metabolism. Members of this family are receptors for endocrine steroids (i.e., corticosteroids, progesterone, androgens and estrogens), retinoic acid, vitamin D3, thyroid hormone, fatty acids, oxysterols, bile acids and numerous xenobiotic molecules derived from the diet and the environment. NRs represent important druggable proteins in a variety of therapeutic indices, including cancer, obesity, diabetes, inflammatory conditions, senescence and infectious disease.
Although published ‘omics scale datasets in the NR field have tremendous potential value through re-use, the infrastructure supporting such re-use is underdeveloped. We have developed a web-based tool, Transcriptomine (v 3.2), that powers sophisticated data analysis and visualization of tissue-specific nuclear receptor (NR) signaling pathway-regulated gene expression profiles.
Omics-scale relative abundance transcriptomic datasets in the NR signaling field are acquired from public archives, manually annotated by domain experts according to community standards and exposed on the NURSA website. Transcriptomine search results are displayed in an interactive visualization interface that provides for intuitive manipulation of fold change data points and the formulation of sophisticated research hypotheses by the bench scientist. Individual fold change data points link back to the underlying datasets to provide context, allowing the user to discover similarly-regulated genes and to find datasets related by RNA Source and regulatory molecule. Links to the datasets from community-based knowledge small molecule (PubChem, ChEBI) and gene-centric (NCBI Entrez Gene, GeneCards) community resources connect diverse disciplines and enhance the visibility of the datasets beyond the field of NR signaling. Direct linkage to datasets from journal articles adds value to research papers and provides for a level of analysis by readers that has not been previously possible. Reciprocal integration of datasets with Transcriptomine connects superficially unrelated datasets and provides point-and-click discovery of unfamiliar NR signaling biology. Finally a RESTful API enables automated integration of NURSA transcriptomic data points with interested collaborators.
Oak Ridge National Laboratory (ORNL) provides exceptional researchers with distinctive
equipment and unique facilities to solve some of the nation’s most compelling challenges.
As the largest US Department of Energy (DOE) laboratory, ORNL’s mission is to deliver
scientific discoveries and technical breakthroughs that will accelerate the development
and deployment of solutions in clean energy and global security while creating economic
opportunities for the nation.
Multi-specialty Outpatient surgical Facility.
Omix Ventures​ PVT Ltd, Project Shivom
Munich, Germany
Companies Genomic Analysis
Companies Life Science
At Shivom, we are working to develop the largest genomic data hub around the globe, enabling complete data privacy and security, full interoperability and genomic data sharing, and allowing for an entirely global reach for genomic sequencing, data processing, and genome analysis. This healthcare ecosystem will be enabled using state of the art blockchain technology, advanced privacy and encryption layers, and a decentralized data app marketplace. With Shivom, users will be able to obtain sequencing data information and gain insights into their fitness and health using apps “docked” on top of a blockchain-based database. Users retain their data ownership, while at the same time they can be incentivized to provide genomic and healthcare data. Data owners can then share access to their data at will with interested third parties such as pharma and research organizations, which can subsequently use that data for advanced drug development and precision medicine. In these ways, and with the help of multiple partnerships and stakeholders Shivom aims to enable and improve healthcare and medicine globally. ​
Omixy
London, United Kingdom
Companies Genomic Analysis
Integrative Omics with video medical consultations
Omixy is a platform as a service which wants to provide a molecular diagnosis trough a personal omics profile with medical video consultations and a close follow up. The objective is to provide a personalized prevention and healthcare, with science, simplicity and empathy .
OmniTier is solving multiomic analysis challenges differently – not by throwing huge cloud and compute resources at the problem, but implementing easy to use, memory leveraged systems and software to deliver greater genomic insights, quicker and cheaper.
“Our vision is to provide affordable, secure and global access to medical services for everyone. Our peer-to-peer platform will connect individuals, pharmaceutical companies, blood- & bio-banks and healthcare providers in a value-driven ecosystem. The data on our platform will help individuals, research and non-profit organizations to better understand ourselves and take more informed decisions to improve our lives. Bio data and the information found therein are the lifeblood of precision medicine.
Genetic data, as one of the most important elements of ourselves, will be a critical part of data to be stored and become part of research. The need to address the humans will in form of the informed consent, is enabled with our Marketplace development, requires interoperability with developments such as driven by GA4GH.”
Oneome is a pharmacogenomics solution company that provides both genomic testing and software solutions. Over the last two years we’ve developed a sophisticated algorithm to predict the response to over 240 medications large. In addition, we are developing software solutions that provide clinical decision support and guidance integrated within the EHR systems to reuse patients genomic information throughout their lifetime.
OnRamp BioInformatics, Inc.
San Diego, United States
Companies Genomic Analysis
Companies Information Technology
OnRamp BioInformatics is a genomics software company that provides cost-effective data management platforms for the analysis, interpretation and storage of genomic datasets.
The OnRamp solutions are deployed onsite within existing HPC clusters, or as a cloud-based Software as a Service. By converging genomic analysis software, advanced data management and hardware architectures optimized for big data, OnRamp solutions provide rapid and accurate interpretation of large scale datasets with comprehensive audit trails and data tracking for all pipelines, applications and data activity.
Whether drug discovery, diagnostic, therapeutic, research or clinically focused, firms utilizing the OnRamp solutions experience accelerated insights, increased research productivity, scalable storage and peace of mind through end-to-end data tracking and auditing capabilities.
Ontario Brain Institute
Toronto, Canada
Research Institute
Research Collaboration or Consortium
The Ontario Brain Institute is a provincially‐funded, not‐for‐profit research centre seeking to maximize the impact of neuroscience and establish Ontario as a world leader in brain research, commercialization and care. We create convergent partnerships between researchers, clinicians, industry, patients, and their advocates to foster discovery and deliver innovative products and services that improve the lives of those living with brain disorders. For more information visit: www.braininstitute.ca
The Ontario Institute for Cancer Research is an independent, not-for-profit translational cancer research institute funded by the Government of Ontario.
The Ontario Personalized Medicine Network (OPMN) is an expert panel created to assess the challenges and opportunities presented by personalized medicine, to ensure Ontario is well positioned to capitalize on this exciting and transformative technology.
Open Commons Consortium
Chicago, Illinois, United States
Research Collaboration or Consortium
Not-For-Profit
The Open Commons Consortium (OCC) is a 501(c)(3) not for profit organization that manages and operates secure FISMA compliant cloud computing, data commons, and data ecosystems infrastructure for social impact. OCC members span the globe and include over 30 universities, companies, government agencies and national laboratories.
Open Genomes is an international tax-deductible non-governmental research and advocacy organization located in the United States and Germany with the following mission:
• Combine the elements of Open Science and crowdsourcing to enhance basic research, improve public health, and save lives.
• Make genomic sequences and research results freely available to the general public throughout the world.
• Conduct research using genomic sequences obtained through a variety of techniques and technologies to get sequences that are as accurate as possible and more completely aligned and phased, derive more accurate phylogenies and ancestral sequences, and make the results public and freely available to all.
• Provide a means for others to sponsor whole genome sequencing for people from underserved groups, and advocate for the rights of people with genetic disabilities.
• Develop phylogenies of all human non-recombining haploid segments, derive the Reconstructed Ancestral Human Reference Sequence, create population-specific linkage maps, and use the phylogenies to help with population genetics, medical and forensic research.
• Use open genomics to help demonstrate the fundamental unity of all mankind, discover human origins, history, and ancestry using archaeogenetics.
• Refute scientific inaccuracies that use genomic data to support genetic determinism, unscientific myths that divide people, and help oppose the commercial exploitation of closed genomic results for private profit.
Open PHACTS Foundation
Cambridge, United Kingdom
Research Collaboration or Consortium
Non-Profit for data services and infrastructure, and pre competitive data infrastrcuture research
The Open PHACTS Foundation is a not-for-profit membership organisation, supporting the Open PHACTS Discovery Platform:
A sustainable, open and interoperable information infrastructure for applied life science research and development.To reduce the barriers to drug discovery in industry, academia and for small businesses, the Open PHACTS Discovery Platform provides tools and services to interact with multiple integrated and publicly available data sources. To integrate this data, extensive cross-referencing of scientific concepts is needed across all databases.
The Open PHACTS Foundation ensures the sustainability of the Open PHACTS Discovery Platform infrastructure and acts as a hub for relevant scientific research and development.
openSNP is a “grass-roots” project to openly share genomic data from customers of direct-to-consumer genotyping companies with (citizen) scientists. By doing so the users of openSNP enable researchers all over the world to use this data for novel research.
Optra HEALTH is an ISO-certified global organization specializing in Life Science Informatics, Medical Devices, Lab Automation and Healthcare IT based solutions. OPTRA’s extensive experience in the life science and healthcare industry, very strong domain focus coupled with best in class software engineering will help in unlocking knowledge in the data enabling to speed up the research. Our team comprises of medical geneticists, imaging experts, bioinformaticians, regulatory experts and seasoned software professionals offering the best software solutions at a very cost effective price. Convergent with the latest technologies we are excellent at creating practical solutions at every level from web APIs down to code optimization, developing performance-critical algorithms, parallel data analysis architectures, user interfaces and visualizations deployed to desktop and cloud.
Optum is a leading health services and innovation company dedicated to helping make the health system work better for everyone. With more than 133,000 people worldwide, Optum combines technology, data and expertise to improve the delivery, quality and efficiency of health care. Optum uniquely collaborates with all participants in health care, connecting them with a shared focus on creating a healthier world. Hospitals, doctors, pharmacies, employers, health plans, government agencies and life sciences companies rely on Optum services and solutions to solve their most complex challenges and meet the growing needs of the people and communities they serve.
Oracle Health Sciences
Leveraging industry-shaping and transformative technologies that optimize clinical R&D, mitigate risk, advance healthcare, and improve patient outcomes.
ORCID is an independent non-profit organization dedicated to providing an open registry of persistent identifiers for researchers and contributors and APIs for the community to embed these identifiers into research workflows in the funding, university, association, and publishing sectors. ORCID works with other identifier systems to support an interoperable infrastructure for the exchange of research information.
Oregon Health & Science University
Portland, United States
Healthcare Research
Healthcare Care Delivery
Oregon Health & Science University is a nationally prominent research university and Oregon’s only public academic health center. Its hospitals and clinics serve more than a quarter of a million patients every year with innovative care and treatment models based on the latest knowledge available.
From humble beginnings in 1887, OHSU has grown into a world-class teaching hospital and research center that draws in students, scientists and patients from across the country and around the globe. At the same time, we retain our strong commitment to serving our local community and to treating each patient as a unique individual with personalized care.
Oregon Health & Science University
Portland, United States
Healthcare Research
Healthcare Care Delivery
Oregon Health & Science University is a nationally prominent research university and Oregon’s only public academic health center. Its hospitals and clinics serve more than a quarter of a million patients every year with innovative care and treatment models based on the latest knowledge available.
From humble beginnings in 1887, OHSU has grown into a world-class teaching hospital and research center that draws in students, scientists and patients from across the country and around the globe. At the same time, we retain our strong commitment to serving our local community and to treating each patient as a unique individual with personalized care.
ORGANIZATION FOR RARE DISEASES INDIA
BENGALURU, India
Societies and NGOs Patient Disease Advocacy
Research Collaboration or Consortium
Organization History:
ORDI was founded to address the many challenges in the management of rare disease in India. A lack of awareness about rare disease even among doctors means that a diagnosis can often take many years. The cost of diagnosis and treatment can also be prohibitively expensive. In the absence of a national government policy surrounding rare disease, there is no push for the development of orphan drugs � the very medicines that can provide relief for patients with a rare disease.
There are numerous disease-specific patient advocacy organizations in India, including groups like the Down Syndrome Federation, the Pompe Foundation, and the Lysosomal Storage Disorders Support Society. However, until now, there has been no group serving as the collective voice of and advocate for rare disease patients throughout the nation. ORDI was formed to address the unmet needs of rare disease patients in India. It will serve as an umbrella organization for rare disease patients and other stakeholders throughout the country. The ORDI team consists of experts in genetics, molecular diagnostics, drug development, bioinformatics, communications, information technology, patient advocacy, and public service.
Our Vision:
We aim to empower rare disease patients and their families in India with access to national and international resources to improve their quality of life.
Our Mission:
We strive to catalyze the rapid development and delivery of affordable diagnostics and treatments for rare diseases through innovative collaborations and partnerships among stakeholders to benefit rare disease patients in India.
Our Objectives
Rare Diseases Patients Helpline and Helpdesk: ORDI runs a national rare disease hotline (+91 8892 555 000) to hear the needs of rare disease patients. ORDI will setup a dedicated helpdesk with the goal of enabling patients, access to information and resources to guide them through the process of diagnosing and dealing with the rare conditions affecting their health and quality of life.
ORDI develops and maintains a public website, a patient portal, organizes awareness campaigns, and an annual rare disease conference in India.
Organize sponsored clinics that are at no cost to the rare disease patients by inviting national and international medical and research experts for selected rare diseases. The scope for this is enormous as there are 7000+ rare diseases and 70+ million patients in India. We will identify 5-10 diseases for the first couple years and coordinate clinics for them in metro cities with attendance by surrounding rural patients to the extent possible.
Rare disease patient registry: Design, develop, maintain and make available, a registry of rare disease patients in India. Initially, this registry could be developed for a single or a group of rare diseases and eventually replicated to accommodate all rare diseases. This registry would be utilized for identifying patients for free/sponsored clinics, enrollment into clinical trials, broadcast important announcements, maintain patient informed consents to participate in special clinical research programs, etc.
Biospecimen repository (bioBank) for rare diseases research: To enable the preservation of and utilization of biospecimens related to rare disease patients in India, ORDI shall provide a biobanking facility and enable access to researchers investigating rare diseases in India. These specimens are shared according to applicable laws and standard operating procedures (SOPs) relevant to human subjects research.
Funding program for rare disease researchers in India: At least five competitive research awards based on external review to winning proposals. The biospecimens in the ORDI Biobank and the ORDI patient registry would be made available as resources to the grantees of these awards. ORDI will also catalyze relevant international collaborations for these grantees.
Orion Health is an award winning health specific software company that develops modern and creative solutions for healthcare organisations across the globe. Since our inception in 1993 by CEO, Ian McCrae, the company has experienced considerable growth and now has over 1,200 employees in 27 offices around the world.
Orion Health is on a mission to revolutionise the way healthcare is delivered. We believe that our software solutions, built on new generation technology, have the ability to give everyone healthier, happier and longer lives.
Our company is driven by open-minded challengers who share a vision for healthcare, where all the relevant information is integrated and placed in the hands of those who can make a difference – when and where they need it.
At Orion Health we already have over 10 years experience in delivering population health management solutions across a diverse range of geographic and healthcare environments. This longevity and continued success has seen us rise to now be considered a global leader in this industry.
Our software is designed to enable a new model for healthcare, that is centred on the patient and aimed at delivering positive outcomes, irrespective of where the treatment occurs. We deliver a significant range of solutions across three health specific market segments: Intelligent Integration, Smarter Hospitals and Healthier Populations.
The mission of the Orphan Disease Center is to develop transformative therapies using platform technologies that can be deployed across multiple rare diseases. The Center will emphasize disorders with substantial unmet need independent of their incidence and will strive to assure access to patients of all populations.
Orphanet is a unique resource, gathering and improving knowledge on rare diseases so as to improve the diagnosis, care and treatment of patients with rare diseases. Orphanet aims to provide high-quality information on rare diseases, and ensure equal access to knowledge for all stakeholders. Orphanet also maintains the Orphanet rare disease nomenclature (ORPHAnumber), essential in improving the visibility of rare diseases in health and research information systems. Orphanet was established in France by the INSERM (French National Institute for Health and Medical Research) and the French Ministry of Health in 1997.This initiative became a European endeavour from 2000, supported by grants from the European Commission: Orphanet has gradually grown to a Consortium of 41 countries, within Europe and across the globe. Over the past 20 years, Orphanet has become the reference source of information on rare diseases. As such, Orphanet is committed to meeting new challenges arise from a rapidly evolving political, scientific, and informatics landscape. In particular, it is crucial to help all audiences access quality information amongst the plethora of information available online, to provide the means to identify rare disease patients and to contribute to generating knowledge by producing massive, computable, re-usable scientific data. Promoting datasharing in the context of the rare diseases, Orphanet adheres to the FAIR principles. The integral role played by Orphanet in the research and care spheres has led to its recognition as an IRDiRC Recognised Resource, and integration in the French node of ELIXIR, a European research infrastructure uniting Europe’s leading life science organisations. Orphanet and the ORPHA nomenclature are also cited as key resources in every European legislative text on rare diseases and as key measures in many national plans/strategies for rare diseases. The ORPHA nomenclature is now used in codification systems in 11 European countries and in Western Australia. Orphanet offers a range of freely accessible services: – A nomenclature of rare diseases mapped with resources as OMIM, ICD10, MeSH, MedDRA, GARD and UMLS and a classification of diseases elaborated using existing published expert classifications. Diseases are also annotated with phenotypic features and frequency using Human Phenotype Ontology, as well as with disability terms issued from the ICF-YA. – An encyclopaedia of rare diseases in English, progressively translated into other languages. – An inventory of orphan drugs at all stages of development. – A directory of expert resources, providing information on expert clinics, medical laboratories, ongoing research projects, clinical trials, registries, networks, technological platforms and patient organisations, in the field of rare diseases, in each of the countries in Orphanet’s consortium. – An encyclopaedia of recommendations and guidelines for emergency medical care and anaesthesia. – A fortnightly newsletter, OrphaNews, which gives an overview of scientific and political current affairs in the field of rare diseases and orphan drugs, in English, French and Italian. – A collection of thematic reports, the Orphanet Reports Series, focusing on overarching themes, directly downloadable from the website. – A platform, Orphadata (www.orphadata.org), providing high-quality datasets related to rare diseases and Orphan Drugs, in a reusable and computable format. – The Orphanet Rare Disease Ontology (ORDO), a structured vocabulary for rare diseases derived from the Orphanet database, capturing relationships between diseases, genes and other relevant features. ORDO provides integrated, re-usable data for computational analysis. Accessible from a sparql Endpoint (http://www.orpha.net/sparql), ORDO is also available on bioportal and Ontologies Lookup Service from EBI. ORDO constitutes the interoperability backbone in the RD field. – The HPO-ORDO ontological module (HOOM), intended to provide the community with an ontological ecosystem allowing for better phenotypic characterisation of diseases and promoting interoperability in the rare disease field.
Osaka University, Graduate School of Medicine
Osaka, Japan
Research University
The Medical Science Department comprises the School of Medicine and the School of Allied Health Medicine. Whilst the School of Medicine offers 6-year courses for future doctors, the School of Allied Health Medicine provides 4-year curricula in nursing, radiological technology and biomedical engineering as well as laboratory sciences for prospective nurses, public health nurses, midwives, radiology technicians and laboratory medical technologists.
Ovation.io focuses on removing software barriers to doing great science. Leveraging deep experience in design and development of software solutions for scientific partners, Ovation.io helps researchers and collaborators find a better way to structure, manage, annotate and exchange data. A rich history in neurobiology and genetics and a diverse set of interests motivates the team at Ovation.io to drive progress in life science research through innovative new tools such as a next-generation scientific data-layer-as-a-service. Ovation.io is taking a fresh approach to helping scientists and service labs capture knowledge, collaborate efficiently and organize their overall scientific life.
Reading through the Global Alliance constitution, I can truly say that our company principles are directly aligned with your mission. We focus our entire company around responsible data sharing, data management and collaboration.
We are a life science software company with a recent series-A round of funding and a burning desire to change the way science is done by unleashing the power of data management, sharing and collaboration. We would like to work with you to make that happen.
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions.
Founded by Professor Sir Edwin Southern, OGT has helped pioneer the molecular medicine revolution by enabling smarter decision making in human healthcare. With customers in over 60 countries worldwide and ambitious expansion plans, OGT has a strong reputation and increasing share in the large and growing genomic medicine market.
The Group’s CytoSure™, Cytocell®, SureSeq™ and Genefficiency™ range of microarray, FISH and next generation sequencing products and services deliver high-quality, high-throughput genetic analysis, enabling accurate identification of the causative variation underlying genetic disease.
P4 Medical Laboratory is Ireland’s first ever precision medicine company. We aim to revolutionise the way we think about health by promoting the maintenance of wellness and the prevention of disease.
• Our Vision is one of collective health intelligence through the building of a global medical community, where data and knowledge is shared.
• Our Mission supports connectivity of clinicians and data sharing in order to inform, empower and transform health and wellness.
P4 refers to precision medicine which provides Predictive, Preventive, Personalised and Participative information, allowing for the creation of a unique and personalised medical pathway for each individual.
Our objective is to make genetic testing and genome sequencing an integral element in mainstream healthcare. This, along with a MultiOMICS approach, will deliver a more targeted approach in dealing with potential DNA mutations. Our goal is to provide new possibilities and actionable insights to improve the lives of patients.
We are one of the major manufacturers of sequencing instruments.
PNDRI is a nonprofit biomedical research organization and leader in the global fight against diabetes. Founded by William B. Hutchinson, Sr., M.D., in 1956, today the Institute employs more than 95 scientists, technical, and professional staff. Its researchers are among the most respected in the industry—multiple Principal Scientists are members of the National Academy of Sciences—and are dedicated to making scientific discoveries that translate into improved health for all people living with, or at risk of developing, diabetes.
Pairend Biyoteknoloji Tic. Ltd. Şti.
Yunusemre, Turkey
Companies Genomic Analysis
Healthcare Research
Parabricks
Ann Arbor, United States
Companies Information Technology
Companies Information Technology
Parabricks provides high performance GPU-based software solutions for analysis of next generation sequencing data, resulting in high throughput at reduced costs compared to other available solutions—in the cloud or on-premise. Parabricks brings proprietary high performance computing techniques to accelerate the data analysis process of the industry-leading genomic pipelines–from days to less than one hour and reduces cost– generating fully equivalent and accurate output. Parabricks software can integrate seamlessly with deep learning techniques, statistical packages and visualization tools, leading to faster data insights.
Parseq Lab specializes in diagnostic assays for analysis of hereditary diseases in human, and comprehensive databases of the most significant genetic variants (mutations and polymorphisms resulting in severe malfunctions formation) development. Company also qualifies in elaborating bioinformatic tools and software for sequencing data interpretation and further application for diagnostic purposes.
Parthenogen is strongly committed to the area of human reproduction, including reproductive endocrinology, genetics and genomics, with projects ranging from innovative drugs and tailored dietary supplements to advanced solutions for the lab.
Partners HealthCare is a not-for-profit health care system that is committed to patient care, research, teaching, and service to the community locally and globally. Collaboration among our institutions and health care professionals is central to our efforts to advance our mission.
Founded in 1994 by Brigham and Women’s Hospital and Massachusetts General Hospital, Partners HealthCare includes community and specialty hospitals, a managed care organization, a physician network, community health centers, home care and other health-related entities.
As a CLIA and CAP accredited global clinical laboratory and forward-thinking healthcare company, we provide physicians and patients with an array of actionable genetic tests that can identify a person’s genetic risk for cancer, cardiac conditions, inherited diseases, nutrition and exercise response, and drug response for medications, specifically those used in pain management and mental health.
PDXen is a venture company which is based on biotechnology, dreaming of global companies to implement the health and happiness of humanity. It has pursued The Next Generation of Biotechnology since 2013.
Pentavere Research Group provides technology and information solutions that enable stakeholders in all segments of the healthcare community to evaluate the safety, effectiveness and value of a medical intervention by bringing objective real world insights of the dynamic between healthcare stakeholders, diagnostics, disease, medications, and outcomes. This is achieved through our core assets and capabilities of:
• A growing and dynamic data platform of over 500,000 aggregated medical records from over 560 clinics and practices across Canada. This platform includes millions of mentions of thousands of unique drugs and diseases
• Ability to extract health insights from unstructured health data through proprietary methods, ontologies, and technology.
Personal Genomics SRL operates in the clinical genomics sector. We sequence and analyse whole genomes, exomes and we develop proprietary panel tests for mendelian disease
The Personal Genome Project was founded in 2005 and is dedicated to creating public genome, health, and trait data. Sharing data is critical to scientific progress, but has been hampered by traditional research practices—our approach is to invite willing participants to publicly share their personal data for the greater good.
PetaGene
Cambridge, United Kingdom
Companies Information Technology
Companies Information Technology
PetaGene was founded in Cambridge to address the rapidly growing data management problems of the genomics industry. PetaGene’s software enables compression of huge amounts of genomic data without compromising on access or data quality. The company’s products go beyond regular data reduction techniques and have twice been recognized by Bio-IT World’s Best of Show Award for their industry-leading performance and usability.
Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.
PHEMI is a big data warehouse company that lets organizations easily access and mine any variety of data at any volume to drive insights that lower costs, improve outcomes, and allow better decisions faster.
With an industry-pioneering approach to privacy, security, and governance, PHEMI protects privacy and ensures legitimate use of data to drive continuous improvement and help organizations meet compliance and governance requirements. An organizational ambassador for Privacy by Design, PHEMI brings both privacy and performance to big data solutions, along with the data management and control formerly only afforded by traditional enterprise data warehouses.
PHEMI uses its proprietary technology to unlock the value hidden in health systems data due to privacy rules. Our platform is a big data technology for security, privacy and governance that enables Trustworthy AI. We are building a global network of data nodes in partnership with health systems, and are developing a federated marketplace for this high value, high dimensional health data. When we succeed, we will change the nature of how health data is used for innovation in life sciences, pharma, epidemiology and even clinical practice.
Phenopolis is a gene to phenotype data browsing and analysis platform that contains exome data from over 6000 HPO-annotated individuals with rare disease (e.g inherited retinal disease, corneal dystrophy, bone marrow failure, early-onset dementia, ARVC) and common disease (inflammatory bowel disorder, fuchs dystrophy) from across the world.
We are focused on developing statistical approaches for discovering gene to phenotype associations and phenotype matching algorithms.
The PHG Foundation is a multidisciplinary, independent health policy think-tank based in Cambridge, UK. Our mission is to make science work for health – identifying the best opportunities for genomics and other emerging technologies to deliver more personalised and effective healthcare, and supporting rapid, responsible and effective clinical implementation. We have twenty years’ experience in issues surrounding the applications of genomics within health services for patient and population benefit.
PHILAB is a 58 years corporation that serve healthcare, education and genomics. We are the founder of the Genomic Institute of Asia. We are also launching our Ilumina X10 facility in 2017 in Clark , Philippines to service Asia providing a capacity of 18,000 whole genome sequences per annum.
Philips is a health technology company focused on improving people’s lives through meaningful innovation across the health continuum – from healthy living and prevention to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips partners with customers to deliver integrated solutions that enable better outcomes at lower cost.
Phosphorus is a computational genomics company. With a New York-based team of experts in genetics, computational biology, and computer science, Phosphorus is building a genomic data network that will help providers, researchers and patients around the world better understand and harness the power of the human genome.
Phosporous Inc. mission is to extend and improve lives by making genomics a foundational part of everyone’s health andwellness journey. We build best-in-class, affordable, medical-grade genetic tests to help humans prevent diseaseand live their healthiest lives.
We simplify bioinformatics and enable discovery of molecular diagnostics, small molecules, vaccines, and other therapeutics through our powerful multi-omics analysis platform, T-BioInfo. Our goal is to bring the exciting new capabilities of big omics data analysis and integration into the hands of biomedical researchers through a simple and intuitive interface, innovative algorithms, integration, and visualization. We believe that, in the hands of biologists and medical researchers, our platform will enable discoveries that will enhance personalized healthcare and precision medicine. Our major scientific partner in bioinformatics, the TAUBER BIOINFORMATICS RESEARCH CENTER at University of Haifa, developed T-BioInfo as a powerful bioinformatics platform for the analysis and integration of heterogeneous types of high-throughput data.
PolyKnomics
's-Hertogenbosch, Netherlands
Companies Genomic Analysis
Companies Information Technology
Polymaths is an innovation-consulting firm that helps organisations discover innovative solutions to complex problems, through complexity science thinking and the computational sciences.
Modelling is at the heart of what we do. We use modelling approaches from across disciplines, whether it is the application of statistical physics to economics, using game theory to understand cancer, applying quantum mechanics in epidemiology, natural selection in astrophysics, or biology in design; we hybridize multiple fields, embracing concepts and methodologies from across disciplines to create innovation. This is central to our vision for creating innovation.
A comprehensive online database for the fission yeast Schizosaccharomyces pombe, providing genome feature and functional annotation, literature curation and access to large-scale data sets.
Precision Health Research, Singapore(Precise)
Singapore, Singapore
Research Collaboration or Consortium
Research Collaboration or Consortium
Precision Health Research, Singapore (PRECISE) is the central entity set up to coordinate a whole of government effort to implement Phase II of Singapore’s 10-year National Precision Medicine (NPM) strategy.
NPM Phase II aims to transform healthcare in Singapore and improve patient outcomes through new insights into the Asian genome and data-driven healthcare solutions. NPM Phase II will also enhance the breadth and depth of the Precision Medicine-related industry by attracting and anchoring overseas companies in Singapore, while yielding new opportunities for home-grown companies.
A vision to democratize the delivery of precision medicine in Africa
Founded in 2004 and located in Marshfield, Wisconsin, PreventionGenetics is a CLIA and ISO 15189:2012 accredited Clinical DNA testing laboratory. PreventionGenetics provides comprehensive germline DNA testing services. We offer sequencing and copy number variant analysis for virtually all clinically relevant genes.
Primbio Genes Bio-Tech (Wuhan) Co.,Ltd
Wuhan, China
Companies Genomic Analysis
Companies Life Science
PrimBio Genes is dedicated to promoting human health by deciphering genomic data.
By advanced high-throughput sequencing technology, we can provide pre-clinical services to assist our clients in their clinical biomarker studies and drug discovery & development activities.
PrimBio was founded in 2011 to advance genomic research by providing high quality results with fast turnaround times and competitive prices.
In addition, we have partnered with Reniguard Life Science, Inc. to provide pre-clinical services to assist our clients in their clinical biomarker studies and drug discovery & development activities.
PrimBio is in the process of becoming CLIA certified lab, so that we can contribute more to the genetic studies of diseases.
The Prince Felipe Research Center (CIPF, http://www.cipf.es) is a private non-profit research organization, depending on the Regional Ministry of Health of Valencia, Spain. The CIPF is dedicated to multidisciplinary research in Health in a global approach, with the aim of taking on new challenges in the field of basic and applied research and encouraging excellence in Health-related disciplines.
The CIPF, through its Computational Genomics scientific program (http://www.cipf.es/web/portada/medicina-computacional), carries out a broad range of tasks in this field, from the complex management and process of the huge volumes of genomic data and the development of innovative algorithms and software to deal with such data, to the use of these developments to study different pathologies, such as cancer or rare diseases. In order to support research in this field, the Chair on Computational Genomics has been created in collaboration with Bull, a world-class IT player.
The CIPF is involved key initiatives related to the use of ICT in Healthcare in the Valencia region, not only from the public perspective but also with the support of other related private stakeholders, such as the FutureClinic project, which aims to foster the adoption of Personalized Medicine based on Genomics, or the Valencia Medical Imaging Data Bank, which is part of the Eurobioimaging pan-European Infrastructure.
Princess Maxima Center for Pediatric Oncology
Utrecht, Netherlands
Healthcare Care Delivery
Healthcare Research
Each year approximately 550 children are diagnosed with cancer in The Netherlands. Although the cure rate has increased tremendously over the last decades, cancer is still the major cause of disease-related death in children in The Netherlands. Concentrating all care, experience and expertise with regard to cancer in children in a single location is essential to further improve patient outcome. The Princess Máxima Center for Pediatric Oncology aims to provide the highest level of care for all children with cancer in The Netherlands and has the ambition to cure all children of cancer and significantly reduce unwanted side effects. The center brings together the best possible care and scientific research, creating a unique interdisciplinary institute for pediatric oncology in Europe.
Healthcare within the Princess Máxima Center is focused on the patient and their family and is concentrated around the type of cancer the child has. The Princess Máxima Center also has the ambition to become one of the best pediatric oncology research institutes in the world. Combining treatment and research in one center enables scientists to work closely with clinicians and develop new therapies much faster and efficiently. This in turn will help improve survival rates and decrease complications during and after treatment. It is the chain of fundamental research, patient-related research and healthcare that will enable future development of personalized medicine based on an in-depth understanding of tumor biology. The Princess Máxima Center has a genome diagnostic program running based on whole-exome and RNA sequencing and also provides access to patient material and data including whole-genome sequencing through a pediatric cancer biobank program, thereby providing key facilities to push genomic research and medicine forward.
At Privitar we aim to facilitate the use, collaboration and trade of data while adopting an uncompromising approach to protecting personal private information.
In a world where data collection has increased exponentially – online is the new offline. Technology and computational advances together with the collection of big data mean it is easier for data to fall afoul of unintended consequences or malicious actions.
ProDuCt – Project Development Consulting JSC is a company whose activity is focused on innovation in the field of personalized medicine and biotechnology.
Our core business is focused on developing and managing logistics projects in the field of companion diagnostics. This involves combining innovative diagnostic technologies with pathological expertise to assess the genetic and molecular characteristics of the tumor in various oncological diseases. The company develops and provides a fully completed diagnostic process to assess the tumor’s mutation / expression status, including providing the appropriate reagents for each type of diagnosis.
The experience gained over the past four years has made us an expert and leader in ensuring the companion diagnostics in the field of oncology diseases in Bulgaria.
The company operates also as a contract research organization (CRO) for clinical trials; organizing and conducting research and applied research in the field of medicine and biotechnology; validation studies for innovations in the field of molecular diagnostics.
Program of Computational Genomics at Center for Genomic Sciences, UNAM
Cuernavaca, Mexico
Research Collaboration or Consortium
Research Institute
The Program of Computational Genomics belongs to the Center for Genomic Sciences of the National Autonomous University of Mexico (UNAM), located in Cuernavaca, Morelos. We have been working for over 20 years in biocuration of transcriptional regulation in E.coli and have recently expanded our research aiming at implementing bioinformatics infrastructure for human genomics. We have initiated the implementation of a consortium of human genomics hoping to catalyze efforts in several institutions in our country to get prepared for the use of genomic knowledge within the clinical environment.
PROMEDITEC was set up by experts in IT, clinical research, and company information management systems, with the shared goal of offering clients innovative solutions and specialized consulting services in Information Management Systems applied to Clinical Research with capabilities to manage Genomic data and analysis
Our consultants draw on extensive experience gained from decades spent working with leading companies and institutions in the pharmaceutical, health, and clinical research sector.
–
PTP is a leading Italian Science and Technology Park operating in the Agrifood, Bioeconomy and Life Sciences sectors. PTP Core Facilities and Research Units are involved in international collaborative research projects and offer services to companies to promote innovation and create value to increase competitiveness. With Alimenta, its business accelerator, PTP supports also the creation of new businesses and start-up.
Public Health England core functions are supporting and enabling
local government, the National Health Service (NHS) and the public to
protect and improve health and wellbeing through the national health
protection services, and preparing for public health emergencies. The
organization employ 5,000 staff (full-time equivalent), mostly
scientists, researchers and public health professionals.
Public Population Project in Genomics and Society (P3G)
Montreal, Canada
Research Collaboration or Consortium
The Public Population Project in Genomics and Society (P3G) is a not-for-profit consortium that provides the international research community with access to the expertise, resources and innovative tools for health and social sciences research. P3G works with researchers from around the world to:
– Encourage collaboration between researchers and biobankers
– Promote harmonization of data
– Optimize the design, set-up and research activities of studies, biobanks, research databases and other similar health and social research infrastructures
– Facilitate the transfer of knowledge and provide training
P3G brings the genomics and health research community together via conferences summer schools as well as online tools. Principles of transparency and collaboration are integral to the P3G approach.
PXE International was founded in 1995 to promote research and support individuals affected by pseudoxanthoma elasticum (PXE). We work on behalf of individuals and their families to improve quality of life through advancing research, educating clinicians and supporting individuals.
PXE International is the prime force in conducting basic and clinical research and providing financial support for applied translational research, product development, and treatment development for PXE. We steward the intellectual property to equitably advance products and services around the world for the individuals and families living with PXE.
Qatar Biomedical Research Institute
Doha, Qatar
Research Institute
Qatar Biomedical Research Institute (QBRI) is a National Research Institute established by Qatar Foundation for Education, Science and Community Development, a private, non-profit organization that is supporting Qatar on its journey from carbon economy to knowledge economy. QBRI is set up under the umbrella of Qatar Foundation Research and Development with the purpose of transforming healthcare through science and innovation and supporting the strategic priorities outlined in Qatar National Vision 2030.
QBRI aims to translate novel scientific discoveries into new, efficient targeted therapies and better preventative and diagnostic strategies for diseases that affect the people of Qatar and the region as identified in the Qatar National Research Strategy. This is being achieved through the creation of disease-focused research centers of excellence that are supported by state-of-the-art core facilities, cutting-edge technologies and enabling platforms, on par with those existing at top institutions around the world.
The Qatar Genome Programme (QGP) is an ambitious population-based project aiming to position Qatar among the pioneering countries in the implementation of precision medicine. The project is generating large databases combining whole genome sequencing and other omics data with the comprehensive phenotypic data collected at Qatar Biobank. The wealth of such data empowers researchers to make breakthrough discoveries as well as help policymakers to better plan for future health care directions in Qatar.
QGP was launched by Qatar Foundation with a comprehensive strategy based on seven building blocks. Those include integrating with Qatar Biobank, utilizing local genomics and bioinformatics infrastructures, forging nationwide research partnerships, investing in local human capacity, drafting policies and regulations, and building a national genome data network and integrating genomics into the clinical settings. QGP’s pilot phase was started in September 2015, and its deliverables included the sequencing of over 10,000 whole genomes, launching the QGP research consortium, establishing genomic research funding schemes, conducting benchmarking surveys for general public and health care professionals, drafting national policies and regulations governing genomic research, in addition to initiating graduate programs in genetic counseling and genomic medicine. In this succeeding phase, QGP is ramping-up sequencing and phenotyping efforts up to the mark of around 10 percent of the population, followed by the final and largest phase where large segments of the whole Qatari population will be sequenced. With its small population, centralized health care system and great resources, Qatar is well positioned to be an international leader in the implementation of precision medicine.
Promoting genomic research in Qatar is one of QGP’s main objectives. Towards this goal, and in partnership with the Qatar National Research Fund (QNRF), the main research funding agency in Qatar, a research funding program under the name Path towards Personalized Medicine (PPM) was launched in the year 2016 to encourage local researchers working in the genomics field. Currently, PPM has launched its 3rd cycle. In parallel, the QGP Research Consortium (QGPRC) has been formed from over 90 local researchers along with their international collaborators to mine data coming from the thousands of genomes being sequenced. Realizing the importance of having the governing policies regulating genomic research in place, QGP worked closely with the Ministry of Public Health (MoPH) to draft a national policy providing guidelines on conducting genomic research in Qatar. The document constitutes an umbrella for all IRB committees looking into related projects in Qatar.
Building local human capacity is another major goal for QGP. In this context, QGP initiated two graduate programs in collaboration with local universities, a Genetic Counseling MSc at Qatar University (QU) and a Genomic Medicine MSc/PhD program at Hamad Bin Khalifa University (HBKU). Such programs will help prepare a generation of health care professionals capable of moving the country into the age of precision medicine. In parallel, QGP regularly holds conferences, workshops and internships on various topics related to genomics and precision medicine.
QGP’s current and future focus is on initiatives with direct clinical impact. In this direction, QGP is supporting more genomic research targeting national priority diseases like diabetes and cardiovascular disorders. Other examples include the development of a comprehensive Qatari genotyping array, the Q-Chip, incorporating locally relevant gene variants identified from whole genome sequence data of thousands of samples. This chip would be used in identifying patients and mutation carriers in national screening programs, whether neonatal or premarital. Furthermore, QGP will be providing genomic reports to thousands of QBB participants on their wellness, diet and pharmacogenomics, followed by reporting on disease risk, which will be coordinated with clinical health care providers.
QGP’s strategy is in alignment with Qatar’s National Vision 2030, which is focusing on providing a better future for its citizens. Providing better future health is at the core of this vision as Qatar seeks to become a regional hub for advanced health care. Working as a platform over which the various national stakeholders come together and interact, QGP is key to achieving such aspired objectives.
QFAB Bioinformatics (QFAB) provides rapid, flexible and customized bioinformatics and biostatistics services to life science and clinical researchers.
Working closely with researchers, the QFAB Team members apply data management, integration, analysis and visualization techniques to unlock the full value of large-scale biological and clinical datasets. The team prides itself in delivering robust, high quality and state-of-the-art outcomes.
As the innovative market and technology leader, QIAGEN creates sample and assay technologies that enable access to content from any biological sample.
Our mission is to enable our customers to achieve outstanding success and breakthroughs in life sciences, applied testing, pharma, and molecular diagnostics. We thereby make improvements in life possible.
Established in 1945 by the Queensland Government, the QIMR Berghofer Medical Research Institute (formerly the Queensland Institute of Medical Research) is a world leading translational research institute focused on cancer, infectious diseases, mental health and a range of complex diseases.
Working in close collaboration with clinicians and other research institutes, our aim is to improve health by developing new diagnostics, better treatments and prevention strategies.
QIMR Berghofer is home to more than 600 scientists, students and support staff in five research departments (in over 50 separate laboratories) and a support division.
Queen’s University Belfast is a member of the Russell Group of 24 leading UK research-intensive universities, providing world-class education underpinned by world-class research.
Founded as Queen’s College in 1845, it became a university in its own right in 1908. Today, it is an international centre of research and education rooted at the heart of Northern Ireland and the UK.
With more than 17,000 students and 3,500 staff, it is a dynamic and diverse institution, a magnet for inward investment, a patron of the arts and a global player in areas ranging from cancer research to sustainability, from cybersecurity to food safety and from pharmaceuticals to creative writing.
The Centre for Cancer Research and Cell Biology (CCRCB) has a significant focus on translating discovery science to clinical application, driving a precsion medicine strategy to deliver personalised care plans for our patients.
Queen’s University Belfast is a member of the Russell Group of 24 leading UK research-intensive universities, providing world-class education underpinned by world-class research.
Founded as Queen’s College in 1845, it became a university in its own right in 1908. Today, it is an international centre of research and education rooted at the heart of Northern Ireland and the UK.
With more than 17,000 students and 3,500 staff, it is a dynamic and diverse institution, a magnet for inward investment, a patron of the arts and a global player in areas ranging from cancer research to sustainability, from cybersecurity to food safety and from pharmaceuticals to creative writing.
The Centre for Cancer Research and Cell Biology (CCRCB) has a significant focus on translating discovery science to clinical application, driving a precsion medicine strategy to deliver personalised care plans for our patients.
QY NODE Informatics Co.,Ltd
Beijing, China
Companies Information Technology
Companies Genomic Analysis
QY NODE is a Chinese bioinformatics startup based on cloud service. With a professional team, QY NODE offers a tool platform to scientists and clinical researchers for exploring genomic data and managing analysis pipeline. It provides clients the easier, better, and faster solutions of data management.
Ramón y Cajal Institute for Health Research (IRYCIS)
Madrid, Spain
Healthcare Research
Research Institute
Since its inception, the VISION of the Ramon y Cajal Health Research Institute (IRYCIS) is that of “leading the basic, clinical and translational scientific research, being a reference of trust for society and international public and private institutions”.
MULTIDISCIPLINAR COOPERATION is among the VALUES that this vision lays down, which is made explicit as follows: cooperation between different researchers and departments, both in basic and clinical research, consolidating multidisciplinary groups, about research performed at Ramón y Cajal University Hospital, towards translational research, which conforms research to the health needs of society.
The MISSION is that of “being a space dedicated to excellent biomedical research, addressed to the generation of useful knowledge for the identification and treatment of actual or potential diseases and, therefore, with a strong translational character and aiming to become a reference with national and international scope, by applying in all its actions a philosophy of quality and continuous improvement.”
In its ORGANIZATIONAL AXIS, the strategy aims at “consolidating an efficient and flexible structure that facilitates translational research and sets the pathway towards the consolidation of the institute”. It includes a PLAN FOR DEVELOPMENT OF RELATIONS BETWEEN THE INSTITUTE´S BASIC AND CLINICAL RESEARCH STAFF, one of whose actions is to conduct an analysis that identifies the models of translational research promotion that best suit the characteristics of the Ramón y Cajal University Hospital. Besides, a milestone is the setting of a plan to attract potential researchers and which promotes translational research. It also includes two separate internal and external communication plans, intended to promote translational research.
Within this mission, one of the major objectives of IRYCIS is promoting the commonplace use of “-omics” technologies in the clinical environment to achieve our long-term goal of realizing predictive and personalized healthcarein the Spanish National Health System. IRYCIS concentrates on developing robust, “best-practice” data analysis, data interpretation, backup and safety procedures, on building a genotypic/phenotypic database, and has a keen interest in developing novel training approaches for data analysts and healthcare professionals, in order to create a pool of experts able to translate genomic data output into clinically useful information. Moreover, we IRYCIS has just started working on a national network-based bioinformatics initiative for clinical genomics that hopefully will become a useful resource for precision medicine, wityhin the framework of shared data and experience sponsored by the GA4GH.
Ranomics has a proprietary technology that creates and analyzes all genetic variants (common and rare) of a human disease gene in a disease model. We are building a database to assist with diagnosis with the goal of eliminating variants of unknown significance in clinical settings.
Rare Voices Australia (RVA) is the national alliance for ALL Australians living with a rare disease. Membership is open to all and includes patient organisations, clinicians, researchers, academics, industry and individuals with an interest in rare disease. RVA is the unified voice of 1.2 million plus people affected by rare diseases throughout Australia (6-8% of the population).
RVA is campaigning for a National Plan for Australian’s impacted by rare diseases. This would co-ordinate in one strategy; research, prevention and diagnosis, treatment and care, information, planning.
RVA advocates for improved quality of life for people living with a rare disease in Australia at a National level, support for research and drug development, networking patient groups, raising awareness and other actions designed to fight against the impact of rare diseases in Australia.
RARE-X
Aliso Viejo, California, United States
Societies and NGOs Professional
Societies and NGOs Patient Disease Advocacy
RARE-X is an ambitious, collaborative global initiative to equip and support rare disease patient communities in gathering, structuring and sharing their data openly and widely, while also providing the research community access to an interoperable federated data sharing platform that will accelerate innovation and progress across rare diseases.
We were founded on the core belief that, in rare disease in particular, global and secure-but-open access to relevant data sets (natural history, genomic, EHR, PRO, wearable/social/digital and other) for research and diagnostic and therapeutic innovation represents the single-most critical gating factor to progress on behalf of rare disease patients and caregivers.
RARE-X is beginning a 24 month pilot phase, powered by the Broad Institute technology and other related partners, addressing a variety of use cases including; scaling and systemitizing patient owned data collection platforms (registries), building a unified platform for cell and gene medicine companies around long term follow-up, developing cost efficient models to support research institutions in standing up patient owned registries for research, building on the Broads federated data platform to support engagement globally, etc.
Raremark builds patient communities online in rare disease so that patients can find out useful knowledge and connections. We will soon be offering genomic testing and genetic counselling through partner companies. Our purpose is to create a future in which rare medical conditions are as recognized as the common.
RD-Connect is a unique global infrastructure project that links up databases, registries, biobanks and clinical bioinformatics data used in rare disease research into a central resource for researchers worldwide.
In a six-year project funded by the European Union but uniting researchers across the world, it will develop an integrated research platform in which complete clinical profiles are combined with -omics data and sample availability for rare disease research, in particular research funded under the International Rare Diseases Research Consortium (IRDiRC).
Real Time Genomics
Hamilton, New Zealand
Companies Information Technology
Companies Genomic Analysis
At Real Time Genomics, we have a passion for genomics. Our core competence is a commitment to know, anticipate and deliver to the needs of leading biological researchers. The company has deep computational expertise in algorithms, coupled with extensive product development capabilities and a seasoned commercial team with over 100 years of success in bringing genomics’ innovation to the life sciences industry.
RENCI is a research institute within the University of North Carolina at Chapel Hill with a joint mission to serve UNC-CH, Duke University, and North Carolina State University. RENCI’s mission is to develop and deploy advanced computing and cyberinfrastructure technologies to enable research discoveries and practical innovations.
A primary focus of RENCI activities are in the Life Sciences, including genomics, biomedical informatics, and translational research.
We are building a platform for facilitating access to and sharing of genomic data. Our platform includes features for discovery of available data, making your data visible to the research community, managing your data sources and initiating data collaborations. Our platform also integrates methods for secure data sharing and a patented mechanism for secure privacy-preserving data access.
We are building models of chromatin structure, and refining them using deep learning of genomic signals. We aim to use this to generate new sets of targets to modify chromatin architecture.
The Center for Integrative Medical Sciences, based in Yokohama, aims to develop revolutionary medical therapies based on collaborative projects between researchers from different areas of science. By achieving a deeper understanding of homeostasis, and how the breakdown of homeostasis leads to disease, scientists at IMS are working to develop personalized preventive medicine and personalized medicine that can allow us to lead healthier lives. The center’s focuses include genomics, immunology, allergies, inflammation, endocrinology, and the new field of metabolomics.
Riken Genesis was established in 2007 as a spin-off company from RIKEN to take over the technologies developed by RIKEN which is one of the international driving forces for genomic medicine. The mission of the company is to widely disseminate genomic analysis technologies established in RIKEN, to promote the realization of personalized medicine, and to contribute by the genomic medicine to improving the quality of life for the people in the world.
The business activity of Riken Genesis is composed of (1)contract genetic analysis service such as SNP Genotyping and whole genome sequencing, (2)companion diagnostics business including the development of IVD reagent kit and fully automated device for the SNP and somatic mutation detection.
As the world leader in invitro diagnostics, Roche supplies a wide range of rapid, reliable instruments and tests for disease screening and diagnosis in laboratories, at the point of care, and for patient self-management.
Roche Sequencing Solutions
Pleasanton, California, United States
Companies Life Science
Companies Genomic Analysis
Roche is dedicated to advancing personalized healthcare by creating diagnostics and treatments tailored to individual genetic and disease profiles. As part of this mission, Roche Sequencing Solutions is unifying next-generation sequencing with the goal of making it routine: Sample in, result out.
Our growing suite of products spans the genomics workflow, from sample acquisition and preparation through data analysis and final result, helping you answer important questions in genetics, cancer and beyond.
Royal Brompton and Harefield NHS Foundation Trust
London, United Kingdom
Healthcare Care Delivery
Healthcare Research
The Royal Brompton & Harefield NHS Foundation Trust is a partnership of two specialist hospitals which are known throughout the world for their expertise, standard of care and research success. As a specialist trust we only provide treatment for people with heart and lung disease. This means our doctors, nurses and other healthcare staff are experts in their chosen field, and many move to our hospitals from throughout the UK, Europe and beyond, so they can develop their particular skills even further.
We carry out some of the most complicated surgery, and offer some of the most sophisticated treatment that is available anywhere in the world and treat patients from all over the UK and around the globe.
We have a worldwide reputation for heart and lung research. We work on numerous research projects that bring benefits to patients in the form of new, more effective and efficient treatments for heart and lung disease. We are also responsible for medical advances taken up across the NHS and beyond. Each year between 500 and 600 papers by researchers associated with the Trust are published in peer-reviewed scientific journals, such as The Lancet and New England Journal of Medicine.
Our main research partner is the National Heart and Lung Institute at Imperial College, London. We run additional research projects with other hospitals and universities in the UK and abroad.
The Royal Children’s Hospital (RCH) has been providing outstanding care for Victoria’s children and their families for over 140 years.
We are the major specialist paediatric hospital in Victoria and our care extends to children from Tasmania, southern New South Wales and other states around Australia and overseas.
With a passionate, highly skilled and committed staff campus wide of close to 4,000, we provide a full range of clinical services, tertiary care and health promotion and prevention programs for children and young people.
We are the designated state-wide major trauma centre for paediatrics in Victoria and a Nationally Funded Centre for cardiac and liver transplantation.
When it comes to training and research we partner with the very best. Our campus partners, the Murdoch Childrens Research Institute (MCRI) and The University of Melbourne Department of Paediatrics, along with the RCH Foundation, are on site with the hospital in Parkville. Together, we are committed to improving the health outcomes for children today and in the future.
The Royal Children’s Hospital (RCH) has been providing outstanding care for Victoria’s children and their families for over 140 years.
We are the major specialist paediatric hospital in Victoria and our care extends to children from Tasmania, southern New South Wales and other states around Australia and overseas.
With a passionate, highly skilled and committed staff campus wide of close to 4,000, we provide a full range of clinical services, tertiary care and health promotion and prevention programs for children and young people.
We are the designated state-wide major trauma centre for paediatrics in Victoria and a Nationally Funded Centre for cardiac and liver transplantation.
When it comes to training and research we partner with the very best. Our campus partners, the Murdoch Childrens Research Institute (MCRI) and The University of Melbourne Department of Paediatrics, along with the RCH Foundation, are on site with the hospital in Parkville. Together, we are committed to improving the health outcomes for children today and in the future.
Royal Devon and Exeter NHS Foundation Trust
Exeter, United Kingdom
Healthcare Care Delivery
Healthcare Research
Our reputation as an innovative leading acute hospital has developed over 250 years. The RD&E was one of the first Foundation Trusts to be created in the country and this status has enabled us to foster closer links and a better understanding of what local people expect and need from us now and for future planning.
We provide specialist and emergency hospital services to residents and visitors primarily in Exeter and East and Mid Devon, though patients also come from further afield in the South West and England because of our excellence.
During 2013/14 the Trust spent £388 million and employed 7,000 staff. The Trust delivers over 300,000 outpatient attendances and over 115,000 day case or inpatient admissions per year, with additional diagnostic and community service activity delivered in local communities.
We also make a significant contribution to world class research and development which improves the quality, experience and effectiveness of healthcare. The RD&E has a track record for piloting new ways of working and patient care for the Department of Health and the National Institute for Innovation, before it is rolled out across the NHS.
At Sage Bionetworks, we work to redefine how complex biological data is gathered, shared and used. We challenge the traditional roles of individuals and groups, patients and researchers. Our work includes the building of platforms and services and undertaking research developing predictors relating to health. Arising in 2009 with initial support of over $2 million from founding contributors the Cure Huntington’s Disease Initiative Foundation, an anonymous donor, Quintiles, and the Canary Foundation, we are a non-profit research organization based in Seattle, US and collaborate with a worldwide network.
We create technology platforms that facilitate collaboration on data, governance platforms that enable data sharing and reuse, run challenges to solve complex biomedical problems, and perform our own cutting-edge computational biology and research.
SAIL Research Network
Cambridge, Massachusetts, United States
Companies Genomic Analysis
Research Collaboration or Consortium
SAIL is a federated database of genomic and biobank databases that uses advanced cryptography to provide genomic data privacy and governance for research collaborations.
Samsung Genome Institute (SGI) was established as an affiliate of SMC to develop a comprehensive system for the implementation of precision medicine based on genome sequencing and bioinformatic analysis. With the vision to become one of the leading institutes for precision medicine in the world, SGI has already begun to (i) perform state-of-the-art genome analysis, (ii) provide clinical-grade genome analysis and (iii) create a new paradigm through open innovation in personalized genome analysis.
SGI consists of three specialized laboratories with the state-of-art equipment which are Translational Genomic Lab(TGL), Translational Bioinformatics Lab(TBL), and Functional Genomics Lab(FGL). TGL features clinical genomics and single cell analysis. Clinical genome sequencing team operates NGS system for disease-specific panel as well as CancerSCAN. Single cell analysis team aims to identify treatment-resistant cells, cancer stem cells and circulating tumor cells, detect low frequency mutations and low amount samples, and to characterize tumor microenvironment cells.
TBL is organized with experienced scientist and computing capacity with 608 cores, 1.5Pb storages and cloud storage. TBL focuses on enhancing analysis pipeline in collaborating with domestic (the government-funded Supercomputing Center and also Korea Telecom and abroad institutes.
FGL is to mainly generate stable isogenic cell models for ‘oncogenic driver’ discovery, and to validate functions of novel variants from cancer patients as well as make shRNA/RGEN screening on cancer cell lines and PDCs.
SGI developed clinical sequencing analysis pipeline for NGS which is coined as “CancerSCAN” and to establish automated bioinformatics analysis pipeline with functional annotation combining two variant callers, reports with the somatic variant classification.
CancerSCAN is a targeted deep sequencing analysis that links to diagnostic interpretation and therapeutic suggestion. The test was optimized to characterize single nucleotide variations (SNVs), short insertions and deletions (INDELs), copy number variation (CNVs), and selected translocation across 83 tumor related genes. The test is fully compatible with routine formalin-fixed and paraffin-embedded (FFPE) clinical samples. A systemic validation study using reference samples of pooled cell lines demonstrated that CancerSCAN achieved high sensitivity with high specificity. CancerSCAN should maximize the appropriate use of targeted therapy and hopefully bridge the patients’ genomic information into precision medicine application.
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Toronto, Canada
Healthcare Research
Healthcare Care Delivery
The Lunenfeld-Tanenbaum Research Institute, located at Mount Sinai Hospital, is one of the leading biomedical research facilities in the world. Created in 1985, the institute is profoundly advancing the understanding of human biology in health and disease. Many of the breakthroughs that began as fundamental research have already resulted in new and better ways to prevent, diagnose and treat common illnesses ― bringing a healthier future to Canadians
Sanofi is a global healthcare leader focused on patients’ needs by engaging in research, development, manufacturing and marketing of innovative therapeutic solutions. Sanofi has core strengths in healthcare, with 7 growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
Saphetor is a personalised medicine company whose goal is to offer clinicians a data-driven solution for making accurate diagnoses, choosing the right therapies and thereby improving patient outcomes. Saphetor can do this because it is pioneering the automation of the currently laborious and disparate processes required for genome-scale analyses and annotation of data from NGS – Next Generation Sequencing – of large “panels” of hundreds or thousands of genes, exome (i.e. important sequences from all genes) or whole genome sequencing data.
School of Information Technology and Mathematical Sciences
Mawspon Lakes, Australia
Research University
Largest IT&Mathematics School in South Australia (and one of the largest in Australia). Our multidisciplinary research activities are supported with close collaboration with the industry and practice (such as Centre for Cancer Biology, Commonwealth Scientific and Industrial Research Organisation, Commonwealth Dpt. of Health and Aging, SA Health, SA/NT Data Link, SA Pathology, Flinders Medical Centre, Human Variome Project, Royal College of Pathologists of Australasia).
More details on relevant research is shown at:
ACRC – http://www.unisa.edu.au/Research/Advanced-Computing-Research-Centre/Research-at-ACRC2/ (especially the Sematic Systems Group focusing on semantic interoperability across diverse systems including ontology reconciliation; and Data Analytics Group focusing on discovery of complex relationships in biological systems from Big data)
Phenomics and Bioinformatics Research Centre (PBRC)- http://www.unisa.edu.au/Research/Phenomics-and-Bioinformatics-Research-Centre/
SciLifeLab (Science for Life Laboratory, www.scilifelab.se) is a Swedish national center for large-scale molecular biosciences. Our mission is to provide Swedish researchers with high-throughput technologies, focusing on health and environmental research. The largest part of the center infrastructure is located at the four host universitites in Stockholm and Uppsala: Karolinska Institutet, KTH Royal Institute of Technology, Stockholm University and Uppsala University. Parts of the infrastructure are located at a number of other universities in Sweden, and the service is provided on equal basis to all national users.
SciLifeLab provides ten national service platforms in different areas of expertise, each offering technologies and services through co-ordinated facilities. As of 2016, there were 451 infrastructure personnel in 41 facilities. The platforms offer advanced technologies, training, know-how and support to researchers from all parts of Sweden. SciLifeLab is governed by a National Board, established through parliamental regulation. In 2016, SciLifeLab received 410 million SEK in governmental funding.
The SciLifeLab environment is further complemented by 154 affiliated research groups.
Scientific Bio-Minds is a research intensive bioinformatics firm and a contract research service provider located in Bangalore, India. Scientific Bio-Minds was founded in 2008 with a mission to create bio-IT solutions for the analysis, interpretation, and application of biological and molecular data. Our solutions help genomics and proteomics researchers in the biopharma industry and in academia leverage computational power to discover new drug leads, verify lab experiments and cut significant research time. Our core technologies are NGS Data analysis, Microarray Data analysis, Drug discovery and Development, bioLITMUS and bioQSAR.
Our focus on bio-therapeutics research, cell and molecular biology, molecular diagnostics, agricultural and veterinary sciences. We help scientist to understand their data using information technology. We offer bioinformatic support to life science researchers – we help you with data analytic, visualization and data integration. We are closely collaborating with our academic partner.
SeekIn is a startup specializing in tumor early detection.
Seoul National University Cancer Research Institute
seoul, South Korea
Research Institute
Research University
The Cancer Research Institute is one of the legal institutes of Seoul National University. It is located in the Medical campus at Yongon-dong, Jongno-gu, Seoul. About 40 professors and 200 scientists and students are working in the CRI. CRI has several decision-making bodies at different levels, as described below:
SeqOne is a life science startup based in Montpellier that seeks to bring genomic medicine into the mainstream by simplifying the analysis of genomic data by offering improved software that manages the entire process of analysis from raw data to final report.
Sequencing.com
https://sequencing.com, United States
Companies Information Technology
Companies Genomic Analysis
Sequencing.com turns genetic data into useful information. We provide free, unlimited and secure storage of all genetic data and our online platform includes straightforward apps that can analyze and interpret the data. Apps available on Sequencing.com make genetic analysis faster and more affordable so that researchers and bioinformatics experts can turn their data into results.
Third party developers can generate revenue and create better genomics software by selling their apps in the Sequencing.com App Marketplace. We make developing apps easy with free developer tools and an open API.
Bringing the power of science to healthcare.
As a life sciences company, Sequenom (NASDAQ: SQNM) has a guiding vision: enable healthier lives through the development of innovative products and services. We serve patients and physicians by providing early patient management information.
What makes this vision a reality? Our deep commitment to “Quality of Science.” For us, only the highest quality is acceptable. We accept nothing less in the science that supports every product and service we offer. From design and development to manufacturing and marketing of innovative technology, instrumentation and tests, “Quality of Science” is the common element in everything we do.
Sequenom Center for Molecular Medicine (doing business as Sequenom Laboratories), a wholly-owned subsidiary of Sequenom, provides best-in-class laboratory testing services with a focus on prenatal diseases and conditions. Our services include the market-leading MaterniT21® PLUS noninvasive prenatal laboratory-developed test intended for use in pregnant women at increased risk for fetal aneuploidies.
Seven Bridges Genomics, Inc.
Cambridge, United States
Companies Genomic Analysis
Companies Information Technology
Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision medicine. The scalable, cloud-based Seven Bridges Platform empowers rapid, collaborative analysis of millions of genomes in concert with other forms of biomedical data. Thousands of researchers in government, biotech, pharmaceutical and academic labs use Seven Bridges, including three of the largest genomics projects in the world: U.S. National Cancer Institute’s Cancer Genomics Cloud pilot, the Million Veteran Program, and Genomics England’s 100,000 Genomes Project. As the NIH’s only commercial Trusted Partner, Seven Bridges authenticates and authorizes access to one of the world’s largest cancer genomics dataset. The company has offices in Cambridge, Mass.; Belgrade; London and San Francisco.
Shanghai Genebank Biotechnology Co.Ltd. was founded on 2014 to empower individuals to discover the values of their genetic information. Our mission is to help people access, understand and benefit from the human genome. We believe that understand one’s genetic information will be the foundation of future healthcare management. We also believe that the value of our genetic information will increase over time because science is constantly moving and the community is becoming stronger.
Having the same dream and passion, professionals with different background gathering in Shanghai started Shanghai Genebank. We focus on bringing the state of the art technology to the Chinese market and leading our customers change towards genetic based healthcare management. We would like to provide a bridge to connect the individuals to the leading edge genetic technology, which would be an informative, authoritative, intuitional and systematic genetic test report built by the hard work of our geneticists, biologists, computer scientists, bioinformaticians, and mathematicians.
Shanghai GeneLTD Bio-Technology Limited
Shanghai, China
Companies Life Science
Companies Genomic Analysis
Our company is a leading provider of personal genomics, aiming to empower individuals to discover the values of their genetic information.
Shanghai Personal Biotechnology Co., Ltd. was established in April 2011 and is a well-known enterprise providing services including next generation sequencing, genetic testing, product development and more. Headquartered in Xuhui District of Shanghai, Personal Biotechnology has set up offices in more than 10 provinces and municipalities, and has collaboration partners throughout China and is actively exploring oversea market. The company owns a number of patents and software copyrights, and obtained the distinguished title of “High-tech Enterprises” in 2013. In 2014 the company was granted the Shanghai Innovation Fund.
PersonalGene is a sub brand of the Shanghai Personal Biotechnology Co. Ltd. Relying on parent company’s technical platforms, we focus on building a series of personal gene examination packages, to improve people’s health management ability and quality of life. Using the Illumina sequencing platforms and reagent certified by FDA, we collect saliva sample from clients, extract DNA to analyze genetic information. The information is then processed through the internationally recognized genome database (OMIM, NCBI, UCSC etc.), checked with professional research literatures and international norms and standards (NCI, FDA, ACMG etc.). Based on these analyses, we will be able to provide predictions of health risks and advice accordingly for clients at the genetic level.
Sheng Ting Group Corporation
Taizhou, China
Companies Genomic Analysis
Companies Information Technology
ShengTing Group is a privately held organization and headquartered in TaiZhou, Zhejiang, China. ShengTing Group Corporation currently has over 10 subdivisions located in various cities in China, such as: ShengTing (TaiZhou) BioTech Co., Ltd., ShengTing (HangZhou) Bioinformatics Co., Ltd., and ShengTing Investment Co., Ltd.. ShengTing has collaborative labs in Europe, Japan and U.S. Commonwealth of Virginia. ShengTing Group has the latest NGS sequencing machines such as HiSeq 2500, MiSeq, Ion Proton, Ion PGM, and BioNano Genomics’s Irys systems etc., and multiple high performance supercomputing clusters; as well as a distinguished team of world leading scientists for genomics and systems biology-based business of agricultural productivity, human health and biodefense, medical biomarker and gene drug target discovery.
The SIB Swiss Institute of Bioinformatics is an internationally recognized non-profit organization dedicated to biological and biomedical data science. It is present in the main academic institutions of Switzerland and leads numerous national and international projects with a major impact on life science research and health.
SIB’s scientists are passionate about creating knowledge and converting complex questions into solutions in many fields, from biodiversity and evolution to medicine. They provide essential databases and software platforms, data management, software engineering and biocuration services, as well as computational biology know-how and training. The institute delivers this expertise to academic groups and clinicians as well as to private companies.
SIB federates the Swiss bioinformatics community of some 800 scientists, encouraging collaboration and knowledge sharing. It also cooperates with national and international institutions on research infrastructure matters.
The institute contributes to keeping Switzerland at the forefront of innovation by fostering progress in biological research and enhancing health.
Sidra Medicine is a 400-bed women’s and children’s hospital, medical education and biomedical research center in Doha, Qatar.
Sidra Medical and Research Center (Sidra) will be a groundbreaking hospital, research and education institution, focusing on the health and wellbeing of women and children regionally and globally. As a fully digital facility, Sidra will incorporate the most advanced information technology applications in clinical, research and business functions. The Research Branch at Sidra is currently operational and serves as a hub for biomedical investigation in Qatar to facilitate the process of clinical testing and discovery by adopting advanced technologies. Its aim is to advance the understanding of mechanisms of disease; to develop preventive, diagnostic and therapeutic tools; and to improve the health outcomes of the children and women of Qatar. The Research Branch aims to develop world-leading science and research programs that will align with Qatar’s National Research Strategy and also help address other public health issues.
Sidra is part of a dynamic research and education environment in Qatar that includes leading international institutions, such as Sidra’s academic partner Weill Cornell Medical College in Qatar. Through strong partnerships and collaboration with leading institutions in Qatar and around the world, Sidra is creating an intellectual ecosystem to help advance scientific discovery through investment in medical research.
Sightline Innovation (SI) is a privately held Canadian company with patented DataTrust technology. This applied artificial intelligence (AI) platform enables enterprises to control their data, derive value from data, and gain better insight from existing data sources across multiple business units. SI provides its services through its proprietary and patented SaaS based platform Sightline Innovation DataTrust (SID). Our current work is in the area of digital agriculture. Sightline provides the software infrastructure to support gene to trait mapping amongst the collaborating parties while maintaining background intellectual property and tracking ownership of derived digital assets (AI models trained on curated datasets). See Protein Industries Canada invests in the development of new high-protein crop varieties https://www.farms.com/news/protein-industries-canada-invests-in-the-development-of-new-high-protein-crop-varieties-159530.aspx Terramera Leads Digital Technology Supercluster Project to Further Its Commitment to Reducing 80% of Synthetic Pesticide Load Globally by 2030 https://www.terramera.com/newsroom/terramera-leads-digital-technology-supercluster-project Previous work applied probabilstic graphical models (PGM) to a clinical study of HIV-resistant Kenyan sex workers on an earlier version of our platform.
Silverberry Genomix
San Francisco, United States
Companies Life Science
Companies Information Technology
SilvSilverberry Genomix is a DNA Lifestyle Company which utilizes the latest advances in genomics science and machine learning methods (AI) to generate personalized wellness reports based on your genes.
Using the saliva sample, 150 Reports are generated in the areas of Nutrition, Exercise, Skincare, Allergy and Personality Development.
contact info@silverberrygenomix.com for more details.
As Canada’s leading community-engaged research university, SFU is defined by its dynamic integration of innovative education, cutting-edge research and far-reaching community engagement. SFU was founded 50 years ago with a mission to be a different kind of university—to bring an interdisciplinary approach to learning, embrace bold initiatives, and engage with communities near and far. With campuses in British Columbia’s three largest cities – Vancouver, Burnaby and Surrey – SFU has eight faculties, delivers almost 150 programs to over 35,000 students, and boasts more than 135,000 alumni in 130 countries around the world. Generally ranked among the top 15 universities in Canada, SFU attracts over $100M of external research funds, and is among the top institutions in Canada with respect to the quality and impact of its research.
The Simons Foundation’s mission is to advance the frontiers of research in mathematics and the basic sciences. We sponsor a range of programs that aim to promote a deeper understanding of our world.
SimulConsult
Chestnut Hill, United States
Companies Genomic Analysis
Companies Information Technology
SimulConsult provides diagnostic decision support for the clinic and the lab.
The company’s Genome-Phenome Analyzer, that supports and speeds up the clinical interpretation of genomic analysis by identifying the most pertinent causative genes from among described Mendelian disorders, highlighting the plausible causative variants in those genes.
The company also offers an Enterprise diagnostic decision support for the clinic, integrated with the major electronic health records.
SingHealth Duke-NUS Institute of Precision Medicine (PRISM)
Singapore, Singapore
Research Institute
Healthcare Research
SingHealth Duke-NUS Institute of PRecISion Medicine (PRISM) is the institutional flagship initiative of SingHealth and Duke-NUS Medical School that aims to drive, promote and standardize the use of Precision Medicine and Precision Health for improving patient care, focusing on diseases relevant to Asian populations.
Snippet is building an open precision medicine platform with genomics at its core. Over 400,000 genotype-phenotype interactions have been submitted to national research knowlegebases, yet only 23 have clinical guidelines. While new clinically-validated drug-gene interactions are continuously discovered, less than 25% of providers have an active pharmacogenomics program. At the same time, over 1.5 million patients each year are impacted by adverse drug reactions, leading to an avoidable cost of over $3.5M annually. Snippet is solving this problem and will build toward a new standard of care where omic, clinical, mHealth, and exogenous data are all integrated and used to help patients avoid diseases and get the right treatment the first time.
SNOMED International determines global standards for health terms, an essential part of improving the health of humankind.
We are committed to maintaining and growing our leadership as the global experts in healthcare terminology, ensuring that SNOMED CT, our world-leading product, is accepted as the global common language for health terms.
SolveBio delivers the critical reference data used by hospitals and companies to run genomic applications. These applications use SolveBio’s data to predict the effects of slight DNA variants on a person’s health. We make the data easy to access so that our customers can focus on building clinical grade molecular diagnostics applications, faster.
Sovereign Cloud Australia Pty Ltd
Kingston, Australia
Companies Information Technology
Research Collaboration or Consortium
AUCloud is the sovereign cloud infrastructure-as-a-service (IaaS) provider, exclusively focused on the Australian Public Sector and Healthcare and Defence communities. Enabled by improvements in cloud technology and based on extensive proven success, AUCloud is proud to deliver a service, which is Assured by design, Agnostic by price, Australian by definition, Agile in delivery and Aligned in values. Citizens’ data will always be protected, tax will be paid, and Government will be more secure, more effective and delivering better value for all. AUCloud’s founders were previously involved with the founding and growth of a leading European cloud platform underpinning healthcare and genomics research and translational activity. AUCloud has similar objectives to establish the leading Australian platform enabling responsible genomic data sharing for the benefit of human health.
The National Biobank Platform, promoted by the Carlos III Health Institute, aims to provide the Spanish biobanking system with added value by creating a harmonious cooperative framework for the benefit of the Scientific Community, favoring the quantitative and qualitative growth of scientific production in Biomedicine by obtaining, handling, and managing human biological samples and their associated information, and offer them to National Health System actors, while guaranteeing the rights of patients within the framework of the ethical standards and the effective legislation.
The platform builds on experience and promotes a more professional management of its services, the promotion of collections of high strategic value and the carrying out of R&D and innovation activities in the field of biobanks.
Spiral Genetics is a Seattle-based bioinformatics company that develops high performance software for next generation sequencing data. We specialize in large-scale DNA data analysis for medical, pharmaceutical and agricultural research. As a company, we value technological and scientific excellence and are constantly pushing the envelope.
SRA International. Inc.
Rockville, United States
Companies Information Technology
Systems Integrator/Professional Services - with a specialty bioinformatics practice for 17 years
SRA was founded in 1978 and employs over 5,300 professionals who are passionate about creating innovative solutions that help solve some of the most complex challenges in health, national and homeland security, counterterrorism and intelligence. We have had a specialty bioinformatics practice for 17 years, and are among the leading providers of bioinformatics services to the U.S. Government. We have over 100 bioinformatics professionals serving the NIH and the CDC in a variety of roles. Among our current bioinformatics projects are:
• The Data Coordinating Center for The Cancer Genome Atlas (TCGA) for the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).
• The TARGET Data Coordinating Center contract for NCI.
• We are part of the ISB team with Google Genomics under Dr. Ilya Shmulevich for one of the three Cancer Genome Cloud Pilots from NCI’s Center for Bioinformatics and Information Technology (CBIIT).
• The Federal Interagency Traumatic Brain Injury Research (FITBIR) and numerous associated projects on neurological disorders, using BRICS and ProFoRMS, for the Division of Computational Biosciences at NIH’s Center for Information Technology.
• Supporting a TCGA Genome Data Analysis Center (GDAC) for Dr. John Weinstein at Baylor College of Medicine; we worked on many of his Miner suite of tools when he was at the NCI.
• Clinical database and Biomedical Translational Research Information System (BTRIS) integration work for the National Heart, Lung, and Blood Institute (NHLBI).
• Four projects at CDC, supporting the NCIRD, and OID bioinformatics cores, scientific computing, and metagenomics.
The mission of St. Jude Children’s Research Hospital is to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment. Consistent with the vision of our founder Danny Thomas, no child is denied treatment based on race, religion or a family’s ability to pay.
The mission of St. Jude Children’s Research Hospital is to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment. Consistent with the vision of our founder Danny Thomas, no child is denied treatment based on race, religion or a family’s ability to pay.
StarshipGene is a genomic analysis company, and provides personal genetics reports in aspects of health risks, inherited diseases, drug reactions, as well as nutritions, sport traits and other personal traits.
Station X is the home of GenePool, a SaaS platform for scientists and clinicians who work with genomics data.
StoreGene
United Kingdom, United Kingdom
Companies Genomic Analysis
Companies Information Technology
StoreGene is London’s leading cardiovascular genetics company.
Spun out from the Centre for Cardiovascular Genetics at University College London, StoreGene provides rare disease and medication response laboratory panel tests translating over 20 years of genetic research into the clinical setting.
We are building on this expertise taking individual laboratory tests, to the cloud by developing the Genome-Wide Intelligence System (G-WIS) which solves the challenge of bioinformatics for genomicists and clinicians enabling rapid translation of genetic discoveries.
G-WIS has an initial focus on the world’s largest killer: cardiovascular disease, responsible for 31% of all deaths.
British Heart Foundation 2020 statistics show that in the UK cardiovascular disease causes 460 deaths per day with 7.4 million people living with heart and circulatory disease; 620,000 of these have a genetic variation causing their condition. Despite prevalence of 1 in 250 people, a genetic condition termed Familial Hypercholesterolemia (FH) is underdiagnosed with less than 8% of cases confirmed. Onset of cardiovascular events for FH patients is treatable with early diagnosis and cholesterol-reducing medication, making diagnosis a priority for the NHS Long Term Plan 2019.
Strand Life Sciences Private Limited
Bengaluru, India
Healthcare Research
Companies Genomic Analysis
Ranked in the top tier of Next Generation Sequencing (NGS) informatics providers by Frost & Sullivan,Strand Life Sciences Pvt.Ltd. is at the forefront,in providing research biologists (the bench) with the informatics needed for data intensive genomics, proteomics and metabolomics. Today, Strand serves well over 1200 life sciences research institutions globally with over 2,000 licensees of its data analytics technologies.
Fuelled by recent investments made in the company by Biomark Capital and fielding perhaps the world’s largest development team in bioinformatics, Strand is rapidly developing the informatics infrastructure required for simplifying diagnostic odysseys at the scale that precision medicine requires.
Strand has close to 200 employees with around 80 computer scientists and 90 life scientists with higher educational training at some of the world’s premier institutions. Strand has a strategic team of around ten employees located in the US and the rest in India. In its first decade, Strand dedicated itself to the creation of some of the finest tools for tertiary data analytics for research biology.
Streamline Genomics is developing a platform to help clinicians routinely use genomic sequencing for their diagnoses.
Suisse Life Science S.A., headquartered in Switzerland – now wholly owned by Suisse Life Science Group plc (London) – is Europe’s leading lifestyle biological intel company.
Suisse Life Science is active since 2014 in creating consumer and professional personalized lifestyle medicine programs through proprietary genotyping developed with Affymetrix/Thermo-Fisher Scientific and related customized products.
Our main focus is multidimensional age management and precision care through living data.
We currently employ the former principal investigator for Human Genomics of EU community.
–
Sunnybrook Research Institute (SRI) is the research enterprise of Sunnybrook Health Sciences Centre and is fully affiliated with the University of Toronto. Scientists at SRI strive to understand and prevent disease, and to develop treatments that enhance and extend life. Our vision is to invent the future of health care. The 290 scientists working at SRI are renowned for excellence in the biological, physical and evaluative clinical sciences. Areas of expertise are diseases of the brain and heart; cancer; musculoskeletal conditions; rehabilitation; trauma, emergency and critical care; women and babies, and veterans and community. Each year, SRI conducts over $100 million in research across 500,000 square feet, including in the world’s first Centre for Research in Image-Guided Therapeutics.
For more information, visit sunnybrook.ca/research.
Sure Genomics, Inc.
Palo Alto, United States
Companies Genomic Analysis
Companies Information Technology
It is our mission help improve the science of proactive health and wellness for consumers through the personal access and intuitive interpretation of DNA sequencing information.
Swagene is a pioneer in personalized medicine that develops and sells molecular diagnostics that will help doctors and patients make better decisions in healthcare and treatment. Each report is tailored to decrease healthcare costs while improving treatment outcomes.
Being a knowledge laboratory, we are frequently invited to speak at various medical/health conferences, and seminars at hospitals and research institutes. The scientists at Swagene vet and curate genetics and genomics research to identify genetic biomarkers that are at a stage advanced enough to improve clinical care, and primarily answer if we would pay for and use such a test, before embarking on developing the assays and selling the diagnostics.
Syapse software enables healthcare providers to deploy precision medicine programs.
Leading academic and community healthcare providers use the Syapse Precision Medicine Data Platform to integrate complex genomic and clinical data to provide clinicians with actionable insights at point of care, enabling diagnosis, treatment, and outcomes tracking. Headquartered in Palo Alto, California, Syapse is backed by The Social+Capital Partnership and Safeguard Scientifics.
Sydney Children's Hospitals Network
WESTMEAD, Australia
Healthcare Research
Healthcare Care Delivery
The Sydney Children’s Hospitals Network incorporates The Children’s Hospital at Westmead, Sydney Children’s Hospital, Randwick, Bear Cottage, the Newborn and paediatric Emergency Transport Service (NETS), the Pregnancy and newborn Services Network (PSN) and the Children’s Court Clinic.
The Sydney Children’s Hospitals Network is the largest network of hospital and services for children in Australia. Each year our services manage:
•51,000 inpatient admissions
•92,000 Emergency Department presentations
•Over one million outpatient service visits
Sydney Children's Hospitals Network
WESTMEAD, Australia
Healthcare Research
Healthcare Care Delivery
The Sydney Children’s Hospitals Network incorporates The Children’s Hospital at Westmead, Sydney Children’s Hospital, Randwick, Bear Cottage, the Newborn and paediatric Emergency Transport Service (NETS), the Pregnancy and newborn Services Network (PSN) and the Children’s Court Clinic.
The Sydney Children’s Hospitals Network is the largest network of hospital and services for children in Australia. Each year our services manage:
•51,000 inpatient admissions
•92,000 Emergency Department presentations
•Over one million outpatient service visits
Sysbiochem
Lexington, United States
Companies Information Technology
Companies Genomic Analysis
Sysbiochem is a provider of tools, services and software implementations for life sciences and healthcare. For the past 12 years, Sysbiochem has been a software product development and services provider in life-sciences and healthcare, specifically focused on enabling genomic technologies.
Professional services to design, and manage genomic studies and clinical genomics programs, and model complex biological systems to recover useful mechanistic insights. We utilize a multitude of knowledge resources, including our own proprietary knowledge bases, graph-based technologies, and advanced learning systems, in combination with human expertise and experience.
Taiwan AI Labs is a non-profit organization, and It is a privately funded research organization based in Taipei. We expect artificial intelligence to have primary and transformative impacts on the landscape of technology, and our goal is to leverage unique advantages in Taiwan to build AI solutions to solve the world’s problems.
We leverage Taiwan’s comprehensive medical data (genomics and medical image) and work with doctors and top scientists to solve complex human health problems.
Our genomics team builds the genomics analysis platform is called TAIGenomics. The TAIGenomics uses the genomic analysis model trained by Taiwan AI Labs to assist professionals in identifying underlying diseases, significantly improving efficiency, accuracy, and quality of medicine while reducing the cost of genomic analysis.
TAIGenomics employs an artificial intelligence system that peruses an extensive amount of medical literature, performs big data analysis on the available information, standardizes the given genomic database, and builds an association graph and prediction model from known diseases, treatment, and cancerous genes. All this, in hopes of a brighter day for Taiwanese genomic analysis.
We collaboration and partners have National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan Foundation for Rare Diseases, National Health Research Institute, and Institute of Biomedical Sciences Academia Sinica, etc.
TB-Seq, Inc. provides experimental and computational services in cutting-edge RNA sequencing technology, consulting, design and execution of customized experimental and computational procedures. TB-Seq, Inc. specializes in application and development of experimental and computational procedures for translatome analysis (ribosome profiling) of microbial (bacteria, archaea) and eukaryotic (e.g., plants, fungi, human and other mammals) organisms, communities, and host/parasite or probiotic systems. Our services include RNA extraction, RNA-seq and RIBO-seq library preparation, sequencing, and customized bioinformatics analysis.
The American Society of Human Genetics (ASHG), founded in 1948, is the primary professional membership organization for human genetics specialists worldwide. The Society’s nearly 8,000 members include researchers, academicians, clinicians, laboratory practice professionals, genetic counselors, nurses and others who have a special interest in the field of human genetics. Our members work in a wide range of settings, including universities, hospitals, institutes, and medical and research laboratories.
University conducting research and teaching, including in biomedical disciplines with strengths in genome biology and genomics in a wide range of species including human.
The Australian Pancreatic Cancer Genome Initiative (APGI)
Sydney, Australia
Research Collaboration or Consortium
Research University
The Australian Pancreatic Cancer Genome Initiative (APGI) is a global research enterprise of over 100 scientists, clinicians and allied health professionals involved in pancreatic cancer research and care. The APGI has mapped the genome of pancreatic cancer in a landmark effort as part of Australia’s contribution to the International Cancer Genome Consortium (ICGC). This fundamental understanding of the genetic underpinnings of Pancreatic Cancer will accelerate the evolution of pancreatic cancer care into the molecular age of oncology. The APGI’s world-class BioResource – biological samples coupled with comprehensive clinical and genomic data – is aiding research worldwide in ongoing discovery and development through quality research and strategic collaborations.
The Children's Brain Tumor Tissue Consortium
Philadelphia, United States
Research University
Research Collaboration or Consortium
The Children’s Brain Tumor Tissue Consortium is an open acces collaborative multi-institutional cooperative research program dedicated to the study of childhood brain tumors. The ultimate goal of the CBTTC is to improve outcomes for children with brain tumors by supporting research on new prognostic biomarkers and therapies. The CBTTC has made great strides towards increasing worldwide collaboration and positioning the CBTTC for long term growth and sustainability through integrating informatics advancements, a state of the art biorepository and the leading experts in the field.
The CBTTC has been successful in collecting over 4,000 biological brain tumor specimens annotated with longitudinal clinical data and is posed to launch genomic analysis.
The Children's Hospital of Philadelphia
Philadelphia, United States
Healthcare Care Delivery
Research Institute
The Children’s Hospital of Philadelphia (CHOP) is the nation’s first hospital devoted exclusively to the care of children. Since our start in 1855, CHOP has been the birthplace for many dramatic firsts in pediatric medicine. The Hospital has fostered medical discoveries and innovations that have improved pediatric healthcare and saved countless children’s lives. Today, families facing complex conditions come to CHOP from all over the world, and our care and innovation has repeatedly earned us a spot on the U.S. News & World Report’s Honor Roll of the nation’s best children’s hospitals.
The Children’s Hospital of Philadelphia has a long and distinguished tradition of research that has spanned nearly a century. The research breakthroughs at Children’s Hospital have improved the lives of countless children throughout the world and put the institution on the course to pediatric research preeminence.
Research at the Hospital had modest beginnings. The Hospital established its first research laboratory in 1922 as a single room in its basement. By 1931, the Hospital founded the “Society of Pediatric Research” for its expanding base of investigators, who conducted their experiments wherever space permitted.
These beginnings gained significant momentum in 1972 when Children’s Hospital designated 70,000 square feet to research and established the Research Institute, the first pediatric research department in the country.
Today, the Hospital’s entire research enterprise is organized under the aegis of the CHOP Research Institute and constitutes a separate organizational, administrative and financial entity within the Hospital.
The Children's Brain Tumor Tissue Consortium
Philadelphia, United States
Research University
Research Collaboration or Consortium
The Children’s Brain Tumor Tissue Consortium is an open acces collaborative multi-institutional cooperative research program dedicated to the study of childhood brain tumors. The ultimate goal of the CBTTC is to improve outcomes for children with brain tumors by supporting research on new prognostic biomarkers and therapies. The CBTTC has made great strides towards increasing worldwide collaboration and positioning the CBTTC for long term growth and sustainability through integrating informatics advancements, a state of the art biorepository and the leading experts in the field.
The CBTTC has been successful in collecting over 4,000 biological brain tumor specimens annotated with longitudinal clinical data and is posed to launch genomic analysis.
The Children's Hospital of Philadelphia
Philadelphia, United States
Healthcare Care Delivery
Research Institute
The Children’s Hospital of Philadelphia (CHOP) is the nation’s first hospital devoted exclusively to the care of children. Since our start in 1855, CHOP has been the birthplace for many dramatic firsts in pediatric medicine. The Hospital has fostered medical discoveries and innovations that have improved pediatric healthcare and saved countless children’s lives. Today, families facing complex conditions come to CHOP from all over the world, and our care and innovation has repeatedly earned us a spot on the U.S. News & World Report’s Honor Roll of the nation’s best children’s hospitals.
The Children’s Hospital of Philadelphia has a long and distinguished tradition of research that has spanned nearly a century. The research breakthroughs at Children’s Hospital have improved the lives of countless children throughout the world and put the institution on the course to pediatric research preeminence.
Research at the Hospital had modest beginnings. The Hospital established its first research laboratory in 1922 as a single room in its basement. By 1931, the Hospital founded the “Society of Pediatric Research” for its expanding base of investigators, who conducted their experiments wherever space permitted.
These beginnings gained significant momentum in 1972 when Children’s Hospital designated 70,000 square feet to research and established the Research Institute, the first pediatric research department in the country.
Today, the Hospital’s entire research enterprise is organized under the aegis of the CHOP Research Institute and constitutes a separate organizational, administrative and financial entity within the Hospital.
The ENCODE Project : ENCyclopedia of DNA Elements
Stanford, United States
Research Collaboration or Consortium
Research University
The ENCODE (Encyclopedia of DNA Elements) Consortium is an international collaboration of research groups funded by the National Human Genome Research Institute (NHGRI). The goal of ENCODE is to build a comprehensive parts list of functional elements in the human genome, including elements that act at the protein and RNA levels, and regulatory elements that control cells and circumstances in which a gene is active. The Consortium is dedicated to provide standards and the highest quality data sets and data processing pipelines to facilitate the exploration of genomics and epigenomics research.
The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. Its work is helping to understand why disease develops and to find new ways to treat, diagnose and prevent illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases.
The Genome Institute at Washington University
Saint Louis, United States
Research Institute
Research University
The Genome Institute (TGI) is a world leader in the fast-paced, constantly changing field of genomics. A truly unique institution, we are pushing the limits of academic research by creating, testing, and implementing new approaches to the study of biology with the goal of understanding human health and disease, as well as evolution and the biology of other organisms.
As one of only three NIH funded large-scale sequencing centers in the United States, The Genome Institute is helping to lead the way in high-speed, comprehensive genomics. Since its inception in 1993, the institute has played a vital role in the field of genome sequencing, receiving over $800 million in funding. The Genome Institute began as a key player in the Human Genome Project – an international effort to decode all 6 billion letters of our genetic blueprint – ultimately contributing 25 percent of the finished sequence.
The Genomic Medicine Foundation
Cardiff, United Kingdom
Companies Life Science
Societies and NGOs Professional
The Genomic Medicine Foundation is a non-profit organization providing up to date and evidence-based information on all aspects of genomics relevant to clinical and preventive medicine and healthcare. The Foundation undertakes a number of professional activities including books & journal, genetic & genomic clinics, dedicated educational seminars and symposium on genetics & genomics, advise and consultancy on developing genomic research projects, setting up genomic diagnostic facilities and providing information to the lay public, press and media.
–
The Hyve is a small international company with offices in Utrecht, Netherlands and Cambridge, MA, USA, that specialises in support for open source software for bioinformatics and translational research. The mission of The Hyve is to enable pre-competitive collaboration in life science R&D by leveraging open source software.
The Hyve offers several services related to the implementation of open source tools, such as requirements analysis and project definition, data loading and application support. The Hyve has considerable expertise in the development and support of open source bioinformatics and translational research software and is active as a major development party in a.o. CTMM TraIT, IMI eTRIKS, IMI EMIF and IMI Translocation. As such, The Hyve employs software engineers that are core committers for open source projects such as tranSMART (translational datawarehouse), OpenClinica (eCRF), XNAT (imaging), Galaxy (bioinformatics workflows), as well as more generic IT solutions such as OpenStack, R and Apache Spark.
The Hyve has a multidisciplinary team of bioinformaticians, clinicians, statisticians, software developers and project managers, and has a both a data science & software development project team as well as a dedicated functional and technical support department.
The Jackson Laboratory (JAX) is a new nonprofit research institute in Connecticut that will transform medicine by improving care, lowering costs, and increasing life span and health span.
The Montreal Neurological Institute and Hospital (The Neuro)
Montreal, Canada
Healthcare Research
Research Institute
The Neuro is built on 3 pillars: integrated research and patient care, open science, and training. Our mission is to: “understand the brain, find cures and effectively treat people with neurological disorders”. A large part of our mission is our focus on research, care and education. Our fundamental research contributes to immediate or future breakthroughs, our translational clinical research benefits patients while they are in our care. We also provide high-quality clinical care to make sure every patient has the best experience when they come to The Neuro.
Our vision is to: “Transform neurological research and care to change lives”. The connection between laboratory science, clinical investigation and patient care is a strength of The Neuro. It has helped enhance our place in the world of neurology and neuroscience research. We are now profoundly redefining the way we work, by reshaping scientific research and the way it’s shared. We believe our Open Science systems and tools will accelerate scientific progress towards solving the most persistent problems in neuroscience, to accelerate discovery, and impact the lives of millions of patients around the world.
Our values are: accountability, diversity, excellence, innovation, integrity, openness, and partnership. In support of our institutional mission and vision— which together articulate The Neuro’s commitment to serving the public good through excellence in research, clinical care and teaching, our values describe the culture that all our staff and community stakeholders will embrace and uphold. At The Neuro, our core institutional values are driven by the empowerment of our transdisciplinary teams of researchers and clinicians, ambassadors, volunteers, patients and the synergy between them.
The Nordic Alliance for Clinical Genomics
Oslo, Norway
Societies and NGOs Professional
Research Collaboration or Consortium
The Nordic Alliance for Clinical Genomics (NACG) is an independent, non-governmental, not-for-profit Nordic association. NACG aims to 1)Facilitate the responsible sharing of genomic data, bioinformatics tools, sequencing methods and best practices for interpretation of genomic data, 2) Enhance quality of genomic data and processes, and explore methodologies to provide assurance, 3)Understand legal barriers to the implementation of personalised medicine and to engage with key stakeholders that influence these barriers, 4) Develop demonstration projects that challenge perceived legal barriers that limit responsible and ethical sharing of genomic and health data, 5) Build bridges between research and clinical communities, technologies and practices to foster innovation
The Rare Genomics Institute is an international non-profit that provides access to cutting edge research technologies, physicians, and scientists across the globe. By providing an expert network and an online crowdfunding mechanism, the Rare Genomics Institute helps families pursue personalized research projects for diseases not otherwise studied. We bring together scientists who share our passion for helping rare disease patients and leverage the crowdfunding capabilities of the Internet to bring the hope of a cure to our patients.
The Scripps Research Institute (TSRI) — one of the world’s largest, private, non-profit research organizations — stands at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life.
The institute — located on campuses in La Jolla, California, and Jupiter, Florida — has become internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases, virology, and vaccine development. Particularly significant is the institute’s study of the basic structure and design of biological molecules; in this arena TSRI is among a handful of the world’s leading centers.
The Scripps Translational Science Institute
La Jolla, United States
Research Institute
Healthcare Research
The Scripps Translational Science Institute (STSI) aims to replace the status-quo of one-size-fits-all-medicine with individualized health care that is based on the known genetic factors influencing health and disease and that takes advantage of advances in digital technology for real-time health monitoring.
The United States Pharmacopeial Convention (USP)
Rockville, United States
Non-profit, standards organization
Societies and NGOs Professional
Safeguarding the quality of medication is fundamental to protecting the public’s health, especially as ingredients and products come from all over the world. USP quality standards serve as the foundation for a robust safety network that assists manufacturers by increasing predictability and reliability, and preserving the integrity of the global supply chain. Within USP Biologics, genomics and personalized medicine is a new area of interest. As an international standards setting organization, USP is interested in exploring this new and rapidly expanding area of medicine to determine how USP may be able to work with key stakeholders to possibly help develop standards and best practices which may be beneficial to the field as a whole.
The company provides a wide range of services such as customized diagnostic solutions and next-generation sequencing (NGS), clinical and medical big data business based on state-of-the-art genome sequencing and analysis technologies.
Thermo Fisher Scientific
Waltham, United States
Companies Life Science
Companies Genomic Analysis
Thermo Fisher Scientific
Tohoku University Tohoku Medical Megabank Organization was founded to establish an advanced medical system to foster the reconstruction from the Great East Japan Earthquake. The organization will develop a biobank that combines medical and genome information during the process of rebuilding the community medical system and supporting health and welfare in the Tohoku area. The information from the biobank will create a new medical system, and, based on the findings of its analysis, the organization aims to attract more medical practitioners from all over the country to the area, promote industry-academic partnerships, create employment in related fields, and restore the medical system in Tohoku.
Clinical genetics information management software provider.
We have a core product which is used by Clinical Genetics professional throughout Australia, the UK and US.
Translational Genomics Research Institute (TGen)
Pheonix, United States
Research Institute
Research Institute
TGen, the Translational Genomics Research Institute, is an affiliate of City of Hope. We are an Arizona-based, nonprofit medical research institute dedicated to conducting groundbreaking research with life-changing results. We work to unravel the genetic components of common and complex diseases, including cancer, neurological disorders, infectious disease, and rare childhood disorders. By identifying treatment options in this manner, we believe medicine becomes more rational, more precise and, well, more personal.
TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz is biopharmaceutical research organization that pursues new diagnostics and drugs for the treatment of cancer and other severe diseases with high medical need. A focus of TRON is the development of novel platforms for individualized therapies and biomarkers, translating basic research into drug applications. TRON partners with academic institutions, biotech companies and the pharmaceutical industry, executing research with leading-edge technologies and supporting the development of innovative drugs to promote human health.
The U.S. Food and Drug Administration (FDA) is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation’s food supply, cosmetics, and products that emit radiation.
FDA also has responsibility for regulating the manufacturing, marketing, and distribution of tobacco products to protect the public health and to reduce tobacco use by minors.
FDA is responsible for advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health.
FDA also plays a significant role in the Nation’s counterterrorism capability. FDA fulfills this responsibility by ensuring the security of the food supply and by fostering development of medical products to respond to deliberate and naturally emerging public health threats.
From basic research to educating the workforce of tomorrow, the ripple effects of higher education radiate outward, contributing to civic engagement, economic health, and social mobility. The state of California has benefited greatly from the University of California as a driver of innovation. Within the UC system, UC Santa Cruz has carved out a distinctive role as a research powerhouse that offers undergraduates and graduates unparalleled opportunities to participate in cutting-edge research. Just ranked by Times Higher Education as #1 in the world in citations per published research paper. UC Santa Cruz is home to leading programs in genomics and bioinformatics, marine science, Earth and planetary sciences, astronomy and astrophysics, sustainable agriculture, and computer game design.
UCL (University College London) is one of the world’s leading universities, founded in London to open up education to all on equal terms. The UCL School of Life and Medical Sciences s a major biomedical research centre and a leader in medical and health research.
We blend research and teaching in medicine with advances in clinical care and population health through partnership with a range of institutions and the wider health community.
UgenTec is a molecular laboratory software provider servicing molecular labs and assay & instrument providers globally across applications in Clinical Molecular Diagnostics, Veterinary health, and AgBio. UgenTec is headquartered in Hasselt, Belgium with offices in Boston, MA and its FastFinder platform has a global installed base of 100+ molecular labs, as well as partnerships with leading molecular diagnostics kit and instrumentation vendors. FastFinder is a modular, clinical-grade Software as a Service platform that uses Artificial Intelligence methods to automate analysis, interpretation support, reporting, QC, workflow automation and lab intelligence. It allows molecular labs of all sizes to standardize and automate their molecular testing operations. FastFinder’s modules include Analysis, Genotyper, Insights and Workflow.
UKCloud
Farnborough, United Kingdom
Companies Information Technology
Companies Information Technology
UKCloud provide highly secure cloud services (IAAS, PAAS and SAAS) to UK Public Sector in accordance with the strict security requirements demanded by our clients. In 2017, UKCloud launched UKCloud Health (www.ukcloudhealth.com) following a number of successful collaborations in UK health and life sciences. UKCloud designed and operates the HPC and storage environments for the 100,000 genomes project in addition to working with entities like the European Bioinformatics Institute to name but a few. UKCloud are further investing into this community in the UK to enable a secure collaboration cloud that will further assist in the research and discovery phases of genomic medicine.
Unai is a UK-based technology consultancy with a mission to accelerate the positive impact that scientists and other experts are having on health, the environment and society. The company specializes in Software Engineering and Data Science and is focused on helping experts solve complex data problems, creating value for those seeking clarity and insight. Unai have a highly-skilled team of UK-based engineers with expertise in the management of complex, sensitive and often personal data; to engage with partners in Healthcare and Life Sciences. Such co-operation is envisaged under research, joint venture or subcontracting agreements.
Universal Patient Key (UPK) provides software for HIPAA compliance support. UPK software is an essential building block for developing a privacy-respecting genomic data analytics ecosystem. UPK software de-identifies healthcare data records by replacing Protected Health Information (PHI) with irreversible unique tokens that can be linked across multiple sources. This de-identification process retains valuable clinical, administrative, and genomic information while protecting the individual patient’s privacy. UPK already serves several members of the GA4GH community. Our open business model is aligned with GA4GH goals and we are committed to supporting the collective GA4GH mission.
Universidad del Desarrollo (UDD) is an independent, coeducational, nondenominational university that provides undergraduate and graduate education in Medicine, Social Sciences, and Engineering. UDD was founded in the city of Concepción, with the objective of giving a different and innovative perspective to the education of outstanding professionals that contribute to the development of Chile.
Genomics research and applications are carried out by an interdisciplinary team at the Institute for Science and Innovation in Medicine (ICIM), which includes clinicians and researchers in genetics, epidemiology, molecular sciences, bioethics, bio- and medical informatics. Among other areas, ICIM works on strategies for the incorporation of genomic tools in health care in the context of middle-income countries.
The UPF is a young, public and modern university founded in 1990. In recent years, the University has begun to figure prominently in some prestigious international rankings. Its indicators have made it a benchmark for the Spanish and European university systems and it is becoming one of the leading European universities. For instance, the UPF is one of the twenty European universities with the most projects funded by the European Research Council (ERC, 2015) or the first Spanish university in research productivity (Ranking 2012 in research production and productivity in the Spanish university public system (published in 2013).
The UPF structures its studies on three main fields of knowledge, closely interconnected and structured on three campuses: Social sciences and humanities, Health and life sciences and Communication and information technologies. In order to promote research and transfer activities undertaken by university researchers and provide them with greater international visibility, the University is developing the UPF Research Park in the fields of social sciences, humanities, communication and information technologies.
The university is committed to offering a high-quality teaching model and outstanding research with international projection, the three axis of the UPF model. Its teaching model is based on comprehensive education and student-centred learning. The success of this model is proven by different indicators, such asthe high demand of UPF studies, the rates of achievement among its students or the excellent rates of graduates employment and satisfaction.
These results are possible due to the high competitiveness of UPF lecturers and researchers. In that sense, the University model is primarily based on a policy of being an institution that is open to the world, incorporating prominent national and international researchers. This commitment is reflected in excellent indicators in research, such as the volume of funds coming from the EU Framework Programmes (FP7 and H2020) or indicators of scientific production.
Since its founding, Université Laval has been training, equipping, and guiding the decision makers who grapple with the major issues of society. Through the advancement and sharing of knowledge, its culture of excellence, and its global outlook, our academic community contributes to the development and international profile of our province. Still today, with the world at a crossroads, Université Laval plays a bigger role than ever in Québec City and on the national and international scene, both as a catalyst for change and a visionary institution where knowledge, curiosity, and innovation are part of everyday life.
As the first French-language university in the Americas, known for its global perspective and commitment to the highest standards, Université Laval contributes to the advancement of society by:
– training skilled, responsible individuals who promote change, and
– advancing and sharing knowledge in a high-energy research and development environment.
Université Laval is a well-rounded university:
– Some 500 programs
– Renowned mobility and exchange programs
– 5 study profiles: Sustainable Development, Entrepreneurial, International, Honours and Research
– Custom, continuing, and distance education programs
– Some 750 partnership agreements with some 500 universities in nearly 70 countries
– A library of over 6 millions documents
– A vibrant and diverse community
– Over 42,500 students
– Some 5,600 international students
– Some 230 student associations
– Over 1500 professors
University at Buffalo Genetics, Genomics & Bioinformatics Program
Buffalo, United States
Research University
Healthcare Research
We mentor innovative and creative scientists, emphasizing the “how and why” of genetics, genomics and bioinformatics research and its broader significance. We give them the specialized knowledge and research skills needed to contribute to drug discovery, animal development and the burgeoning fields of personalized and regenerative medicine.
University at Buffalo Genetics, Genomics & Bioinformatics Program
Buffalo, United States
Research University
Healthcare Research
We mentor innovative and creative scientists, emphasizing the “how and why” of genetics, genomics and bioinformatics research and its broader significance. We give them the specialized knowledge and research skills needed to contribute to drug discovery, animal development and the burgeoning fields of personalized and regenerative medicine.
University of Alabama at Birmingham Department of Genetics
Birmingham, United States
Research University
Healthcare Care Delivery
The UAB Department of Genetics is both a clinical and basic science department. Faculty provide patient care, including diagnosis, counseling, and management of genetic disorders, and also conduct research on genetics and genomics. The Department offers genomic sequencing and analysis on a research basis, as well as interpretation of data obtained in the course of clinical testing.
University of Bradford
Bradford, West Yorkshire, United Kingdom
Research University
Research University
The University of Bradford (UoB) through a range of initiatives—such as the Born in Bradford project, Wolfson Centre for Applied Research, Centre for Skin Sciences, and Institute for Cancer Therapeutics—is actively involved in translating life science and genomic research into healthcare. The UoB is a member of the ELIXIR-UK node and actively participates in works of ELIXIR Human Data Communities.
Academic researchers publish books or journal articles that contribute new knowledge to their fields of expertise and encourage new avenues of research. UBC research is consistently published in the most widely read academic journals in the world, including Science and Nature. UBC Press, the University’s publishing branch, is acknowledged as one of Canada’s foremost publishers of books in political science, Native studies, and forestry.
UBC is a leader among North American universities in the area of technology transfer. Many of our 130+ spin-off companies are based in British Columbia and have made a significant contribution to the provincial economy, as well as providing numerous societal benefits in the areas of health care and technology. The processes of commercialization and patenting at UBC are stewarded by the University-Industry Liaison Office.
In 2007, UBC became the first university in Canada to adopt Global Access Principles to make UBC technologies, including new medicines, available and affordable to developing nations.
UBC supports a thriving community of talented research faculty and staff whose ideas, discoveries and innovations seek to advance our community and our society. This community includes over 12,000 faculty and staff members, 8,000 graduate students, and a growing number of undergraduate researchers.
Our researchers are based at UBC’s Vancouver and Okanagan campuses, as well as in affiliated hospitals and research institutes around the province.
Many new faculty members are drawn to UBC – and choose to remain here – because of a well-supported and open-minded research environment. We encourage interdisciplinary collaboration and allow investigators the latitude to respond to emerging lines of inquiry, or to ask fundamental questions about the world, while providing the infrastructure they require to pursue answers.
UBC actively encourages interdisciplinary research through the Peter Wall Institute for Advanced Studies, Green College, and the College for Interdisciplinary Studies. Collaborations between faculties and departments help to break down traditional disciplinary boundaries and promote discovery and innovation.
The Office of the Vice Chancellor for Research has overall managerial responsibility for Berkeley’s research enterprise. It seeks to maintain a research environment that fosters creativity, collaboration and community. Its specific goals are to provide effective support for campus-wide research efforts; to advocate for research needs and resources; and to maximize the benefits of Berkeley’s research to the scholarly community, and to the quality of life in the local community, the state, and the nation.
In support of these goals, the Office of the Vice Chancellor for Research:
Supervises over 50 research units, six museums, and seven field stations;
Administers the flow of research funding to the Berkeley campus;
Oversees the compliance of campus research with federal, state and university regulations;
Facilitates relations between University researchers and private industry for the benefit of society.
The leading university exclusively focused on health, UC San Francisco is driven by the idea that when the best research, the best education and the best patient care converge, great breakthroughs are achieved.
A hallmark of its excellence is UCSF’s spirit of collaboration that is carried through its partnerships across the campus and the world in pursuit of its advancing health worldwide™ mission.
Its faculty include five Nobel laureates, who have made seminal contributions to advance the understanding of cancer, neurodegenerative diseases, aging and stem cell research.
Founded in 1209, the mission of the University of Cambridge is to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. To date, 90 affiliates of the University have won the Nobel Prize and it is one of the leading research universities in the world.
The University of Campinas (Portuguese: Universidade Estadual de Campinas, UNICAMP) is a government founded (public) university in the state of São Paulo, Brazil. Created in 1962, UNICAMP’s goal was to promote science education in the industrial pole of São Paulo’s interior region. As of 2011, the university had 17,500 undergraduate students, 19,000 graduate students, and 2000 faculty members. UNICAMP is responsible for around 15% of Brazilian research and it has 53.6% of its students at the graduate level. According to the Times Higher Education 2013-2014 World University Rankings, UNICAMP is ranked within the category of 301st through 350th best universities in the world and the second best in both Brazil and Latin America.The Times Higher Education-QS World University Rankings also pointed UNICAMP, one of the 50 best “young” universities in the world.
UCT aspires to become a premier academic meeting point between South Africa, the rest of Africa and the world. Taking advantage of expanding global networks and our distinct vantage point in Africa, we are committed, through innovative research and scholarship, to grapple with the key issues of our natural and social worlds. We aim to produce graduates whose qualifications are internationally recognised and locally applicable, underpinned by values of engaged citizenship and social justice. UCT will promote diversity and transformation within our institution and beyond, including growing the next generation of academics.
One of the world’s premier academic and research institutions, the University of Chicago has driven new ways of thinking since our 1890 founding. Today, UChicago is an intellectual destination that draws inspired scholars to our Hyde Park and international campuses, keeping UChicago at the nexus of ideas that challenge and change the world.
University of Maryland Center for Bioinformatics and Computational Biology
College Park, United States
Research University
The University of Maryland Center for Bioinformatics and Computational Biology is a multidisciplinary center dedicated to research on questions arising from the genome revolution. CBCB brings together scientists and engineers from many fields, including computer science, molecular biology, genomics, genetics, mathematics, statistics, and physics, all of whom share a common interest in gaining a better understanding of how life works. The Center for Bioinformatics and Computational Biology is organized as a center within the University of Maryland Institute for Advanced Computer Studies (UMIACS), an interdisciplinary research institute supporting high-impact computing research across the College Park campus.
University of Melbourne Center for Cancer Research
Melbourne, Australia
Research University
The University of Melbourne Centre for Cancer Research (UMCCR) seeks to improve cancer patient outcome through Cancer Genome Discovery, Translation and Personalised Medicine. To achieve this the UMCCR needs to create solutions for rapid research and diagnostics at scale, decoding the genetic damage present in each patient’s cancer genome, with the rigor and speed needed for a clinical setting.
The combination of being globally ambitious and regionally rooted forms the basis for Newcastle University’s vision for the future.
We believe in, and strive for, world-class academic excellence – but excellence with a purpose.
We work on the supply side of knowledge creation and dissemination, and respond to the demand side of societal challenges. We are a large employer and a magnet for tens of thousands of young people, and form an integral part of civil society. That is the hallmark of a civic university.
The search for a combination of global excellence and local relevance is one replicated in many places in the world. We believe that our success as a civic university will in itself become an exportable commodity.
The University of Northampton is firmly committed to healthcare research and teaching. Genomics is playing an increasing role in research and training of future healthcare professionals.
Oxford is a collegiate university, consisting of the central University and colleges. The central University is composed of academic departments and research centres, administrative departments, libraries and museums. The 38 colleges are self-governing and financially independent institutions, which are related to the central University in a federal system. There are also six permanent private halls, which were founded by different Christian denominations and which still retain their Christian character.
Melanoma research.
University of Puerto Rico, Medical Sciences Campus
San Juan, Puerto Rico
Research University
Healthcare Care Delivery
The University of Puerto Rico, Medical Sciences Campus aims to prepare health professionals through academic offerings at the professional, undergraduate, graduate, postgraduate, and continuing education levels to improve the health of the people of Puerto Rico and foreign; and strengthen patient care services through knowledge and Innovation generated by the research activity.
Comprehensive, public University and the largest in Canada. Ranked 20 in the world on the THE world rankings. Reaches into the health care sector via the Toronto Academic Health Sciences Network with 9 fully affiliated academic hospitals and their research institutes.
The McLaughlin Centre (previously called McLaughlin Centre for Molecular Medicine or MCMM) was founded in 2001 by a $50M bequest from the R. Samuel McLaughlin Foundation. As a joint initiative between the University of Toronto and partner hospital institutions, the McLaughlin Centre entered a new phase in 2010 focusing on the advancement of genome-based individualized medicine through research and education. Supporting this mandate the McLaughlin Centre promotes and funds inter-institutional grant applications in genomic medicine as well as the MD/PhD Program at the University of Toronto and workshops aimed at exploring outreach and knowledge transfer opportunities. Specifically, the goals are to (1) support new research projects in genomic medicine emphasizing excellence and partnership, (2) educate clinicians, scientists, and health care professionals in genomic medicine and (3) ensure the Toronto health-research community leads Canada and the world in delivering 21st-century genomic medicine.
The University of Utah, located in Salt Lake City in the foothills of the Wasatch Mountains, is the flagship institution of higher learning in Utah. Founded in 1850, it serves over 31,000 students from across the U.S. and the world. With close to 100 major subjects at the undergraduate level and more than 90 major fields of study at the graduate level, including law and medicine, the university prepares students to live and compete in the global workplace.
In the heart of Waterloo Region, at the forefront of innovation, the University of Waterloo is home to world-changing research and inspired teaching. At the hub of a growing network of global partnerships, Waterloo will shape the future by building bridges with industry and between disciplines, institutions and communities.
From quantum computing and nanotechnology to clinical psychology, engineering and health sciences research, ideas that change the world are at the heart of who we are.
The University of Zurich is one of the leading research universities in Europe and offers the widest range of study courses in Switzerland. (from the official UZH website)
Vanderbilt University Medical Center
Nashville, United States
Healthcare Research
Healthcare Care Delivery
Vanderbilt University Medical Center is a nonprofit, academic medical institution dedicated to advancing health and wellness through preeminent programs in patient care, research and education.
Variant Interpretation for Cancer Consortium (VICC)
St Louis, United States
Research Collaboration or Consortium
The field of precision medicine aspires to a future in which a cancer patient’s molecular information can be used to inform diagnosis, prognosis and treatment options most likely to benefit that individual patient. Many groups have created knowledgebases to annotate cancer genomic mutations associated with evidence of pathogenicity or relevant treatment options. However, clinicians and researchers are unable to fully utilize the accumulated knowledge derived from such efforts. Integration of the available knowledge is currently infeasible because each group (often redundantly) curates their own knowledgebase without adherence to any interoperability standards. Therefore, there is a clear need to standardize and coordinate clinical-genomics curation efforts, and create a public community resource able to query the aggregated information. To this end we have formed the Variant Interpretation for Cancer Consortium (VICC) to bring together the leading institutions that are independently developing comprehensive cancer variant interpretation databases. VICC participants share a desire to coordinate efforts and thus enhance the value of each independent effort. Each participant has agreed to: (1) sharing at least a minimal set of required data elements for cancer variant interpretations; (2) Protecting patient privacy by focusing on only clinical interpretations of variants derived from published findings, not individual patient/variant-level observations, thus avoiding the possibility of linking variants to individuals; (3) Sharing all or a significant proportion of interpretations accumulated by their ongoing curation efforts; (4) Releasing content under a permissive license (free and non-exclusive for research use); (5) Releasing software in public repositories with open source licenses; (6) Making data available through publicly accessible and documented APIs and as cross-knowlegebase bulk downloads; and (7) Using the existing schemas, APIs, and demonstration implementations developed by GA4GH.
VENEZUELA SOCIETY OF HUMAN GENETICS
Caracas, Venezuela
Societies and NGOs Professional
The Venezuelan Society of Human Genetics has 140 member, mainly clinical and molecular geneticist and molecular biologists. Organize monthly and annual meetings, Congress every two years.
Ventana Medical Systems, Inc.
Tucson, United States
Companies Life Science
Companies Genomic Analysis
Ventana Medical Systems, Inc. is a member of the Roche Group and a market leader in anatomic pathology and IVD.
Next-generation sequencing clinical laboratory
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives. Founded in 1989 in Cambridge, MA, Vertex today has research and development sites and commercial offices around the world in the United States, Canada, Europe and Australia.
Delivering modern pathology services to the NHS.
Viviphi Ltd
Greenwood Village, United States
Companies Information Technology
Companies Genomic Analysis
Viviphi’s pathway and cognitive computing platform includes codified clinical rules in support of genomic-based targeted therapies, immunotherapies and complex combination treatments. The Viviphi™ platform was designed to be a clinical peer-to-peer knowledge transfer platform where physicians can get immediate access to standards of care and expert knowledge pertaining to genomic-based targeted and immunotherapies personalized to the specific patient being treated.
The Walter and Eliza Hall Institute is the oldest medical research institute in Australia and will celebrate its centenary in 2015. Today it is one of the world’s leading medical research centres and staying true to our mission of ‘Mastery of Disease Through Discovery’, over 750 researchers in 80 multi-disciplinary research teams are developing new approaches to the prevention and treatment of cancer, immune disorders and infectious diseases through basic, translational and clinical research. More than 100 national and international clinical trials are based on discoveries made here.
The Institute offers postgraduate training as the Department of Medical Biology of The University of Melbourne, and is affiliated with the University and The Royal Melbourne Hospital. Registered as a charity on legal and tax status, the Walter and Eliza Hall Institute is governed by a strong independent Board of Directors, Institute Director, senior executive and faculty members who drive its strategic direction. The Institute receives 68% of funding from Government through competitive grants and the balance from philanthropic sources such as trusts, foundations, bequests and donations. The Institute has an extensive network of national and international collaborations including memberships to research associations/alliances, funding support from various organizations and partnerships with biotech companies worldwide.
Wanyi is a professional organization providing health risk management service by offering direct-to-consumer genetic testing and personal health-related information management.
WeGene is aimed to provide comprehensive personal genome interpretation for Chinese.
Weill Cornell Medical College of Cornell University
New York, United States
Research University
Research Collaboration or Consortium
Medical College / Research university
Welgene Biotech is based in Taipei, Taiwan. Welgene is the solo dealer of Genimics product line of Agilent Technologies in Taiwan, and also provides NGS, microarray, and bioinfomatics services to academy or clinics.
The Wellcome Sanger Institute is a charitably funded genomic research centre located in Hinxton, Cambridge, UK.
A leader in the Human Genome Project, we are now focused on understanding the role of genetics in health and disease. Our passion for discovery drives our quest to uncover the basis of genetic and infectious disease. We aim to provide results that can be translated into diagnostics, treatments or therapies that reduce global health burdens.
A Land-grant State University dedicated to the vision and mission of education, research and population health
Wits Health Sciences Biomedical Informatics
Johannesburg, South Africa
Research Collaboration or Consortium
We aim to develop capacity and instruments for the capture, curation and repurposing of healthcare data in under the University of the Witwatersrand Faculty of Health Sciences footprint in South Africa.
A genomic information company using sequence data to improve health for people around the world. Based in Cambridge with offices in Shanghai and Iceland.
Xcode Life Sciences Private Limited
Chennai, India
Companies Life Science
Companies Genomic Analysis
Xcode is a B2B Genomic service provider to clinics, hospitals and wellness professionals. Our core focus is building decision support engines for various professional practices, incorporating genomics and other data.
Xcoo, Inc. provides bioinformatics solutions based on the advanced computer and information technologies. Our solution “Chrovis” brings brilliant discoveries from massive volumes of genomic, biological, medical, and clinical data. We contribute to the sustainable development of
genomic and medical research, personalized medicine, drug development, and molecular diagnostics.
xD Bio is a startup bioinformatics company that was formed to empower biological research to go beyond traditional genome analysis by integrating data from many types of experiments in a non-centralized online collaboration environment.
The discoveries of the next decade require researchers to look beyond the genome sequence by collaborating and integrating multiple data types.
Yotta Biomed, LLC.
Bethesda, United States
Companies Genomic Analysis
Companies Information Technology
Yotta Biomed LLC., is a small startup company located in Bethesda, Maryland, founded in 2013. The company has a very specialized niche in Bioinformatics and Next Generation Sequencing (NGS). Hence, the company specializes in the analysis and management of big-data being generated from any next generation sequencing machines including Illumina.
Zeta Biosciences(Shanghai) Co.,Ltd
Shanghai, China
Companies Life Science
Companies Genomic Analysis
Zeta Biosciences is a startup inspired by envisions of the Global Microbial Identifier. We dedicated to provide solutions for microbial and infectious disease identification and diagnostics.
Zettagene Sp. z o.o.
Stalowa Wola, Poland
Companies Information Technology
Companies Genomic Analysis
Zettagene is a technology company that is leveraging a power of Big Data technologies in the field of genomics. We are building platform using Open Source solutions to handle genomic analysis at scale. We are aiming at handling thousands of WGS samples in a secure and efficient way. We enhance data analytics algorithms to better fit into genomics data.
We are closely related to academia – we are actively working on research projects and publishing papers in top journals.
We analyse 2,400 health conditions through our own AI based algorithms.
There are no matches for your search criteria